# PeptideScanner evidence objects: Leuprolide

Every published version of the records placed with Leuprolide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/leuprolide.json. Selected public evidence only; not medical advice.

- Objects: 231
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00001259-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00001259

> PeptideScanner retained ClinicalTrials.gov record NCT00001259 at 2026-07-30T19:15:14.515Z. Its registry update date was 2023-03-02, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00001259-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-03-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00001259-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00001259-leuprolide-v1
- Content SHA-256: `7f506734458675cec4bc9996cc00ef7368e947fdc4d80834f0045927bd66df4e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00001259 ([`ctg-observation-nct00001259-2023-03-02-3c6170b496b3`](#source-ctg-observation-nct00001259-2023-03-02-3c6170b496b3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00001259 at 2026-07-30T19:15:14.515Z. Its registry update date was 2023-03-02, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00001259-2023-03-02-3c6170b496b3`](#source-ctg-observation-nct00001259-2023-03-02-3c6170b496b3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00001259 at 2026-07-30T19:15:14.515Z. Its registry update date was 2023-03-02, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00001259-2023-03-02-3c6170b496b3`](#source-ctg-observation-nct00001259-2023-03-02-3c6170b496b3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00001259-2023-03-02-3c6170b496b3`](#source-ctg-observation-nct00001259-2023-03-02-3c6170b496b3))

### Sources

<a id="source-ctg-observation-nct00001259-2023-03-02-3c6170b496b3"></a>
- **ClinicalTrials.gov record NCT00001259 · retained source version 2023-03-02:3c6170b496b3a87d5822f0e4d3707a1bacebb0ea0bd6e0ab25b05bd2daf31456** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00001259) (`ctg-observation-nct00001259-2023-03-02-3c6170b496b3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00001259." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00001259-leuprolide-v1 SHA-256: 7f506734458675cec4bc9996cc00ef7368e947fdc4d80834f0045927bd66df4e.

---

<a id="clinicaltrials-gov-nct00001481-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00001481

> PeptideScanner retained ClinicalTrials.gov record NCT00001481 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00001481-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00001481-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00001481-leuprolide-v1
- Content SHA-256: `6fee12b1af57e1c9228e598c87422bc1376e814ac1ab64da87ed6637bbf8cc09`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00001481 ([`ctg-observation-nct00001481-2025-12-05-cd2a94485865`](#source-ctg-observation-nct00001481-2025-12-05-cd2a94485865))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00001481 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00001481-2025-12-05-cd2a94485865`](#source-ctg-observation-nct00001481-2025-12-05-cd2a94485865))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00001481 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00001481-2025-12-05-cd2a94485865`](#source-ctg-observation-nct00001481-2025-12-05-cd2a94485865))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00001481-2025-12-05-cd2a94485865`](#source-ctg-observation-nct00001481-2025-12-05-cd2a94485865))

### Sources

<a id="source-ctg-observation-nct00001481-2025-12-05-cd2a94485865"></a>
- **ClinicalTrials.gov record NCT00001481 · retained source version 2025-12-05:cd2a944858654feabd33530ce681439026a5dc2bb5e61a0793b5c0c6882880fe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00001481) (`ctg-observation-nct00001481-2025-12-05-cd2a94485865`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00001481." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00001481-leuprolide-v1 SHA-256: 6fee12b1af57e1c9228e598c87422bc1376e814ac1ab64da87ed6637bbf8cc09.

---

<a id="clinicaltrials-gov-nct00002580-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00002580

> PeptideScanner retained ClinicalTrials.gov record NCT00002580 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-11-06, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00002580-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-11-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00002580-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002580-leuprolide-v1
- Content SHA-256: `b267a1e5063383f236086b8f8d626b6c33b9c9d86027a92310dbfe264fbe918f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00002580 ([`ctg-observation-nct00002580-2013-11-06-88f7ee711f26`](#source-ctg-observation-nct00002580-2013-11-06-88f7ee711f26))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00002580 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-11-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002580-2013-11-06-88f7ee711f26`](#source-ctg-observation-nct00002580-2013-11-06-88f7ee711f26))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00002580 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-11-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002580-2013-11-06-88f7ee711f26`](#source-ctg-observation-nct00002580-2013-11-06-88f7ee711f26))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00002580-2013-11-06-88f7ee711f26`](#source-ctg-observation-nct00002580-2013-11-06-88f7ee711f26))

### Sources

<a id="source-ctg-observation-nct00002580-2013-11-06-88f7ee711f26"></a>
- **ClinicalTrials.gov record NCT00002580 · retained source version 2013-11-06:88f7ee711f26df8a9d23d2d7020f052640f5f022c2e59e3ed8a4f8a7e6def87e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00002580) (`ctg-observation-nct00002580-2013-11-06-88f7ee711f26`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00002580." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002580-leuprolide-v1 SHA-256: b267a1e5063383f236086b8f8d626b6c33b9c9d86027a92310dbfe264fbe918f.

---

<a id="clinicaltrials-gov-nct00002582-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00002582

> PeptideScanner retained ClinicalTrials.gov record NCT00002582 at 2026-07-30T21:55:56.631Z. Its registry update date was 2013-08-02, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00002582-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-08-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00002582-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002582-leuprolide-v1
- Content SHA-256: `66ba7239b5d6433e6f9379fb385d8414af22a3eb3090fee14b1d54bb30faf201`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00002582 ([`ctg-observation-nct00002582-2013-08-02-39855c4ed8fa`](#source-ctg-observation-nct00002582-2013-08-02-39855c4ed8fa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00002582 at 2026-07-30T21:55:56.631Z. Its registry update date was 2013-08-02, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002582-2013-08-02-39855c4ed8fa`](#source-ctg-observation-nct00002582-2013-08-02-39855c4ed8fa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00002582 at 2026-07-30T21:55:56.631Z. Its registry update date was 2013-08-02, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002582-2013-08-02-39855c4ed8fa`](#source-ctg-observation-nct00002582-2013-08-02-39855c4ed8fa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00002582-2013-08-02-39855c4ed8fa`](#source-ctg-observation-nct00002582-2013-08-02-39855c4ed8fa))

### Sources

<a id="source-ctg-observation-nct00002582-2013-08-02-39855c4ed8fa"></a>
- **ClinicalTrials.gov record NCT00002582 · retained source version 2013-08-02:39855c4ed8face965ae6d3964dbddaa1850e06726791d26d5ea475bab1b1aa6b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00002582) (`ctg-observation-nct00002582-2013-08-02-39855c4ed8fa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00002582." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002582-leuprolide-v1 SHA-256: 66ba7239b5d6433e6f9379fb385d8414af22a3eb3090fee14b1d54bb30faf201.

---

<a id="clinicaltrials-gov-nct00002597-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00002597

> PeptideScanner retained ClinicalTrials.gov record NCT00002597 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-06-14, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00002597-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-06-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00002597-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002597-leuprolide-v1
- Content SHA-256: `50b8719f25109bc974ade16ff1efbd6bd3856a7061965831d877ab09885c8a2c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00002597 ([`ctg-observation-nct00002597-2018-06-14-3b28a936f8bb`](#source-ctg-observation-nct00002597-2018-06-14-3b28a936f8bb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00002597 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-06-14, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002597-2018-06-14-3b28a936f8bb`](#source-ctg-observation-nct00002597-2018-06-14-3b28a936f8bb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00002597 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-06-14, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002597-2018-06-14-3b28a936f8bb`](#source-ctg-observation-nct00002597-2018-06-14-3b28a936f8bb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00002597-2018-06-14-3b28a936f8bb`](#source-ctg-observation-nct00002597-2018-06-14-3b28a936f8bb))

### Sources

<a id="source-ctg-observation-nct00002597-2018-06-14-3b28a936f8bb"></a>
- **ClinicalTrials.gov record NCT00002597 · retained source version 2018-06-14:3b28a936f8bb2b7ee0150ccd9530b0dda1f3878bd6f333d9ab1ac57729c33750** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00002597) (`ctg-observation-nct00002597-2018-06-14-3b28a936f8bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00002597." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002597-leuprolide-v1 SHA-256: 50b8719f25109bc974ade16ff1efbd6bd3856a7061965831d877ab09885c8a2c.

---

<a id="clinicaltrials-gov-nct00002633-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00002633

> PeptideScanner retained ClinicalTrials.gov record NCT00002633 at 2026-07-30T20:29:13.591Z. Its registry update date was 2020-04-03, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00002633-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-04-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00002633-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002633-leuprolide-v1
- Content SHA-256: `a85c7ec52db21c58c94a7d4bd3064d4c5ffd3650f75de14ec7bd2d3e2a719e54`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00002633 ([`ctg-observation-nct00002633-2020-04-03-b21c3675db33`](#source-ctg-observation-nct00002633-2020-04-03-b21c3675db33))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00002633 at 2026-07-30T20:29:13.591Z. Its registry update date was 2020-04-03, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002633-2020-04-03-b21c3675db33`](#source-ctg-observation-nct00002633-2020-04-03-b21c3675db33))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00002633 at 2026-07-30T20:29:13.591Z. Its registry update date was 2020-04-03, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002633-2020-04-03-b21c3675db33`](#source-ctg-observation-nct00002633-2020-04-03-b21c3675db33))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00002633-2020-04-03-b21c3675db33`](#source-ctg-observation-nct00002633-2020-04-03-b21c3675db33))

### Sources

<a id="source-ctg-observation-nct00002633-2020-04-03-b21c3675db33"></a>
- **ClinicalTrials.gov record NCT00002633 · retained source version 2020-04-03:b21c3675db33ba6e6ce158a30055fa50a76f186868a8341758947f1bb2f2392e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00002633) (`ctg-observation-nct00002633-2020-04-03-b21c3675db33`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00002633." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002633-leuprolide-v1 SHA-256: a85c7ec52db21c58c94a7d4bd3064d4c5ffd3650f75de14ec7bd2d3e2a719e54.

---

<a id="clinicaltrials-gov-nct00002881-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00002881

> PeptideScanner retained ClinicalTrials.gov record NCT00002881 at 2026-07-30T22:25:23.114Z. Its registry update date was 2010-11-09, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00002881-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2010-11-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00002881-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002881-leuprolide-v1
- Content SHA-256: `92be74d76d993ce4d9b64c947bd40d473dd082b7d7b2c598cc321d0725834caf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00002881 ([`ctg-observation-nct00002881-2010-11-09-50f02993a703`](#source-ctg-observation-nct00002881-2010-11-09-50f02993a703))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00002881 at 2026-07-30T22:25:23.114Z. Its registry update date was 2010-11-09, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002881-2010-11-09-50f02993a703`](#source-ctg-observation-nct00002881-2010-11-09-50f02993a703))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00002881 at 2026-07-30T22:25:23.114Z. Its registry update date was 2010-11-09, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002881-2010-11-09-50f02993a703`](#source-ctg-observation-nct00002881-2010-11-09-50f02993a703))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00002881-2010-11-09-50f02993a703`](#source-ctg-observation-nct00002881-2010-11-09-50f02993a703))

### Sources

<a id="source-ctg-observation-nct00002881-2010-11-09-50f02993a703"></a>
- **ClinicalTrials.gov record NCT00002881 · retained source version 2010-11-09:50f02993a703b71a84613ce27e5db0fb8b6a91992e74f23905bb08573f1758dc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00002881) (`ctg-observation-nct00002881-2010-11-09-50f02993a703`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00002881." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002881-leuprolide-v1 SHA-256: 92be74d76d993ce4d9b64c947bd40d473dd082b7d7b2c598cc321d0725834caf.

---

<a id="clinicaltrials-gov-nct00002889-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00002889

> PeptideScanner retained ClinicalTrials.gov record NCT00002889 at 2026-07-30T19:09:38.368Z. Its registry update date was 2023-08-18, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00002889-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-08-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00002889-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002889-leuprolide-v1
- Content SHA-256: `804fa1f1b2800bdc9c1b4a0f85bc8c328e034263a3a9d614c9fe6bff30030529`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00002889 ([`ctg-observation-nct00002889-2023-08-18-6423ebf19db3`](#source-ctg-observation-nct00002889-2023-08-18-6423ebf19db3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00002889 at 2026-07-30T19:09:38.368Z. Its registry update date was 2023-08-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002889-2023-08-18-6423ebf19db3`](#source-ctg-observation-nct00002889-2023-08-18-6423ebf19db3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00002889 at 2026-07-30T19:09:38.368Z. Its registry update date was 2023-08-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00002889-2023-08-18-6423ebf19db3`](#source-ctg-observation-nct00002889-2023-08-18-6423ebf19db3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00002889-2023-08-18-6423ebf19db3`](#source-ctg-observation-nct00002889-2023-08-18-6423ebf19db3))

### Sources

<a id="source-ctg-observation-nct00002889-2023-08-18-6423ebf19db3"></a>
- **ClinicalTrials.gov record NCT00002889 · retained source version 2023-08-18:6423ebf19db3b5b7627d445c60a6d0ea00a199d208a0b9d0d48546dce88eb08e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00002889) (`ctg-observation-nct00002889-2023-08-18-6423ebf19db3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00002889." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00002889-leuprolide-v1 SHA-256: 804fa1f1b2800bdc9c1b4a0f85bc8c328e034263a3a9d614c9fe6bff30030529.

---

<a id="clinicaltrials-gov-nct00003124-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00003124

> PeptideScanner retained ClinicalTrials.gov record NCT00003124 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-01-06, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00003124-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-01-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00003124-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00003124-leuprolide-v1
- Content SHA-256: `ce7105d85e7a35554bcb5352c80970714dda7b60b00a46f6f749689721e6fd15`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00003124 ([`ctg-observation-nct00003124-2014-01-06-b1e0340b94b1`](#source-ctg-observation-nct00003124-2014-01-06-b1e0340b94b1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00003124 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-01-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00003124-2014-01-06-b1e0340b94b1`](#source-ctg-observation-nct00003124-2014-01-06-b1e0340b94b1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00003124 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-01-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00003124-2014-01-06-b1e0340b94b1`](#source-ctg-observation-nct00003124-2014-01-06-b1e0340b94b1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00003124-2014-01-06-b1e0340b94b1`](#source-ctg-observation-nct00003124-2014-01-06-b1e0340b94b1))

### Sources

<a id="source-ctg-observation-nct00003124-2014-01-06-b1e0340b94b1"></a>
- **ClinicalTrials.gov record NCT00003124 · retained source version 2014-01-06:b1e0340b94b192f1df423f18a4bf353b55a29b88f60b1f231579785bab192fc6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00003124) (`ctg-observation-nct00003124-2014-01-06-b1e0340b94b1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00003124." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00003124-leuprolide-v1 SHA-256: ce7105d85e7a35554bcb5352c80970714dda7b60b00a46f6f749689721e6fd15.

---

<a id="clinicaltrials-gov-nct00003394-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00003394

> PeptideScanner retained ClinicalTrials.gov record NCT00003394 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00003394-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-06-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00003394-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00003394-leuprolide-v1
- Content SHA-256: `27718e2c2274a316373b1448fb6f44aff02dc3d2bec7c091413a179ef248e575`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00003394 ([`ctg-observation-nct00003394-2013-06-24-582654927f00`](#source-ctg-observation-nct00003394-2013-06-24-582654927f00))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00003394 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-06-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00003394-2013-06-24-582654927f00`](#source-ctg-observation-nct00003394-2013-06-24-582654927f00))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00003394 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-06-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00003394-2013-06-24-582654927f00`](#source-ctg-observation-nct00003394-2013-06-24-582654927f00))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00003394-2013-06-24-582654927f00`](#source-ctg-observation-nct00003394-2013-06-24-582654927f00))

### Sources

<a id="source-ctg-observation-nct00003394-2013-06-24-582654927f00"></a>
- **ClinicalTrials.gov record NCT00003394 · retained source version 2013-06-24:582654927f00f5ae3e7d12e477d2938c1ffde1dc3d375aa691b82e0285503092** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00003394) (`ctg-observation-nct00003394-2013-06-24-582654927f00`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00003394." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00003394-leuprolide-v1 SHA-256: 27718e2c2274a316373b1448fb6f44aff02dc3d2bec7c091413a179ef248e575.

---

<a id="clinicaltrials-gov-nct00003653-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00003653

> PeptideScanner retained ClinicalTrials.gov record NCT00003653 at 2026-07-30T20:02:09.393Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00003653-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00003653-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00003653-leuprolide-v1
- Content SHA-256: `0759a024857835950bdc8cadcf1d381b4a9565fcc6656594648adc40736b5ee3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00003653 ([`ctg-observation-nct00003653-2021-06-23-63b58d705555`](#source-ctg-observation-nct00003653-2021-06-23-63b58d705555))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00003653 at 2026-07-30T20:02:09.393Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00003653-2021-06-23-63b58d705555`](#source-ctg-observation-nct00003653-2021-06-23-63b58d705555))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00003653 at 2026-07-30T20:02:09.393Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00003653-2021-06-23-63b58d705555`](#source-ctg-observation-nct00003653-2021-06-23-63b58d705555))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00003653-2021-06-23-63b58d705555`](#source-ctg-observation-nct00003653-2021-06-23-63b58d705555))

### Sources

<a id="source-ctg-observation-nct00003653-2021-06-23-63b58d705555"></a>
- **ClinicalTrials.gov record NCT00003653 · retained source version 2021-06-23:63b58d70555536c9e488c4938b94aed059ead98c4736ec69f798bfcbc4f44a8c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00003653) (`ctg-observation-nct00003653-2021-06-23-63b58d705555`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00003653." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00003653-leuprolide-v1 SHA-256: 0759a024857835950bdc8cadcf1d381b4a9565fcc6656594648adc40736b5ee3.

---

<a id="clinicaltrials-gov-nct00004311-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00004311

> PeptideScanner retained ClinicalTrials.gov record NCT00004311 at 2026-07-30T22:50:58.187Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00004311-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2005-06-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00004311-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004311-leuprolide-v1
- Content SHA-256: `180429be79deb39ee9c9198026316b014a3b286f2e58670423795cf4c522d7ad`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00004311 ([`ctg-observation-nct00004311-2005-06-24-25420fcd8b17`](#source-ctg-observation-nct00004311-2005-06-24-25420fcd8b17))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00004311 at 2026-07-30T22:50:58.187Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004311-2005-06-24-25420fcd8b17`](#source-ctg-observation-nct00004311-2005-06-24-25420fcd8b17))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00004311 at 2026-07-30T22:50:58.187Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004311-2005-06-24-25420fcd8b17`](#source-ctg-observation-nct00004311-2005-06-24-25420fcd8b17))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00004311-2005-06-24-25420fcd8b17`](#source-ctg-observation-nct00004311-2005-06-24-25420fcd8b17))

### Sources

<a id="source-ctg-observation-nct00004311-2005-06-24-25420fcd8b17"></a>
- **ClinicalTrials.gov record NCT00004311 · retained source version 2005-06-24:25420fcd8b1744afd6db5c2a7bdfcf150f01d41e6886df6b8a2a38066d7f9d03** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00004311) (`ctg-observation-nct00004311-2005-06-24-25420fcd8b17`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00004311." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004311-leuprolide-v1 SHA-256: 180429be79deb39ee9c9198026316b014a3b286f2e58670423795cf4c522d7ad.

---

<a id="clinicaltrials-gov-nct00004344-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00004344

> PeptideScanner retained ClinicalTrials.gov record NCT00004344 at 2026-07-30T22:50:58.186Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00004344-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2005-06-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00004344-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004344-leuprolide-v1
- Content SHA-256: `32b1441909eeb2e52648c14b383e1a585915310ab8861ffbe59ee49f11abf106`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00004344 ([`ctg-observation-nct00004344-2005-06-24-993ca3b80a36`](#source-ctg-observation-nct00004344-2005-06-24-993ca3b80a36))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00004344 at 2026-07-30T22:50:58.186Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004344-2005-06-24-993ca3b80a36`](#source-ctg-observation-nct00004344-2005-06-24-993ca3b80a36))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00004344 at 2026-07-30T22:50:58.186Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004344-2005-06-24-993ca3b80a36`](#source-ctg-observation-nct00004344-2005-06-24-993ca3b80a36))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00004344-2005-06-24-993ca3b80a36`](#source-ctg-observation-nct00004344-2005-06-24-993ca3b80a36))

### Sources

<a id="source-ctg-observation-nct00004344-2005-06-24-993ca3b80a36"></a>
- **ClinicalTrials.gov record NCT00004344 · retained source version 2005-06-24:993ca3b80a361f54141acb17e40861b9b3b703405ac5fadaec2878277c3f364e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00004344) (`ctg-observation-nct00004344-2005-06-24-993ca3b80a36`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00004344." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004344-leuprolide-v1 SHA-256: 32b1441909eeb2e52648c14b383e1a585915310ab8861ffbe59ee49f11abf106.

---

<a id="clinicaltrials-gov-nct00004426-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00004426

> PeptideScanner retained ClinicalTrials.gov record NCT00004426 at 2026-07-30T21:43:54.469Z. Its registry update date was 2015-03-26, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00004426-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-03-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00004426-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004426-leuprolide-v1
- Content SHA-256: `e9bf7cccac86cc0a1fac245c3f8dfb1fb46c39f25e690519b465c7e696639e86`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00004426 ([`ctg-observation-nct00004426-2015-03-26-183b25b7e564`](#source-ctg-observation-nct00004426-2015-03-26-183b25b7e564))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00004426 at 2026-07-30T21:43:54.469Z. Its registry update date was 2015-03-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004426-2015-03-26-183b25b7e564`](#source-ctg-observation-nct00004426-2015-03-26-183b25b7e564))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00004426 at 2026-07-30T21:43:54.469Z. Its registry update date was 2015-03-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004426-2015-03-26-183b25b7e564`](#source-ctg-observation-nct00004426-2015-03-26-183b25b7e564))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00004426-2015-03-26-183b25b7e564`](#source-ctg-observation-nct00004426-2015-03-26-183b25b7e564))

### Sources

<a id="source-ctg-observation-nct00004426-2015-03-26-183b25b7e564"></a>
- **ClinicalTrials.gov record NCT00004426 · retained source version 2015-03-26:183b25b7e564c227ca18637704b73d3be5352fb036c572662ef9ffe5a374e478** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00004426) (`ctg-observation-nct00004426-2015-03-26-183b25b7e564`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00004426." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004426-leuprolide-v1 SHA-256: e9bf7cccac86cc0a1fac245c3f8dfb1fb46c39f25e690519b465c7e696639e86.

---

<a id="clinicaltrials-gov-nct00004436-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00004436

> PeptideScanner retained ClinicalTrials.gov record NCT00004436 at 2026-07-30T21:43:54.456Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00004436-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-03-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00004436-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004436-leuprolide-v1
- Content SHA-256: `67a1812b445d8b8624105032d4c3dcd279cb027f3d767621d6dd7ee82991dbf6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00004436 ([`ctg-observation-nct00004436-2015-03-25-0b77ad10dfd9`](#source-ctg-observation-nct00004436-2015-03-25-0b77ad10dfd9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00004436 at 2026-07-30T21:43:54.456Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004436-2015-03-25-0b77ad10dfd9`](#source-ctg-observation-nct00004436-2015-03-25-0b77ad10dfd9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00004436 at 2026-07-30T21:43:54.456Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004436-2015-03-25-0b77ad10dfd9`](#source-ctg-observation-nct00004436-2015-03-25-0b77ad10dfd9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00004436-2015-03-25-0b77ad10dfd9`](#source-ctg-observation-nct00004436-2015-03-25-0b77ad10dfd9))

### Sources

<a id="source-ctg-observation-nct00004436-2015-03-25-0b77ad10dfd9"></a>
- **ClinicalTrials.gov record NCT00004436 · retained source version 2015-03-25:0b77ad10dfd97eb212fa82583d517cdb0b9d14b317fdb34247f51dec25561f89** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00004436) (`ctg-observation-nct00004436-2015-03-25-0b77ad10dfd9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00004436." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004436-leuprolide-v1 SHA-256: 67a1812b445d8b8624105032d4c3dcd279cb027f3d767621d6dd7ee82991dbf6.

---

<a id="clinicaltrials-gov-nct00004438-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00004438

> PeptideScanner retained ClinicalTrials.gov record NCT00004438 at 2026-07-30T21:43:54.452Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00004438-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-03-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00004438-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004438-leuprolide-v1
- Content SHA-256: `d2d5285c3414df295ac1c11789d5578e3fba0d77ad835331364ce1c961d63857`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00004438 ([`ctg-observation-nct00004438-2015-03-25-8ffde2b47a08`](#source-ctg-observation-nct00004438-2015-03-25-8ffde2b47a08))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00004438 at 2026-07-30T21:43:54.452Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004438-2015-03-25-8ffde2b47a08`](#source-ctg-observation-nct00004438-2015-03-25-8ffde2b47a08))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00004438 at 2026-07-30T21:43:54.452Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004438-2015-03-25-8ffde2b47a08`](#source-ctg-observation-nct00004438-2015-03-25-8ffde2b47a08))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00004438-2015-03-25-8ffde2b47a08`](#source-ctg-observation-nct00004438-2015-03-25-8ffde2b47a08))

### Sources

<a id="source-ctg-observation-nct00004438-2015-03-25-8ffde2b47a08"></a>
- **ClinicalTrials.gov record NCT00004438 · retained source version 2015-03-25:8ffde2b47a084cf35c4bbc491984eb59bd6912fe87ee5286e3d90454c86c8129** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00004438) (`ctg-observation-nct00004438-2015-03-25-8ffde2b47a08`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00004438." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004438-leuprolide-v1 SHA-256: d2d5285c3414df295ac1c11789d5578e3fba0d77ad835331364ce1c961d63857.

---

<a id="clinicaltrials-gov-nct00004635-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00004635

> PeptideScanner retained ClinicalTrials.gov record NCT00004635 at 2026-07-30T21:11:31.039Z. Its registry update date was 2018-05-22, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00004635-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-05-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00004635-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004635-leuprolide-v1
- Content SHA-256: `74142ebcffda18b3fc80ccdca345bc568b6bdc2e50ecabbe1b420276419c98de`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00004635 ([`ctg-observation-nct00004635-2018-05-22-1737802bd24f`](#source-ctg-observation-nct00004635-2018-05-22-1737802bd24f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00004635 at 2026-07-30T21:11:31.039Z. Its registry update date was 2018-05-22, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004635-2018-05-22-1737802bd24f`](#source-ctg-observation-nct00004635-2018-05-22-1737802bd24f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00004635 at 2026-07-30T21:11:31.039Z. Its registry update date was 2018-05-22, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004635-2018-05-22-1737802bd24f`](#source-ctg-observation-nct00004635-2018-05-22-1737802bd24f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00004635-2018-05-22-1737802bd24f`](#source-ctg-observation-nct00004635-2018-05-22-1737802bd24f))

### Sources

<a id="source-ctg-observation-nct00004635-2018-05-22-1737802bd24f"></a>
- **ClinicalTrials.gov record NCT00004635 · retained source version 2018-05-22:1737802bd24f6ec834ec0a2853d8aab5386187451e747b822fbbf23ebe96eec3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00004635) (`ctg-observation-nct00004635-2018-05-22-1737802bd24f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00004635." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004635-leuprolide-v1 SHA-256: 74142ebcffda18b3fc80ccdca345bc568b6bdc2e50ecabbe1b420276419c98de.

---

<a id="clinicaltrials-gov-nct00004771-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00004771

> PeptideScanner retained ClinicalTrials.gov record NCT00004771 at 2026-07-30T22:50:58.183Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00004771-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2005-06-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00004771-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004771-leuprolide-v1
- Content SHA-256: `1619fa1cf74d5588f179c991f2a258671025afa9bab101a56d2e9b4c9d2f51a2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00004771 ([`ctg-observation-nct00004771-2005-06-24-eb713fc418a0`](#source-ctg-observation-nct00004771-2005-06-24-eb713fc418a0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00004771 at 2026-07-30T22:50:58.183Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004771-2005-06-24-eb713fc418a0`](#source-ctg-observation-nct00004771-2005-06-24-eb713fc418a0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00004771 at 2026-07-30T22:50:58.183Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00004771-2005-06-24-eb713fc418a0`](#source-ctg-observation-nct00004771-2005-06-24-eb713fc418a0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00004771-2005-06-24-eb713fc418a0`](#source-ctg-observation-nct00004771-2005-06-24-eb713fc418a0))

### Sources

<a id="source-ctg-observation-nct00004771-2005-06-24-eb713fc418a0"></a>
- **ClinicalTrials.gov record NCT00004771 · retained source version 2005-06-24:eb713fc418a0f2571d9509acef3d5fa00783a0d8b159dd60d6a5e642ee119277** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00004771) (`ctg-observation-nct00004771-2005-06-24-eb713fc418a0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00004771." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00004771-leuprolide-v1 SHA-256: 1619fa1cf74d5588f179c991f2a258671025afa9bab101a56d2e9b4c9d2f51a2.

---

<a id="clinicaltrials-gov-nct00063310-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00063310

> PeptideScanner retained ClinicalTrials.gov record NCT00063310 at 2026-07-30T22:26:45.017Z. Its registry update date was 2009-12-11, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00063310-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-12-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00063310-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00063310-leuprolide-v1
- Content SHA-256: `98a65ff93880a919c21de8e2b483ffa8b221a7fa347c67c872e931438ef6d550`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00063310 ([`ctg-observation-nct00063310-2009-12-11-2102c77b3054`](#source-ctg-observation-nct00063310-2009-12-11-2102c77b3054))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00063310 at 2026-07-30T22:26:45.017Z. Its registry update date was 2009-12-11, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00063310-2009-12-11-2102c77b3054`](#source-ctg-observation-nct00063310-2009-12-11-2102c77b3054))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00063310 at 2026-07-30T22:26:45.017Z. Its registry update date was 2009-12-11, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00063310-2009-12-11-2102c77b3054`](#source-ctg-observation-nct00063310-2009-12-11-2102c77b3054))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00063310-2009-12-11-2102c77b3054`](#source-ctg-observation-nct00063310-2009-12-11-2102c77b3054))

### Sources

<a id="source-ctg-observation-nct00063310-2009-12-11-2102c77b3054"></a>
- **ClinicalTrials.gov record NCT00063310 · retained source version 2009-12-11:2102c77b3054d8165099fd75942ec2bafa56f044994625484285ab7e908fb3b5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00063310) (`ctg-observation-nct00063310-2009-12-11-2102c77b3054`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00063310." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00063310-leuprolide-v1 SHA-256: 98a65ff93880a919c21de8e2b483ffa8b221a7fa347c67c872e931438ef6d550.

---

<a id="clinicaltrials-gov-nct00099086-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00099086

> PeptideScanner retained ClinicalTrials.gov record NCT00099086 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00099086-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-01-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00099086-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00099086-leuprolide-v1
- Content SHA-256: `3c2b95480ccba6b054597c743e831f66be22b56bbce878228169cffc856fbd44`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00099086 ([`ctg-observation-nct00099086-2024-01-31-30d1ac4d8d84`](#source-ctg-observation-nct00099086-2024-01-31-30d1ac4d8d84))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00099086 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00099086-2024-01-31-30d1ac4d8d84`](#source-ctg-observation-nct00099086-2024-01-31-30d1ac4d8d84))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00099086 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00099086-2024-01-31-30d1ac4d8d84`](#source-ctg-observation-nct00099086-2024-01-31-30d1ac4d8d84))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00099086-2024-01-31-30d1ac4d8d84`](#source-ctg-observation-nct00099086-2024-01-31-30d1ac4d8d84))

### Sources

<a id="source-ctg-observation-nct00099086-2024-01-31-30d1ac4d8d84"></a>
- **ClinicalTrials.gov record NCT00099086 · retained source version 2024-01-31:30d1ac4d8d84143c81ce08ba0574b5b0711236d45ab23c168fad4f9fbce4a565** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00099086) (`ctg-observation-nct00099086-2024-01-31-30d1ac4d8d84`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00099086." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00099086-leuprolide-v1 SHA-256: 3c2b95480ccba6b054597c743e831f66be22b56bbce878228169cffc856fbd44.

---

<a id="clinicaltrials-gov-nct00170157-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00170157

> PeptideScanner retained ClinicalTrials.gov record NCT00170157 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00170157-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00170157-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00170157-leuprolide-v1
- Content SHA-256: `313fc5b7ddd77d1848a76588a9a964db24ccb354fbb74dfc81c33830d1ce777a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00170157 ([`ctg-observation-nct00170157-2017-05-15-699cb48e8061`](#source-ctg-observation-nct00170157-2017-05-15-699cb48e8061))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00170157 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-05-15, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00170157-2017-05-15-699cb48e8061`](#source-ctg-observation-nct00170157-2017-05-15-699cb48e8061))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00170157 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-05-15, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00170157-2017-05-15-699cb48e8061`](#source-ctg-observation-nct00170157-2017-05-15-699cb48e8061))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00170157-2017-05-15-699cb48e8061`](#source-ctg-observation-nct00170157-2017-05-15-699cb48e8061))

### Sources

<a id="source-ctg-observation-nct00170157-2017-05-15-699cb48e8061"></a>
- **ClinicalTrials.gov record NCT00170157 · retained source version 2017-05-15:699cb48e806146ff2f92251dd2a41d06b5c00f6faf50ae271159c636faaf1dcf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00170157) (`ctg-observation-nct00170157-2017-05-15-699cb48e8061`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00170157." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00170157-leuprolide-v1 SHA-256: 313fc5b7ddd77d1848a76588a9a964db24ccb354fbb74dfc81c33830d1ce777a.

---

<a id="clinicaltrials-gov-nct00223665-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00223665

> PeptideScanner retained ClinicalTrials.gov record NCT00223665 at 2026-07-30T21:10:02.996Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00223665-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-08-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00223665-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00223665-leuprolide-v1
- Content SHA-256: `eccf203db051106cab9fe5d92a452e628261889cb96bff43c788b17e83c7d87a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00223665 ([`ctg-observation-nct00223665-2018-08-07-7dab5eb55be7`](#source-ctg-observation-nct00223665-2018-08-07-7dab5eb55be7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00223665 at 2026-07-30T21:10:02.996Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00223665-2018-08-07-7dab5eb55be7`](#source-ctg-observation-nct00223665-2018-08-07-7dab5eb55be7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00223665 at 2026-07-30T21:10:02.996Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00223665-2018-08-07-7dab5eb55be7`](#source-ctg-observation-nct00223665-2018-08-07-7dab5eb55be7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00223665-2018-08-07-7dab5eb55be7`](#source-ctg-observation-nct00223665-2018-08-07-7dab5eb55be7))

### Sources

<a id="source-ctg-observation-nct00223665-2018-08-07-7dab5eb55be7"></a>
- **ClinicalTrials.gov record NCT00223665 · retained source version 2018-08-07:7dab5eb55be740bca2d13d5ee4992df8d14d3d3548dfcf8362627a0990a37ea5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00223665) (`ctg-observation-nct00223665-2018-08-07-7dab5eb55be7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00223665." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00223665-leuprolide-v1 SHA-256: eccf203db051106cab9fe5d92a452e628261889cb96bff43c788b17e83c7d87a.

---

<a id="clinicaltrials-gov-nct00225420-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00225420

> PeptideScanner retained ClinicalTrials.gov record NCT00225420 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-06-01, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00225420-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-06-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00225420-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00225420-leuprolide-v1
- Content SHA-256: `165c91c80a97377d7e962b503a52b15cc52652705fc3ddfebcda204189643ef7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00225420 ([`ctg-observation-nct00225420-2017-06-01-70f6c76b363f`](#source-ctg-observation-nct00225420-2017-06-01-70f6c76b363f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00225420 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-06-01, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00225420-2017-06-01-70f6c76b363f`](#source-ctg-observation-nct00225420-2017-06-01-70f6c76b363f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00225420 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-06-01, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00225420-2017-06-01-70f6c76b363f`](#source-ctg-observation-nct00225420-2017-06-01-70f6c76b363f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00225420-2017-06-01-70f6c76b363f`](#source-ctg-observation-nct00225420-2017-06-01-70f6c76b363f))

### Sources

<a id="source-ctg-observation-nct00225420-2017-06-01-70f6c76b363f"></a>
- **ClinicalTrials.gov record NCT00225420 · retained source version 2017-06-01:70f6c76b363f2427e23c77769f30484e2eb769fb8819581d7079908fb17018b8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00225420) (`ctg-observation-nct00225420-2017-06-01-70f6c76b363f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00225420." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00225420-leuprolide-v1 SHA-256: 165c91c80a97377d7e962b503a52b15cc52652705fc3ddfebcda204189643ef7.

---

<a id="clinicaltrials-gov-nct00254397-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00254397

> PeptideScanner retained ClinicalTrials.gov record NCT00254397 at 2026-07-30T20:44:36.700Z. Its registry update date was 2019-10-16, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00254397-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-10-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00254397-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00254397-leuprolide-v1
- Content SHA-256: `6ee8759c557637aab7663224fb712b9795325f8c8ab8c2b725668977e834a2e0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00254397 ([`ctg-observation-nct00254397-2019-10-16-2463c3f8eaa6`](#source-ctg-observation-nct00254397-2019-10-16-2463c3f8eaa6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00254397 at 2026-07-30T20:44:36.700Z. Its registry update date was 2019-10-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00254397-2019-10-16-2463c3f8eaa6`](#source-ctg-observation-nct00254397-2019-10-16-2463c3f8eaa6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00254397 at 2026-07-30T20:44:36.700Z. Its registry update date was 2019-10-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00254397-2019-10-16-2463c3f8eaa6`](#source-ctg-observation-nct00254397-2019-10-16-2463c3f8eaa6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00254397-2019-10-16-2463c3f8eaa6`](#source-ctg-observation-nct00254397-2019-10-16-2463c3f8eaa6))

### Sources

<a id="source-ctg-observation-nct00254397-2019-10-16-2463c3f8eaa6"></a>
- **ClinicalTrials.gov record NCT00254397 · retained source version 2019-10-16:2463c3f8eaa6214bede64f871799659bbe964c02894023dbe9bdb42be2a96a86** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00254397) (`ctg-observation-nct00254397-2019-10-16-2463c3f8eaa6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00254397." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00254397-leuprolide-v1 SHA-256: 6ee8759c557637aab7663224fb712b9795325f8c8ab8c2b725668977e834a2e0.

---

<a id="clinicaltrials-gov-nct00329043-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00329043

> PeptideScanner retained ClinicalTrials.gov record NCT00329043 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00329043-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00329043-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00329043-leuprolide-v1
- Content SHA-256: `9d8464f5a3e15c2ad026d1fdf8768d2cda7a41eb7808dd05f7b851b2f7e01ad1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00329043 ([`ctg-observation-nct00329043-2026-06-12-341c66034d84`](#source-ctg-observation-nct00329043-2026-06-12-341c66034d84))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00329043 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00329043-2026-06-12-341c66034d84`](#source-ctg-observation-nct00329043-2026-06-12-341c66034d84))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00329043 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00329043-2026-06-12-341c66034d84`](#source-ctg-observation-nct00329043-2026-06-12-341c66034d84))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00329043-2026-06-12-341c66034d84`](#source-ctg-observation-nct00329043-2026-06-12-341c66034d84))

### Sources

<a id="source-ctg-observation-nct00329043-2026-06-12-341c66034d84"></a>
- **ClinicalTrials.gov record NCT00329043 · retained source version 2026-06-12:341c66034d84051ef8d9faf98aa10890c9af736bcaecf9e574e4be23d025f520** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00329043) (`ctg-observation-nct00329043-2026-06-12-341c66034d84`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00329043." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00329043-leuprolide-v1 SHA-256: 9d8464f5a3e15c2ad026d1fdf8768d2cda7a41eb7808dd05f7b851b2f7e01ad1.

---

<a id="clinicaltrials-gov-nct00349258-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00349258

> PeptideScanner retained ClinicalTrials.gov record NCT00349258 at 2026-07-30T22:49:18.182Z. Its registry update date was 2006-07-06, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00349258-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2006-07-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00349258-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00349258-leuprolide-v1
- Content SHA-256: `d2fc1c750f3d812ad6ba155961c37bbe2595ba1ca715e89a93f6a50597844eb0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00349258 ([`ctg-observation-nct00349258-2006-07-06-10f981e16035`](#source-ctg-observation-nct00349258-2006-07-06-10f981e16035))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00349258 at 2026-07-30T22:49:18.182Z. Its registry update date was 2006-07-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00349258-2006-07-06-10f981e16035`](#source-ctg-observation-nct00349258-2006-07-06-10f981e16035))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00349258 at 2026-07-30T22:49:18.182Z. Its registry update date was 2006-07-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00349258-2006-07-06-10f981e16035`](#source-ctg-observation-nct00349258-2006-07-06-10f981e16035))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00349258-2006-07-06-10f981e16035`](#source-ctg-observation-nct00349258-2006-07-06-10f981e16035))

### Sources

<a id="source-ctg-observation-nct00349258-2006-07-06-10f981e16035"></a>
- **ClinicalTrials.gov record NCT00349258 · retained source version 2006-07-06:10f981e160358bf728f195746e0f753dd3241e7669fc7a0b4391d2cb29b39577** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00349258) (`ctg-observation-nct00349258-2006-07-06-10f981e16035`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00349258." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00349258-leuprolide-v1 SHA-256: d2fc1c750f3d812ad6ba155961c37bbe2595ba1ca715e89a93f6a50597844eb0.

---

<a id="clinicaltrials-gov-nct00380406-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00380406

> PeptideScanner retained ClinicalTrials.gov record NCT00380406 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00380406-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00380406-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00380406-leuprolide-v1
- Content SHA-256: `7b49fd8f97e7018807215c0c1670d38f647a4c393bcab1c735fa83b9b08c0133`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00380406 ([`ctg-observation-nct00380406-2017-04-05-5640666fb5cf`](#source-ctg-observation-nct00380406-2017-04-05-5640666fb5cf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00380406 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00380406-2017-04-05-5640666fb5cf`](#source-ctg-observation-nct00380406-2017-04-05-5640666fb5cf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00380406 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00380406-2017-04-05-5640666fb5cf`](#source-ctg-observation-nct00380406-2017-04-05-5640666fb5cf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00380406-2017-04-05-5640666fb5cf`](#source-ctg-observation-nct00380406-2017-04-05-5640666fb5cf))

### Sources

<a id="source-ctg-observation-nct00380406-2017-04-05-5640666fb5cf"></a>
- **ClinicalTrials.gov record NCT00380406 · retained source version 2017-04-05:5640666fb5cf47502d1cac76e23982dfbf2c936f357d7e0fe1377f32535ab8ce** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00380406) (`ctg-observation-nct00380406-2017-04-05-5640666fb5cf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00380406." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00380406-leuprolide-v1 SHA-256: 7b49fd8f97e7018807215c0c1670d38f647a4c393bcab1c735fa83b9b08c0133.

---

<a id="clinicaltrials-gov-nct00429494-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00429494

> PeptideScanner retained ClinicalTrials.gov record NCT00429494 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-07-09, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00429494-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-07-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00429494-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00429494-leuprolide-v1
- Content SHA-256: `fdd550b6fbddc6c0fa73197872339decf0f96a81c03bfeefa0cad7cc3b7ba8d2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00429494 ([`ctg-observation-nct00429494-2013-07-09-41c72b5fe380`](#source-ctg-observation-nct00429494-2013-07-09-41c72b5fe380))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00429494 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-07-09, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00429494-2013-07-09-41c72b5fe380`](#source-ctg-observation-nct00429494-2013-07-09-41c72b5fe380))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00429494 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-07-09, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00429494-2013-07-09-41c72b5fe380`](#source-ctg-observation-nct00429494-2013-07-09-41c72b5fe380))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00429494-2013-07-09-41c72b5fe380`](#source-ctg-observation-nct00429494-2013-07-09-41c72b5fe380))

### Sources

<a id="source-ctg-observation-nct00429494-2013-07-09-41c72b5fe380"></a>
- **ClinicalTrials.gov record NCT00429494 · retained source version 2013-07-09:41c72b5fe38072214650929de85a1904d43f154256bf502e221975155eb8dbf6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00429494) (`ctg-observation-nct00429494-2013-07-09-41c72b5fe380`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00429494." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00429494-leuprolide-v1 SHA-256: fdd550b6fbddc6c0fa73197872339decf0f96a81c03bfeefa0cad7cc3b7ba8d2.

---

<a id="clinicaltrials-gov-nct00454571-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00454571

> PeptideScanner retained ClinicalTrials.gov record NCT00454571 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-02-10, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00454571-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-02-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00454571-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00454571-leuprolide-v1
- Content SHA-256: `f05d85d553d1fd779d3f639d667272c6fd77338ae65f0f229fde71f485f53798`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00454571 ([`ctg-observation-nct00454571-2016-02-10-433da49f1224`](#source-ctg-observation-nct00454571-2016-02-10-433da49f1224))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00454571 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-02-10, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00454571-2016-02-10-433da49f1224`](#source-ctg-observation-nct00454571-2016-02-10-433da49f1224))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00454571 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-02-10, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00454571-2016-02-10-433da49f1224`](#source-ctg-observation-nct00454571-2016-02-10-433da49f1224))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00454571-2016-02-10-433da49f1224`](#source-ctg-observation-nct00454571-2016-02-10-433da49f1224))

### Sources

<a id="source-ctg-observation-nct00454571-2016-02-10-433da49f1224"></a>
- **ClinicalTrials.gov record NCT00454571 · retained source version 2016-02-10:433da49f122492febc9be651c3dfce0a97ccca1be2d4180dcac0f3795c8bfeb3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00454571) (`ctg-observation-nct00454571-2016-02-10-433da49f1224`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00454571." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00454571-leuprolide-v1 SHA-256: f05d85d553d1fd779d3f639d667272c6fd77338ae65f0f229fde71f485f53798.

---

<a id="clinicaltrials-gov-nct00455689-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00455689

> PeptideScanner retained ClinicalTrials.gov record NCT00455689 at 2026-07-30T21:10:02.989Z. Its registry update date was 2018-09-18, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00455689-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-09-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00455689-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00455689-leuprolide-v1
- Content SHA-256: `986deaf7568d7d0600f4a1a9ab6694d6d8406ae567c842c6b265a80c4ac0bc55`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00455689 ([`ctg-observation-nct00455689-2018-09-18-780800d6d69c`](#source-ctg-observation-nct00455689-2018-09-18-780800d6d69c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00455689 at 2026-07-30T21:10:02.989Z. Its registry update date was 2018-09-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00455689-2018-09-18-780800d6d69c`](#source-ctg-observation-nct00455689-2018-09-18-780800d6d69c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00455689 at 2026-07-30T21:10:02.989Z. Its registry update date was 2018-09-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00455689-2018-09-18-780800d6d69c`](#source-ctg-observation-nct00455689-2018-09-18-780800d6d69c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00455689-2018-09-18-780800d6d69c`](#source-ctg-observation-nct00455689-2018-09-18-780800d6d69c))

### Sources

<a id="source-ctg-observation-nct00455689-2018-09-18-780800d6d69c"></a>
- **ClinicalTrials.gov record NCT00455689 · retained source version 2018-09-18:780800d6d69c198c00173aa8dc4ac45f1bda50510c22a1a646a7d686f6d78857** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00455689) (`ctg-observation-nct00455689-2018-09-18-780800d6d69c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00455689." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00455689-leuprolide-v1 SHA-256: 986deaf7568d7d0600f4a1a9ab6694d6d8406ae567c842c6b265a80c4ac0bc55.

---

<a id="clinicaltrials-gov-nct00500110-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00500110

> PeptideScanner retained ClinicalTrials.gov record NCT00500110 at 2026-07-30T21:42:40.792Z. Its registry update date was 2015-04-28, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00500110-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00500110-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00500110-leuprolide-v1
- Content SHA-256: `1d8a0741da85669c29afc836ce3bec556d12c23570c957330e3abf22b4e8704d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00500110 ([`ctg-observation-nct00500110-2015-04-28-9e3de8c6e2fe`](#source-ctg-observation-nct00500110-2015-04-28-9e3de8c6e2fe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00500110 at 2026-07-30T21:42:40.792Z. Its registry update date was 2015-04-28, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00500110-2015-04-28-9e3de8c6e2fe`](#source-ctg-observation-nct00500110-2015-04-28-9e3de8c6e2fe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00500110 at 2026-07-30T21:42:40.792Z. Its registry update date was 2015-04-28, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00500110-2015-04-28-9e3de8c6e2fe`](#source-ctg-observation-nct00500110-2015-04-28-9e3de8c6e2fe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00500110-2015-04-28-9e3de8c6e2fe`](#source-ctg-observation-nct00500110-2015-04-28-9e3de8c6e2fe))

### Sources

<a id="source-ctg-observation-nct00500110-2015-04-28-9e3de8c6e2fe"></a>
- **ClinicalTrials.gov record NCT00500110 · retained source version 2015-04-28:9e3de8c6e2feac1fc06d2256d4cc27f48b68281e11ae922cd8798013e315cb4c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00500110) (`ctg-observation-nct00500110-2015-04-28-9e3de8c6e2fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00500110." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00500110-leuprolide-v1 SHA-256: 1d8a0741da85669c29afc836ce3bec556d12c23570c957330e3abf22b4e8704d.

---

<a id="clinicaltrials-gov-nct00541047-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00541047

> PeptideScanner retained ClinicalTrials.gov record NCT00541047 at 2026-07-30T19:04:52.204Z. Its registry update date was 2023-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00541047-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-11-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00541047-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00541047-leuprolide-v1
- Content SHA-256: `2aabe56419c6f2d5c2d219a39316a213a993d8906d8eaba7c457abff7b899481`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00541047 ([`ctg-observation-nct00541047-2023-11-13-11df636e1667`](#source-ctg-observation-nct00541047-2023-11-13-11df636e1667))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00541047 at 2026-07-30T19:04:52.204Z. Its registry update date was 2023-11-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00541047-2023-11-13-11df636e1667`](#source-ctg-observation-nct00541047-2023-11-13-11df636e1667))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00541047 at 2026-07-30T19:04:52.204Z. Its registry update date was 2023-11-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00541047-2023-11-13-11df636e1667`](#source-ctg-observation-nct00541047-2023-11-13-11df636e1667))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00541047-2023-11-13-11df636e1667`](#source-ctg-observation-nct00541047-2023-11-13-11df636e1667))

### Sources

<a id="source-ctg-observation-nct00541047-2023-11-13-11df636e1667"></a>
- **ClinicalTrials.gov record NCT00541047 · retained source version 2023-11-13:11df636e166735ba35e4c7a30dd3eb521b803194b709d12cc0af80f7325f07c2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00541047) (`ctg-observation-nct00541047-2023-11-13-11df636e1667`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00541047." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00541047-leuprolide-v1 SHA-256: 2aabe56419c6f2d5c2d219a39316a213a993d8906d8eaba7c457abff7b899481.

---

<a id="clinicaltrials-gov-nct00544830-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00544830

> PeptideScanner retained ClinicalTrials.gov record NCT00544830 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00544830-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00544830-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00544830-leuprolide-v1
- Content SHA-256: `2657425f473cb06c54dc382ee93ae73da0a5d73d8ecdf9eed03815cb07e811cd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00544830 ([`ctg-observation-nct00544830-2026-05-15-e0ad3462d102`](#source-ctg-observation-nct00544830-2026-05-15-e0ad3462d102))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00544830 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00544830-2026-05-15-e0ad3462d102`](#source-ctg-observation-nct00544830-2026-05-15-e0ad3462d102))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00544830 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00544830-2026-05-15-e0ad3462d102`](#source-ctg-observation-nct00544830-2026-05-15-e0ad3462d102))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00544830-2026-05-15-e0ad3462d102`](#source-ctg-observation-nct00544830-2026-05-15-e0ad3462d102))

### Sources

<a id="source-ctg-observation-nct00544830-2026-05-15-e0ad3462d102"></a>
- **ClinicalTrials.gov record NCT00544830 · retained source version 2026-05-15:e0ad3462d102751c79eec39cd0161e4df459484ea6dd585510b336dd149246b7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00544830) (`ctg-observation-nct00544830-2026-05-15-e0ad3462d102`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00544830." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00544830-leuprolide-v1 SHA-256: 2657425f473cb06c54dc382ee93ae73da0a5d73d8ecdf9eed03815cb07e811cd.

---

<a id="clinicaltrials-gov-nct00589472-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00589472

> PeptideScanner retained ClinicalTrials.gov record NCT00589472 at 2026-07-30T21:22:00.251Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00589472-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-10-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00589472-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00589472-leuprolide-v1
- Content SHA-256: `fd899fc5adf3de7f218b6cb7cf068b58cee518b5dce89e6384473efd41683daa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00589472 ([`ctg-observation-nct00589472-2017-10-06-babd4e5099da`](#source-ctg-observation-nct00589472-2017-10-06-babd4e5099da))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00589472 at 2026-07-30T21:22:00.251Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00589472-2017-10-06-babd4e5099da`](#source-ctg-observation-nct00589472-2017-10-06-babd4e5099da))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00589472 at 2026-07-30T21:22:00.251Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00589472-2017-10-06-babd4e5099da`](#source-ctg-observation-nct00589472-2017-10-06-babd4e5099da))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00589472-2017-10-06-babd4e5099da`](#source-ctg-observation-nct00589472-2017-10-06-babd4e5099da))

### Sources

<a id="source-ctg-observation-nct00589472-2017-10-06-babd4e5099da"></a>
- **ClinicalTrials.gov record NCT00589472 · retained source version 2017-10-06:babd4e5099da448225b5d65afe5d11c9a5112ea68846fab26ac36dfb3471b742** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00589472) (`ctg-observation-nct00589472-2017-10-06-babd4e5099da`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00589472." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00589472-leuprolide-v1 SHA-256: fd899fc5adf3de7f218b6cb7cf068b58cee518b5dce89e6384473efd41683daa.

---

<a id="clinicaltrials-gov-nct00631527-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00631527

> PeptideScanner retained ClinicalTrials.gov record NCT00631527 at 2026-07-30T21:43:54.453Z. Its registry update date was 2015-01-29, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00631527-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-01-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00631527-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00631527-leuprolide-v1
- Content SHA-256: `3a225b71d57f9c661ca0a9b69875f3f676aaac95866db21eaa2d19db9294dbf3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00631527 ([`ctg-observation-nct00631527-2015-01-29-f0b2ed50f61b`](#source-ctg-observation-nct00631527-2015-01-29-f0b2ed50f61b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00631527 at 2026-07-30T21:43:54.453Z. Its registry update date was 2015-01-29, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00631527-2015-01-29-f0b2ed50f61b`](#source-ctg-observation-nct00631527-2015-01-29-f0b2ed50f61b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00631527 at 2026-07-30T21:43:54.453Z. Its registry update date was 2015-01-29, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00631527-2015-01-29-f0b2ed50f61b`](#source-ctg-observation-nct00631527-2015-01-29-f0b2ed50f61b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00631527-2015-01-29-f0b2ed50f61b`](#source-ctg-observation-nct00631527-2015-01-29-f0b2ed50f61b))

### Sources

<a id="source-ctg-observation-nct00631527-2015-01-29-f0b2ed50f61b"></a>
- **ClinicalTrials.gov record NCT00631527 · retained source version 2015-01-29:f0b2ed50f61b6f2a1819f32b558331dd12fd6bd1642ac1cd20d607a548846761** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00631527) (`ctg-observation-nct00631527-2015-01-29-f0b2ed50f61b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00631527." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00631527-leuprolide-v1 SHA-256: 3a225b71d57f9c661ca0a9b69875f3f676aaac95866db21eaa2d19db9294dbf3.

---

<a id="clinicaltrials-gov-nct00653757-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00653757

> PeptideScanner retained ClinicalTrials.gov record NCT00653757 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-03-19, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00653757-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-03-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00653757-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00653757-leuprolide-v1
- Content SHA-256: `c83ee680a83daa731825c27f98fae84f4963b2f4ce33e398252e18710fad23b8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00653757 ([`ctg-observation-nct00653757-2012-03-19-b51fefbc2ee1`](#source-ctg-observation-nct00653757-2012-03-19-b51fefbc2ee1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00653757 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-03-19, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00653757-2012-03-19-b51fefbc2ee1`](#source-ctg-observation-nct00653757-2012-03-19-b51fefbc2ee1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00653757 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-03-19, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00653757-2012-03-19-b51fefbc2ee1`](#source-ctg-observation-nct00653757-2012-03-19-b51fefbc2ee1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00653757-2012-03-19-b51fefbc2ee1`](#source-ctg-observation-nct00653757-2012-03-19-b51fefbc2ee1))

### Sources

<a id="source-ctg-observation-nct00653757-2012-03-19-b51fefbc2ee1"></a>
- **ClinicalTrials.gov record NCT00653757 · retained source version 2012-03-19:b51fefbc2ee13d0a6067e943e8bac80c40661ab992b4dfe3987803389301b920** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00653757) (`ctg-observation-nct00653757-2012-03-19-b51fefbc2ee1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00653757." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00653757-leuprolide-v1 SHA-256: c83ee680a83daa731825c27f98fae84f4963b2f4ce33e398252e18710fad23b8.

---

<a id="clinicaltrials-gov-nct00669162-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00669162

> PeptideScanner retained ClinicalTrials.gov record NCT00669162 at 2026-07-30T20:48:52.438Z. Its registry update date was 2019-07-24, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00669162-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-07-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00669162-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00669162-leuprolide-v1
- Content SHA-256: `515a50ad8a3149d18745ad200b097024c804396e84d98f3c2fee1d624fb13001`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00669162 ([`ctg-observation-nct00669162-2019-07-24-2951722899ee`](#source-ctg-observation-nct00669162-2019-07-24-2951722899ee))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00669162 at 2026-07-30T20:48:52.438Z. Its registry update date was 2019-07-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00669162-2019-07-24-2951722899ee`](#source-ctg-observation-nct00669162-2019-07-24-2951722899ee))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00669162 at 2026-07-30T20:48:52.438Z. Its registry update date was 2019-07-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00669162-2019-07-24-2951722899ee`](#source-ctg-observation-nct00669162-2019-07-24-2951722899ee))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00669162-2019-07-24-2951722899ee`](#source-ctg-observation-nct00669162-2019-07-24-2951722899ee))

### Sources

<a id="source-ctg-observation-nct00669162-2019-07-24-2951722899ee"></a>
- **ClinicalTrials.gov record NCT00669162 · retained source version 2019-07-24:2951722899ee8f27a83841a3d632ec832a17c4ae9e41344690de16001452b52b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00669162) (`ctg-observation-nct00669162-2019-07-24-2951722899ee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00669162." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00669162-leuprolide-v1 SHA-256: 515a50ad8a3149d18745ad200b097024c804396e84d98f3c2fee1d624fb13001.

---

<a id="clinicaltrials-gov-nct00687739-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00687739

> PeptideScanner retained ClinicalTrials.gov record NCT00687739 at 2026-07-30T18:29:04.227Z. Its registry update date was 2025-04-01, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00687739-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00687739-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00687739-leuprolide-v1
- Content SHA-256: `3e9af549bfc8b732399b1c98e6aec95dd1f1d9638d8baf5b161d91b8631fc085`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00687739 ([`ctg-observation-nct00687739-2025-04-01-1fdaf5a914bd`](#source-ctg-observation-nct00687739-2025-04-01-1fdaf5a914bd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00687739 at 2026-07-30T18:29:04.227Z. Its registry update date was 2025-04-01, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00687739-2025-04-01-1fdaf5a914bd`](#source-ctg-observation-nct00687739-2025-04-01-1fdaf5a914bd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00687739 at 2026-07-30T18:29:04.227Z. Its registry update date was 2025-04-01, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00687739-2025-04-01-1fdaf5a914bd`](#source-ctg-observation-nct00687739-2025-04-01-1fdaf5a914bd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00687739-2025-04-01-1fdaf5a914bd`](#source-ctg-observation-nct00687739-2025-04-01-1fdaf5a914bd))

### Sources

<a id="source-ctg-observation-nct00687739-2025-04-01-1fdaf5a914bd"></a>
- **ClinicalTrials.gov record NCT00687739 · retained source version 2025-04-01:1fdaf5a914bd05131aab07def47d7f3e218e9fb793be6ae3ff8c425c271dae78** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00687739) (`ctg-observation-nct00687739-2025-04-01-1fdaf5a914bd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00687739." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00687739-leuprolide-v1 SHA-256: 3e9af549bfc8b732399b1c98e6aec95dd1f1d9638d8baf5b161d91b8631fc085.

---

<a id="clinicaltrials-gov-nct00805935-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00805935

> PeptideScanner retained ClinicalTrials.gov record NCT00805935 at 2026-07-30T22:14:20.915Z. Its registry update date was 2012-01-27, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00805935-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00805935-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00805935-leuprolide-v1
- Content SHA-256: `e1f4da00265dc4ed01b299a9bbd5150490a887aeb5f9565a971342bd40ed9fa1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00805935 ([`ctg-observation-nct00805935-2012-01-27-727b8c958905`](#source-ctg-observation-nct00805935-2012-01-27-727b8c958905))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00805935 at 2026-07-30T22:14:20.915Z. Its registry update date was 2012-01-27, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00805935-2012-01-27-727b8c958905`](#source-ctg-observation-nct00805935-2012-01-27-727b8c958905))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00805935 at 2026-07-30T22:14:20.915Z. Its registry update date was 2012-01-27, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00805935-2012-01-27-727b8c958905`](#source-ctg-observation-nct00805935-2012-01-27-727b8c958905))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00805935-2012-01-27-727b8c958905`](#source-ctg-observation-nct00805935-2012-01-27-727b8c958905))

### Sources

<a id="source-ctg-observation-nct00805935-2012-01-27-727b8c958905"></a>
- **ClinicalTrials.gov record NCT00805935 · retained source version 2012-01-27:727b8c958905cdb24f744a7aeaed2515609e08c427ee9255ba458cd94f6d4ca4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00805935) (`ctg-observation-nct00805935-2012-01-27-727b8c958905`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00805935." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00805935-leuprolide-v1 SHA-256: e1f4da00265dc4ed01b299a9bbd5150490a887aeb5f9565a971342bd40ed9fa1.

---

<a id="clinicaltrials-gov-nct00903162-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00903162

> PeptideScanner retained ClinicalTrials.gov record NCT00903162 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-18, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00903162-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-04-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00903162-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00903162-leuprolide-v1
- Content SHA-256: `41b8b8a9c7c652959f979af9d66bd54ca6708e6b279b3ebeee265b6577121a25`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00903162 ([`ctg-observation-nct00903162-2016-04-18-8e8d4e7351d1`](#source-ctg-observation-nct00903162-2016-04-18-8e8d4e7351d1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00903162 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00903162-2016-04-18-8e8d4e7351d1`](#source-ctg-observation-nct00903162-2016-04-18-8e8d4e7351d1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00903162 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00903162-2016-04-18-8e8d4e7351d1`](#source-ctg-observation-nct00903162-2016-04-18-8e8d4e7351d1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00903162-2016-04-18-8e8d4e7351d1`](#source-ctg-observation-nct00903162-2016-04-18-8e8d4e7351d1))

### Sources

<a id="source-ctg-observation-nct00903162-2016-04-18-8e8d4e7351d1"></a>
- **ClinicalTrials.gov record NCT00903162 · retained source version 2016-04-18:8e8d4e7351d14b57dcbe2e4145dd2be2bce30f7542eba6c9499dc12d19eb6790** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00903162) (`ctg-observation-nct00903162-2016-04-18-8e8d4e7351d1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00903162." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00903162-leuprolide-v1 SHA-256: 41b8b8a9c7c652959f979af9d66bd54ca6708e6b279b3ebeee265b6577121a25.

---

<a id="clinicaltrials-gov-nct00928434-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00928434

> PeptideScanner retained ClinicalTrials.gov record NCT00928434 at 2026-07-30T21:34:56.510Z. Its registry update date was 2016-12-13, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00928434-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-12-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00928434-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00928434-leuprolide-v1
- Content SHA-256: `24a9b14e634222f9f14ec402e12297ace9f4ebcf413cf603f5cde329208fed19`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00928434 ([`ctg-observation-nct00928434-2016-12-13-4abcb47214e2`](#source-ctg-observation-nct00928434-2016-12-13-4abcb47214e2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00928434 at 2026-07-30T21:34:56.510Z. Its registry update date was 2016-12-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00928434-2016-12-13-4abcb47214e2`](#source-ctg-observation-nct00928434-2016-12-13-4abcb47214e2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00928434 at 2026-07-30T21:34:56.510Z. Its registry update date was 2016-12-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00928434-2016-12-13-4abcb47214e2`](#source-ctg-observation-nct00928434-2016-12-13-4abcb47214e2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00928434-2016-12-13-4abcb47214e2`](#source-ctg-observation-nct00928434-2016-12-13-4abcb47214e2))

### Sources

<a id="source-ctg-observation-nct00928434-2016-12-13-4abcb47214e2"></a>
- **ClinicalTrials.gov record NCT00928434 · retained source version 2016-12-13:4abcb47214e22cf477bedf03f853abf09232ce934edb533a6d07e5d0ca31ebb7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00928434) (`ctg-observation-nct00928434-2016-12-13-4abcb47214e2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00928434." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00928434-leuprolide-v1 SHA-256: 24a9b14e634222f9f14ec402e12297ace9f4ebcf413cf603f5cde329208fed19.

---

<a id="clinicaltrials-gov-nct00936390-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00936390

> PeptideScanner retained ClinicalTrials.gov record NCT00936390 at 2026-07-30T16:22:22.345Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00936390-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00936390-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00936390-leuprolide-v1
- Content SHA-256: `fe811ee377d7d00f6941dbf48a15b7f047747622fb93b330b4fdd7abe13970a8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00936390 ([`ctg-observation-nct00936390-2026-03-06-2606c319011f`](#source-ctg-observation-nct00936390-2026-03-06-2606c319011f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00936390 at 2026-07-30T16:22:22.345Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00936390-2026-03-06-2606c319011f`](#source-ctg-observation-nct00936390-2026-03-06-2606c319011f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00936390 at 2026-07-30T16:22:22.345Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00936390-2026-03-06-2606c319011f`](#source-ctg-observation-nct00936390-2026-03-06-2606c319011f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00936390-2026-03-06-2606c319011f`](#source-ctg-observation-nct00936390-2026-03-06-2606c319011f))

### Sources

<a id="source-ctg-observation-nct00936390-2026-03-06-2606c319011f"></a>
- **ClinicalTrials.gov record NCT00936390 · retained source version 2026-03-06:2606c319011f624b02a5eb3729225332374e14a218f145e7d4a3944f228985c8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00936390) (`ctg-observation-nct00936390-2026-03-06-2606c319011f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00936390." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00936390-leuprolide-v1 SHA-256: fe811ee377d7d00f6941dbf48a15b7f047747622fb93b330b4fdd7abe13970a8.

---

<a id="clinicaltrials-gov-nct00943956-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT00943956

> PeptideScanner retained ClinicalTrials.gov record NCT00943956 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-05-25, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct00943956-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-05-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00943956-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00943956-leuprolide-v1
- Content SHA-256: `905efe96a4e20a35a8688f54aeb4db9833984b8f625282f530831c16b23a9c96`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00943956 ([`ctg-observation-nct00943956-2016-05-25-c5304ce387ab`](#source-ctg-observation-nct00943956-2016-05-25-c5304ce387ab))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00943956 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-05-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00943956-2016-05-25-c5304ce387ab`](#source-ctg-observation-nct00943956-2016-05-25-c5304ce387ab))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00943956 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-05-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct00943956-2016-05-25-c5304ce387ab`](#source-ctg-observation-nct00943956-2016-05-25-c5304ce387ab))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00943956-2016-05-25-c5304ce387ab`](#source-ctg-observation-nct00943956-2016-05-25-c5304ce387ab))

### Sources

<a id="source-ctg-observation-nct00943956-2016-05-25-c5304ce387ab"></a>
- **ClinicalTrials.gov record NCT00943956 · retained source version 2016-05-25:c5304ce387ab5703a8a3162d15b3be23236c9314bc4da6c9c8302196ce16f929** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00943956) (`ctg-observation-nct00943956-2016-05-25-c5304ce387ab`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00943956." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct00943956-leuprolide-v1 SHA-256: 905efe96a4e20a35a8688f54aeb4db9833984b8f625282f530831c16b23a9c96.

---

<a id="clinicaltrials-gov-nct01023061-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01023061

> PeptideScanner retained ClinicalTrials.gov record NCT01023061 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01023061-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-06-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01023061-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01023061-leuprolide-v1
- Content SHA-256: `aad35cde4b1b986ed8d064642802d785a4de941c674d84d56a78b7fa71178086`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01023061 ([`ctg-observation-nct01023061-2017-06-06-efa8c9e2ef9f`](#source-ctg-observation-nct01023061-2017-06-06-efa8c9e2ef9f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01023061 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01023061-2017-06-06-efa8c9e2ef9f`](#source-ctg-observation-nct01023061-2017-06-06-efa8c9e2ef9f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01023061 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01023061-2017-06-06-efa8c9e2ef9f`](#source-ctg-observation-nct01023061-2017-06-06-efa8c9e2ef9f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01023061-2017-06-06-efa8c9e2ef9f`](#source-ctg-observation-nct01023061-2017-06-06-efa8c9e2ef9f))

### Sources

<a id="source-ctg-observation-nct01023061-2017-06-06-efa8c9e2ef9f"></a>
- **ClinicalTrials.gov record NCT01023061 · retained source version 2017-06-06:efa8c9e2ef9fee3dc6a7b7682eb3f77b907ac5cb94f33d6e6a14bd4a893d78f3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01023061) (`ctg-observation-nct01023061-2017-06-06-efa8c9e2ef9f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01023061." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01023061-leuprolide-v1 SHA-256: aad35cde4b1b986ed8d064642802d785a4de941c674d84d56a78b7fa71178086.

---

<a id="clinicaltrials-gov-nct01076335-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01076335

> PeptideScanner retained ClinicalTrials.gov record NCT01076335 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-09-19, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01076335-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-09-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01076335-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01076335-leuprolide-v1
- Content SHA-256: `5b2e95601246f32e59896ebea7cd61e92215199cc6cb2ef8b609985ae7aa5637`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01076335 ([`ctg-observation-nct01076335-2016-09-19-154c30320fed`](#source-ctg-observation-nct01076335-2016-09-19-154c30320fed))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01076335 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-09-19, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01076335-2016-09-19-154c30320fed`](#source-ctg-observation-nct01076335-2016-09-19-154c30320fed))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01076335 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-09-19, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01076335-2016-09-19-154c30320fed`](#source-ctg-observation-nct01076335-2016-09-19-154c30320fed))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01076335-2016-09-19-154c30320fed`](#source-ctg-observation-nct01076335-2016-09-19-154c30320fed))

### Sources

<a id="source-ctg-observation-nct01076335-2016-09-19-154c30320fed"></a>
- **ClinicalTrials.gov record NCT01076335 · retained source version 2016-09-19:154c30320fed8077a5df6b53421946ce32b5c0d498507a7a133817415cd393d2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01076335) (`ctg-observation-nct01076335-2016-09-19-154c30320fed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01076335." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01076335-leuprolide-v1 SHA-256: 5b2e95601246f32e59896ebea7cd61e92215199cc6cb2ef8b609985ae7aa5637.

---

<a id="clinicaltrials-gov-nct01088529-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01088529

> PeptideScanner retained ClinicalTrials.gov record NCT01088529 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01088529-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-05-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01088529-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01088529-leuprolide-v1
- Content SHA-256: `31ee7f75f41b3a237cad3c4eddcebef44d6bcc714c2d9fe0689b2ecdb81ed3c0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01088529 ([`ctg-observation-nct01088529-2014-05-15-4b8b20b0f21c`](#source-ctg-observation-nct01088529-2014-05-15-4b8b20b0f21c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01088529 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-05-15, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01088529-2014-05-15-4b8b20b0f21c`](#source-ctg-observation-nct01088529-2014-05-15-4b8b20b0f21c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01088529 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-05-15, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01088529-2014-05-15-4b8b20b0f21c`](#source-ctg-observation-nct01088529-2014-05-15-4b8b20b0f21c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01088529-2014-05-15-4b8b20b0f21c`](#source-ctg-observation-nct01088529-2014-05-15-4b8b20b0f21c))

### Sources

<a id="source-ctg-observation-nct01088529-2014-05-15-4b8b20b0f21c"></a>
- **ClinicalTrials.gov record NCT01088529 · retained source version 2014-05-15:4b8b20b0f21cab674b1e7de600d7ffe58dc0a18fc6c24221d462f75891c4344b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01088529) (`ctg-observation-nct01088529-2014-05-15-4b8b20b0f21c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01088529." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01088529-leuprolide-v1 SHA-256: 31ee7f75f41b3a237cad3c4eddcebef44d6bcc714c2d9fe0689b2ecdb81ed3c0.

---

<a id="clinicaltrials-gov-nct01116401-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01116401

> PeptideScanner retained ClinicalTrials.gov record NCT01116401 at 2026-07-30T21:12:47.405Z. Its registry update date was 2018-01-23, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01116401-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-01-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01116401-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01116401-leuprolide-v1
- Content SHA-256: `982a9db1fbebbce13dcdaffc7fc348e1b9eb6ecb00bc80989c8aaae42088c683`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01116401 ([`ctg-observation-nct01116401-2018-01-23-5662ad964406`](#source-ctg-observation-nct01116401-2018-01-23-5662ad964406))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01116401 at 2026-07-30T21:12:47.405Z. Its registry update date was 2018-01-23, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01116401-2018-01-23-5662ad964406`](#source-ctg-observation-nct01116401-2018-01-23-5662ad964406))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01116401 at 2026-07-30T21:12:47.405Z. Its registry update date was 2018-01-23, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01116401-2018-01-23-5662ad964406`](#source-ctg-observation-nct01116401-2018-01-23-5662ad964406))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01116401-2018-01-23-5662ad964406`](#source-ctg-observation-nct01116401-2018-01-23-5662ad964406))

### Sources

<a id="source-ctg-observation-nct01116401-2018-01-23-5662ad964406"></a>
- **ClinicalTrials.gov record NCT01116401 · retained source version 2018-01-23:5662ad964406f5c3b034e0b1c388212858317bf068b4d1be51c3bee19d2253d7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01116401) (`ctg-observation-nct01116401-2018-01-23-5662ad964406`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01116401." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01116401-leuprolide-v1 SHA-256: 982a9db1fbebbce13dcdaffc7fc348e1b9eb6ecb00bc80989c8aaae42088c683.

---

<a id="clinicaltrials-gov-nct01120236-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01120236

> PeptideScanner retained ClinicalTrials.gov record NCT01120236 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01120236-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-02-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01120236-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01120236-leuprolide-v1
- Content SHA-256: `0287f154adc94405ecd376c3a1a2329a2d7d46926c89fff34219d4fad405b338`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01120236 ([`ctg-observation-nct01120236-2018-02-26-5e1c156754fa`](#source-ctg-observation-nct01120236-2018-02-26-5e1c156754fa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01120236 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-02-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01120236-2018-02-26-5e1c156754fa`](#source-ctg-observation-nct01120236-2018-02-26-5e1c156754fa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01120236 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-02-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01120236-2018-02-26-5e1c156754fa`](#source-ctg-observation-nct01120236-2018-02-26-5e1c156754fa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01120236-2018-02-26-5e1c156754fa`](#source-ctg-observation-nct01120236-2018-02-26-5e1c156754fa))

### Sources

<a id="source-ctg-observation-nct01120236-2018-02-26-5e1c156754fa"></a>
- **ClinicalTrials.gov record NCT01120236 · retained source version 2018-02-26:5e1c156754faa67ad7ef941711ecbe5eaf92f4900a8259d54125f6d4d9236b96** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01120236) (`ctg-observation-nct01120236-2018-02-26-5e1c156754fa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01120236." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01120236-leuprolide-v1 SHA-256: 0287f154adc94405ecd376c3a1a2329a2d7d46926c89fff34219d4fad405b338.

---

<a id="clinicaltrials-gov-nct01160328-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01160328

> PeptideScanner retained ClinicalTrials.gov record NCT01160328 at 2026-07-30T21:54:46.559Z. Its registry update date was 2014-05-14, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01160328-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-05-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01160328-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01160328-leuprolide-v1
- Content SHA-256: `278cd30fae4aa5bb7d368bf5dc67825626051c18426e8eed9ac88b27fa55fa3e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01160328 ([`ctg-observation-nct01160328-2014-05-14-d8b13898e74f`](#source-ctg-observation-nct01160328-2014-05-14-d8b13898e74f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01160328 at 2026-07-30T21:54:46.559Z. Its registry update date was 2014-05-14, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01160328-2014-05-14-d8b13898e74f`](#source-ctg-observation-nct01160328-2014-05-14-d8b13898e74f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01160328 at 2026-07-30T21:54:46.559Z. Its registry update date was 2014-05-14, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01160328-2014-05-14-d8b13898e74f`](#source-ctg-observation-nct01160328-2014-05-14-d8b13898e74f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01160328-2014-05-14-d8b13898e74f`](#source-ctg-observation-nct01160328-2014-05-14-d8b13898e74f))

### Sources

<a id="source-ctg-observation-nct01160328-2014-05-14-d8b13898e74f"></a>
- **ClinicalTrials.gov record NCT01160328 · retained source version 2014-05-14:d8b13898e74fbcbcae4cb486f536be85beb991d31f927fe93f71875bffadbb44** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01160328) (`ctg-observation-nct01160328-2014-05-14-d8b13898e74f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01160328." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01160328-leuprolide-v1 SHA-256: 278cd30fae4aa5bb7d368bf5dc67825626051c18426e8eed9ac88b27fa55fa3e.

---

<a id="clinicaltrials-gov-nct01194271-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01194271

> PeptideScanner retained ClinicalTrials.gov record NCT01194271 at 2026-07-30T18:43:56.180Z. Its registry update date was 2024-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01194271-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-06-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01194271-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01194271-leuprolide-v1
- Content SHA-256: `b532f4afba33b931e51cb45bf4594412e89171f0ffe8eec06d04255fbd01f102`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01194271 ([`ctg-observation-nct01194271-2024-06-06-d707664a9439`](#source-ctg-observation-nct01194271-2024-06-06-d707664a9439))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01194271 at 2026-07-30T18:43:56.180Z. Its registry update date was 2024-06-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01194271-2024-06-06-d707664a9439`](#source-ctg-observation-nct01194271-2024-06-06-d707664a9439))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01194271 at 2026-07-30T18:43:56.180Z. Its registry update date was 2024-06-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01194271-2024-06-06-d707664a9439`](#source-ctg-observation-nct01194271-2024-06-06-d707664a9439))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01194271-2024-06-06-d707664a9439`](#source-ctg-observation-nct01194271-2024-06-06-d707664a9439))

### Sources

<a id="source-ctg-observation-nct01194271-2024-06-06-d707664a9439"></a>
- **ClinicalTrials.gov record NCT01194271 · retained source version 2024-06-06:d707664a94399809aa7614d92a09f7bcfdd2335b7ee4863fd26c99a482df3c32** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01194271) (`ctg-observation-nct01194271-2024-06-06-d707664a9439`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01194271." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01194271-leuprolide-v1 SHA-256: b532f4afba33b931e51cb45bf4594412e89171f0ffe8eec06d04255fbd01f102.

---

<a id="clinicaltrials-gov-nct01338987-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01338987

> PeptideScanner retained ClinicalTrials.gov record NCT01338987 at 2026-07-30T20:05:17.853Z. Its registry update date was 2021-03-18, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01338987-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-03-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01338987-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01338987-leuprolide-v1
- Content SHA-256: `afd638a6fa528008c35280df48b7cbc902fcc955dde0988e7c4ddf33ac16c7bf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01338987 ([`ctg-observation-nct01338987-2021-03-18-8d21eaf9e97b`](#source-ctg-observation-nct01338987-2021-03-18-8d21eaf9e97b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01338987 at 2026-07-30T20:05:17.853Z. Its registry update date was 2021-03-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01338987-2021-03-18-8d21eaf9e97b`](#source-ctg-observation-nct01338987-2021-03-18-8d21eaf9e97b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01338987 at 2026-07-30T20:05:17.853Z. Its registry update date was 2021-03-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01338987-2021-03-18-8d21eaf9e97b`](#source-ctg-observation-nct01338987-2021-03-18-8d21eaf9e97b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01338987-2021-03-18-8d21eaf9e97b`](#source-ctg-observation-nct01338987-2021-03-18-8d21eaf9e97b))

### Sources

<a id="source-ctg-observation-nct01338987-2021-03-18-8d21eaf9e97b"></a>
- **ClinicalTrials.gov record NCT01338987 · retained source version 2021-03-18:8d21eaf9e97b84bfbcc950b658c0b86edfefc91df86fecf0a8d27cd86b46d076** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01338987) (`ctg-observation-nct01338987-2021-03-18-8d21eaf9e97b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01338987." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01338987-leuprolide-v1 SHA-256: afd638a6fa528008c35280df48b7cbc902fcc955dde0988e7c4ddf33ac16c7bf.

---

<a id="clinicaltrials-gov-nct01431391-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01431391

> PeptideScanner retained ClinicalTrials.gov record NCT01431391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-30, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01431391-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01431391-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01431391-leuprolide-v1
- Content SHA-256: `6fe9fda1badb3696b26f9b7c832a495e893f816d4531c136e70c372fb6edf4ca`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01431391 ([`ctg-observation-nct01431391-2017-05-30-e8997f72c533`](#source-ctg-observation-nct01431391-2017-05-30-e8997f72c533))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01431391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-30, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01431391-2017-05-30-e8997f72c533`](#source-ctg-observation-nct01431391-2017-05-30-e8997f72c533))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01431391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-30, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01431391-2017-05-30-e8997f72c533`](#source-ctg-observation-nct01431391-2017-05-30-e8997f72c533))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01431391-2017-05-30-e8997f72c533`](#source-ctg-observation-nct01431391-2017-05-30-e8997f72c533))

### Sources

<a id="source-ctg-observation-nct01431391-2017-05-30-e8997f72c533"></a>
- **ClinicalTrials.gov record NCT01431391 · retained source version 2017-05-30:e8997f72c533e9a58e6df211dba467baf8ed1d679f7603c04b9d2e307a506df1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01431391) (`ctg-observation-nct01431391-2017-05-30-e8997f72c533`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01431391." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01431391-leuprolide-v1 SHA-256: 6fe9fda1badb3696b26f9b7c832a495e893f816d4531c136e70c372fb6edf4ca.

---

<a id="clinicaltrials-gov-nct01669291-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01669291

> PeptideScanner retained ClinicalTrials.gov record NCT01669291 at 2026-07-30T21:54:46.557Z. Its registry update date was 2014-06-04, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01669291-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-06-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01669291-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01669291-leuprolide-v1
- Content SHA-256: `f9d3c48f76072f960b7d325511bd01009568cd153c3a14fe3fd76429b6b8a7ea`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01669291 ([`ctg-observation-nct01669291-2014-06-04-84f8fadef97f`](#source-ctg-observation-nct01669291-2014-06-04-84f8fadef97f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01669291 at 2026-07-30T21:54:46.557Z. Its registry update date was 2014-06-04, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01669291-2014-06-04-84f8fadef97f`](#source-ctg-observation-nct01669291-2014-06-04-84f8fadef97f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01669291 at 2026-07-30T21:54:46.557Z. Its registry update date was 2014-06-04, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01669291-2014-06-04-84f8fadef97f`](#source-ctg-observation-nct01669291-2014-06-04-84f8fadef97f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01669291-2014-06-04-84f8fadef97f`](#source-ctg-observation-nct01669291-2014-06-04-84f8fadef97f))

### Sources

<a id="source-ctg-observation-nct01669291-2014-06-04-84f8fadef97f"></a>
- **ClinicalTrials.gov record NCT01669291 · retained source version 2014-06-04:84f8fadef97fab545b32c73318502533ed21104aedc9064f9b7eefaafcc30cf6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01669291) (`ctg-observation-nct01669291-2014-06-04-84f8fadef97f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01669291." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01669291-leuprolide-v1 SHA-256: f9d3c48f76072f960b7d325511bd01009568cd153c3a14fe3fd76429b6b8a7ea.

---

<a id="clinicaltrials-gov-nct01674140-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01674140

> PeptideScanner retained ClinicalTrials.gov record NCT01674140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01674140-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-23
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01674140-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01674140-leuprolide-v1
- Content SHA-256: `f0a7a3eb0b281ecaca006c65c8ebe6e8b1fc6f2d7d500fc089508720e3f870c7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01674140 ([`ctg-observation-nct01674140-2026-10-23-2d242ec578f5`](#source-ctg-observation-nct01674140-2026-10-23-2d242ec578f5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01674140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01674140-2026-10-23-2d242ec578f5`](#source-ctg-observation-nct01674140-2026-10-23-2d242ec578f5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01674140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01674140-2026-10-23-2d242ec578f5`](#source-ctg-observation-nct01674140-2026-10-23-2d242ec578f5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01674140-2026-10-23-2d242ec578f5`](#source-ctg-observation-nct01674140-2026-10-23-2d242ec578f5))

### Sources

<a id="source-ctg-observation-nct01674140-2026-10-23-2d242ec578f5"></a>
- **ClinicalTrials.gov record NCT01674140 · retained source version 2026-10-23:2d242ec578f53685073115f4e9610fb1d84161940ff186463b7b7f565b47f48c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01674140) (`ctg-observation-nct01674140-2026-10-23-2d242ec578f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01674140." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01674140-leuprolide-v1 SHA-256: f0a7a3eb0b281ecaca006c65c8ebe6e8b1fc6f2d7d500fc089508720e3f870c7.

---

<a id="clinicaltrials-gov-nct01750398-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01750398

> PeptideScanner retained ClinicalTrials.gov record NCT01750398 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-05, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01750398-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-12-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01750398-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01750398-leuprolide-v1
- Content SHA-256: `12b081d0f36d5348c3400dbd4430c101085cf08e353d4c271ee4fa14c6328812`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01750398 ([`ctg-observation-nct01750398-2016-12-05-cd377aa439fc`](#source-ctg-observation-nct01750398-2016-12-05-cd377aa439fc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01750398 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-05, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01750398-2016-12-05-cd377aa439fc`](#source-ctg-observation-nct01750398-2016-12-05-cd377aa439fc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01750398 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-05, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01750398-2016-12-05-cd377aa439fc`](#source-ctg-observation-nct01750398-2016-12-05-cd377aa439fc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01750398-2016-12-05-cd377aa439fc`](#source-ctg-observation-nct01750398-2016-12-05-cd377aa439fc))

### Sources

<a id="source-ctg-observation-nct01750398-2016-12-05-cd377aa439fc"></a>
- **ClinicalTrials.gov record NCT01750398 · retained source version 2016-12-05:cd377aa439fcc1b575467dea09f4efd7faba9828fa34f3f645286d68684299f4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01750398) (`ctg-observation-nct01750398-2016-12-05-cd377aa439fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01750398." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01750398-leuprolide-v1 SHA-256: 12b081d0f36d5348c3400dbd4430c101085cf08e353d4c271ee4fa14c6328812.

---

<a id="clinicaltrials-gov-nct01762943-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01762943

> PeptideScanner retained ClinicalTrials.gov record NCT01762943 at 2026-07-30T21:22:00.263Z. Its registry update date was 2017-11-20, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01762943-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-11-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01762943-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01762943-leuprolide-v1
- Content SHA-256: `ee7aa0ea5d65efb5bcdc6fa332e5e2ae98d291c5cd23fcc2f89a1f16a3bc23c9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01762943 ([`ctg-observation-nct01762943-2017-11-20-c02f4091bcc2`](#source-ctg-observation-nct01762943-2017-11-20-c02f4091bcc2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01762943 at 2026-07-30T21:22:00.263Z. Its registry update date was 2017-11-20, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01762943-2017-11-20-c02f4091bcc2`](#source-ctg-observation-nct01762943-2017-11-20-c02f4091bcc2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01762943 at 2026-07-30T21:22:00.263Z. Its registry update date was 2017-11-20, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01762943-2017-11-20-c02f4091bcc2`](#source-ctg-observation-nct01762943-2017-11-20-c02f4091bcc2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01762943-2017-11-20-c02f4091bcc2`](#source-ctg-observation-nct01762943-2017-11-20-c02f4091bcc2))

### Sources

<a id="source-ctg-observation-nct01762943-2017-11-20-c02f4091bcc2"></a>
- **ClinicalTrials.gov record NCT01762943 · retained source version 2017-11-20:c02f4091bcc28960fd81ee74bec95ce1bc4246e81c5d269b02baf956a897fb41** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01762943) (`ctg-observation-nct01762943-2017-11-20-c02f4091bcc2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01762943." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01762943-leuprolide-v1 SHA-256: ee7aa0ea5d65efb5bcdc6fa332e5e2ae98d291c5cd23fcc2f89a1f16a3bc23c9.

---

<a id="clinicaltrials-gov-nct01786265-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT01786265

> PeptideScanner retained ClinicalTrials.gov record NCT01786265 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct01786265-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01786265-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01786265-leuprolide-v1
- Content SHA-256: `419f57cd7fb0e58a1357894e19c25f2ef2f112e52c5d13270f6738c235a86118`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01786265 ([`ctg-observation-nct01786265-2026-02-20-909ce07f04f7`](#source-ctg-observation-nct01786265-2026-02-20-909ce07f04f7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01786265 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01786265-2026-02-20-909ce07f04f7`](#source-ctg-observation-nct01786265-2026-02-20-909ce07f04f7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01786265 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct01786265-2026-02-20-909ce07f04f7`](#source-ctg-observation-nct01786265-2026-02-20-909ce07f04f7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01786265-2026-02-20-909ce07f04f7`](#source-ctg-observation-nct01786265-2026-02-20-909ce07f04f7))

### Sources

<a id="source-ctg-observation-nct01786265-2026-02-20-909ce07f04f7"></a>
- **ClinicalTrials.gov record NCT01786265 · retained source version 2026-02-20:909ce07f04f700017952f13e21051f84c150cc225cf3f83197605152a72919a0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01786265) (`ctg-observation-nct01786265-2026-02-20-909ce07f04f7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01786265." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct01786265-leuprolide-v1 SHA-256: 419f57cd7fb0e58a1357894e19c25f2ef2f112e52c5d13270f6738c235a86118.

---

<a id="clinicaltrials-gov-nct02023463-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02023463

> PeptideScanner retained ClinicalTrials.gov record NCT02023463 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02023463-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02023463-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02023463-leuprolide-v1
- Content SHA-256: `5ce68a8c38e0603f65090ef179967be52b63e4d3145bd25980f629e0bb634b1a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02023463 ([`ctg-observation-nct02023463-2025-11-25-557cd0274966`](#source-ctg-observation-nct02023463-2025-11-25-557cd0274966))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02023463 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02023463-2025-11-25-557cd0274966`](#source-ctg-observation-nct02023463-2025-11-25-557cd0274966))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02023463 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02023463-2025-11-25-557cd0274966`](#source-ctg-observation-nct02023463-2025-11-25-557cd0274966))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02023463-2025-11-25-557cd0274966`](#source-ctg-observation-nct02023463-2025-11-25-557cd0274966))

### Sources

<a id="source-ctg-observation-nct02023463-2025-11-25-557cd0274966"></a>
- **ClinicalTrials.gov record NCT02023463 · retained source version 2025-11-25:557cd02749669b598e441e9893ff63273654c35cf6f45a93f312dba01d7644af** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02023463) (`ctg-observation-nct02023463-2025-11-25-557cd0274966`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02023463." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02023463-leuprolide-v1 SHA-256: 5ce68a8c38e0603f65090ef179967be52b63e4d3145bd25980f629e0bb634b1a.

---

<a id="clinicaltrials-gov-nct02058706-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02058706

> PeptideScanner retained ClinicalTrials.gov record NCT02058706 at 2026-07-30T19:13:03.747Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02058706-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-05-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02058706-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02058706-leuprolide-v1
- Content SHA-256: `37875ed5fce5e1abff3bca61198b983dd024cb9c870f5e3398d1e5ca35168f99`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02058706 ([`ctg-observation-nct02058706-2023-05-10-c475e3365e41`](#source-ctg-observation-nct02058706-2023-05-10-c475e3365e41))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02058706 at 2026-07-30T19:13:03.747Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02058706-2023-05-10-c475e3365e41`](#source-ctg-observation-nct02058706-2023-05-10-c475e3365e41))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02058706 at 2026-07-30T19:13:03.747Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02058706-2023-05-10-c475e3365e41`](#source-ctg-observation-nct02058706-2023-05-10-c475e3365e41))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02058706-2023-05-10-c475e3365e41`](#source-ctg-observation-nct02058706-2023-05-10-c475e3365e41))

### Sources

<a id="source-ctg-observation-nct02058706-2023-05-10-c475e3365e41"></a>
- **ClinicalTrials.gov record NCT02058706 · retained source version 2023-05-10:c475e3365e412a752cd1a7630ebbadfd07749829c8a8cfdec6845acbb251db70** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02058706) (`ctg-observation-nct02058706-2023-05-10-c475e3365e41`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02058706." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02058706-leuprolide-v1 SHA-256: 37875ed5fce5e1abff3bca61198b983dd024cb9c870f5e3398d1e5ca35168f99.

---

<a id="clinicaltrials-gov-nct02059213-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02059213

> PeptideScanner retained ClinicalTrials.gov record NCT02059213 at 2026-07-30T20:22:36.939Z. Its registry update date was 2020-09-16, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02059213-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-09-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02059213-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02059213-leuprolide-v1
- Content SHA-256: `ed53b39a9869cbe85cdef42a17fa0b39a17c289936b998c019a1872c3d379737`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02059213 ([`ctg-observation-nct02059213-2020-09-16-036385976f6c`](#source-ctg-observation-nct02059213-2020-09-16-036385976f6c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02059213 at 2026-07-30T20:22:36.939Z. Its registry update date was 2020-09-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02059213-2020-09-16-036385976f6c`](#source-ctg-observation-nct02059213-2020-09-16-036385976f6c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02059213 at 2026-07-30T20:22:36.939Z. Its registry update date was 2020-09-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02059213-2020-09-16-036385976f6c`](#source-ctg-observation-nct02059213-2020-09-16-036385976f6c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02059213-2020-09-16-036385976f6c`](#source-ctg-observation-nct02059213-2020-09-16-036385976f6c))

### Sources

<a id="source-ctg-observation-nct02059213-2020-09-16-036385976f6c"></a>
- **ClinicalTrials.gov record NCT02059213 · retained source version 2020-09-16:036385976f6c9d58102064b4880ae3dc1702e5bd37440d665b9de0b6bf148d3e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02059213) (`ctg-observation-nct02059213-2020-09-16-036385976f6c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02059213." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02059213-leuprolide-v1 SHA-256: ed53b39a9869cbe85cdef42a17fa0b39a17c289936b998c019a1872c3d379737.

---

<a id="clinicaltrials-gov-nct02064036-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02064036

> PeptideScanner retained ClinicalTrials.gov record NCT02064036 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-18, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02064036-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-10-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02064036-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02064036-leuprolide-v1
- Content SHA-256: `ebeefc46982c529e7732e7b727362871cda7ef5911dc1ca240faa203c9c356c4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02064036 ([`ctg-observation-nct02064036-2022-10-18-7f576b6f5d72`](#source-ctg-observation-nct02064036-2022-10-18-7f576b6f5d72))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02064036 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02064036-2022-10-18-7f576b6f5d72`](#source-ctg-observation-nct02064036-2022-10-18-7f576b6f5d72))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02064036 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02064036-2022-10-18-7f576b6f5d72`](#source-ctg-observation-nct02064036-2022-10-18-7f576b6f5d72))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02064036-2022-10-18-7f576b6f5d72`](#source-ctg-observation-nct02064036-2022-10-18-7f576b6f5d72))

### Sources

<a id="source-ctg-observation-nct02064036-2022-10-18-7f576b6f5d72"></a>
- **ClinicalTrials.gov record NCT02064036 · retained source version 2022-10-18:7f576b6f5d726378b095f53e246fc9a3b50eb12e4bc04a5ce49fd642678befc2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02064036) (`ctg-observation-nct02064036-2022-10-18-7f576b6f5d72`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02064036." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02064036-leuprolide-v1 SHA-256: ebeefc46982c529e7732e7b727362871cda7ef5911dc1ca240faa203c9c356c4.

---

<a id="clinicaltrials-gov-nct02064582-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02064582

> PeptideScanner retained ClinicalTrials.gov record NCT02064582 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-12, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02064582-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-10-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02064582-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02064582-leuprolide-v1
- Content SHA-256: `9fe8dfbbba56af476b7264f2b0cc9725734e9f0d5219f3ffe76a274d5aca0879`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02064582 ([`ctg-observation-nct02064582-2020-10-12-5dddc1d384cc`](#source-ctg-observation-nct02064582-2020-10-12-5dddc1d384cc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02064582 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-12, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02064582-2020-10-12-5dddc1d384cc`](#source-ctg-observation-nct02064582-2020-10-12-5dddc1d384cc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02064582 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-12, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02064582-2020-10-12-5dddc1d384cc`](#source-ctg-observation-nct02064582-2020-10-12-5dddc1d384cc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02064582-2020-10-12-5dddc1d384cc`](#source-ctg-observation-nct02064582-2020-10-12-5dddc1d384cc))

### Sources

<a id="source-ctg-observation-nct02064582-2020-10-12-5dddc1d384cc"></a>
- **ClinicalTrials.gov record NCT02064582 · retained source version 2020-10-12:5dddc1d384cc316ca6363ac5cc1a68b9be51f38847246c2aad3d36c43210b377** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02064582) (`ctg-observation-nct02064582-2020-10-12-5dddc1d384cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02064582." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02064582-leuprolide-v1 SHA-256: 9fe8dfbbba56af476b7264f2b0cc9725734e9f0d5219f3ffe76a274d5aca0879.

---

<a id="clinicaltrials-gov-nct02107391-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02107391

> PeptideScanner retained ClinicalTrials.gov record NCT02107391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-24, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02107391-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02107391-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02107391-leuprolide-v1
- Content SHA-256: `022edfec3e46040e627beda27f5627116cc9b6a0de8cbfb4c2bbb9c20de0de9a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02107391 ([`ctg-observation-nct02107391-2017-05-24-d57bcbd1b2ad`](#source-ctg-observation-nct02107391-2017-05-24-d57bcbd1b2ad))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02107391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02107391-2017-05-24-d57bcbd1b2ad`](#source-ctg-observation-nct02107391-2017-05-24-d57bcbd1b2ad))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02107391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02107391-2017-05-24-d57bcbd1b2ad`](#source-ctg-observation-nct02107391-2017-05-24-d57bcbd1b2ad))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02107391-2017-05-24-d57bcbd1b2ad`](#source-ctg-observation-nct02107391-2017-05-24-d57bcbd1b2ad))

### Sources

<a id="source-ctg-observation-nct02107391-2017-05-24-d57bcbd1b2ad"></a>
- **ClinicalTrials.gov record NCT02107391 · retained source version 2017-05-24:d57bcbd1b2ad15428b0504265322704a7828ec7eb672f5f6378aa57dcd83ce5f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02107391) (`ctg-observation-nct02107391-2017-05-24-d57bcbd1b2ad`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02107391." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02107391-leuprolide-v1 SHA-256: 022edfec3e46040e627beda27f5627116cc9b6a0de8cbfb4c2bbb9c20de0de9a.

---

<a id="clinicaltrials-gov-nct02122198-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02122198

> PeptideScanner retained ClinicalTrials.gov record NCT02122198 at 2026-07-30T19:44:52.962Z. Its registry update date was 2022-01-10, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02122198-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-01-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02122198-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02122198-leuprolide-v1
- Content SHA-256: `400526c0860a7027bb8b68f7a8a3f5875b632733521b42f72a41923fa08b8f2f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02122198 ([`ctg-observation-nct02122198-2022-01-10-fa3f7b250b84`](#source-ctg-observation-nct02122198-2022-01-10-fa3f7b250b84))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02122198 at 2026-07-30T19:44:52.962Z. Its registry update date was 2022-01-10, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02122198-2022-01-10-fa3f7b250b84`](#source-ctg-observation-nct02122198-2022-01-10-fa3f7b250b84))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02122198 at 2026-07-30T19:44:52.962Z. Its registry update date was 2022-01-10, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02122198-2022-01-10-fa3f7b250b84`](#source-ctg-observation-nct02122198-2022-01-10-fa3f7b250b84))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02122198-2022-01-10-fa3f7b250b84`](#source-ctg-observation-nct02122198-2022-01-10-fa3f7b250b84))

### Sources

<a id="source-ctg-observation-nct02122198-2022-01-10-fa3f7b250b84"></a>
- **ClinicalTrials.gov record NCT02122198 · retained source version 2022-01-10:fa3f7b250b84900b127d73474bd512624833c6c7df10d262a692f80e922262bf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02122198) (`ctg-observation-nct02122198-2022-01-10-fa3f7b250b84`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02122198." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02122198-leuprolide-v1 SHA-256: 400526c0860a7027bb8b68f7a8a3f5875b632733521b42f72a41923fa08b8f2f.

---

<a id="clinicaltrials-gov-nct02268175-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02268175

> PeptideScanner retained ClinicalTrials.gov record NCT02268175 at 2026-07-30T19:40:58.917Z. Its registry update date was 2022-04-19, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02268175-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-04-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02268175-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02268175-leuprolide-v1
- Content SHA-256: `d3fe21bd09a2ebb9c40a04805fd604f2c36a009b9a5cdda645febb02129abcfb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02268175 ([`ctg-observation-nct02268175-2022-04-19-b395e1507c2c`](#source-ctg-observation-nct02268175-2022-04-19-b395e1507c2c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02268175 at 2026-07-30T19:40:58.917Z. Its registry update date was 2022-04-19, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02268175-2022-04-19-b395e1507c2c`](#source-ctg-observation-nct02268175-2022-04-19-b395e1507c2c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02268175 at 2026-07-30T19:40:58.917Z. Its registry update date was 2022-04-19, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02268175-2022-04-19-b395e1507c2c`](#source-ctg-observation-nct02268175-2022-04-19-b395e1507c2c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02268175-2022-04-19-b395e1507c2c`](#source-ctg-observation-nct02268175-2022-04-19-b395e1507c2c))

### Sources

<a id="source-ctg-observation-nct02268175-2022-04-19-b395e1507c2c"></a>
- **ClinicalTrials.gov record NCT02268175 · retained source version 2022-04-19:b395e1507c2c070a06e01cc4172ab56498539c655caf2a0cac0f203b77818a5c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02268175) (`ctg-observation-nct02268175-2022-04-19-b395e1507c2c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02268175." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02268175-leuprolide-v1 SHA-256: d3fe21bd09a2ebb9c40a04805fd604f2c36a009b9a5cdda645febb02129abcfb.

---

<a id="clinicaltrials-gov-nct02278185-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02278185

> PeptideScanner retained ClinicalTrials.gov record NCT02278185 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-11, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02278185-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02278185-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02278185-leuprolide-v1
- Content SHA-256: `23bb1ff17875eeba809c900f4de5b9006f6b9a58593f9fa1d06d8eca2cb47974`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02278185 ([`ctg-observation-nct02278185-2025-05-11-2a93dfe0b83c`](#source-ctg-observation-nct02278185-2025-05-11-2a93dfe0b83c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02278185 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-11, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02278185-2025-05-11-2a93dfe0b83c`](#source-ctg-observation-nct02278185-2025-05-11-2a93dfe0b83c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02278185 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-11, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02278185-2025-05-11-2a93dfe0b83c`](#source-ctg-observation-nct02278185-2025-05-11-2a93dfe0b83c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02278185-2025-05-11-2a93dfe0b83c`](#source-ctg-observation-nct02278185-2025-05-11-2a93dfe0b83c))

### Sources

<a id="source-ctg-observation-nct02278185-2025-05-11-2a93dfe0b83c"></a>
- **ClinicalTrials.gov record NCT02278185 · retained source version 2025-05-11:2a93dfe0b83ce705b7bf910da8041000355afc5104e4d2b4d4b0656fff89ee29** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02278185) (`ctg-observation-nct02278185-2025-05-11-2a93dfe0b83c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02278185." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02278185-leuprolide-v1 SHA-256: 23bb1ff17875eeba809c900f4de5b9006f6b9a58593f9fa1d06d8eca2cb47974.

---

<a id="clinicaltrials-gov-nct02319837-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02319837

> PeptideScanner retained ClinicalTrials.gov record NCT02319837 at 2026-08-10T18:10:03.933Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02319837-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02319837-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02319837-leuprolide-v1
- Content SHA-256: `00c8e3a51fbb797a5c016fd91b8f009386f0310d46c33ad02610cd94989a84a6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02319837 ([`ctg-observation-nct02319837-2026-07-09-55b32ef9265c`](#source-ctg-observation-nct02319837-2026-07-09-55b32ef9265c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02319837 at 2026-08-10T18:10:03.933Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02319837-2026-07-09-55b32ef9265c`](#source-ctg-observation-nct02319837-2026-07-09-55b32ef9265c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02319837 at 2026-08-10T18:10:03.933Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02319837-2026-07-09-55b32ef9265c`](#source-ctg-observation-nct02319837-2026-07-09-55b32ef9265c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02319837-2026-07-09-55b32ef9265c`](#source-ctg-observation-nct02319837-2026-07-09-55b32ef9265c))

### Sources

<a id="source-ctg-observation-nct02319837-2026-07-09-55b32ef9265c"></a>
- **ClinicalTrials.gov record NCT02319837 · retained source version 2026-07-09:55b32ef9265c11a8ab2d78aae5254007b51026b78f7af7137e19466158f70982** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02319837) (`ctg-observation-nct02319837-2026-07-09-55b32ef9265c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02319837." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02319837-leuprolide-v1 SHA-256: 00c8e3a51fbb797a5c016fd91b8f009386f0310d46c33ad02610cd94989a84a6.

---

<a id="clinicaltrials-gov-nct02366494-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02366494

> PeptideScanner retained ClinicalTrials.gov record NCT02366494 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02366494-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02366494-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02366494-leuprolide-v1
- Content SHA-256: `f830f01189e59f98d83cf959d902f0dc51c0fb650efc05eeaf194a010abd0785`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02366494 ([`ctg-observation-nct02366494-2024-11-25-360181d94a99`](#source-ctg-observation-nct02366494-2024-11-25-360181d94a99))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02366494 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02366494-2024-11-25-360181d94a99`](#source-ctg-observation-nct02366494-2024-11-25-360181d94a99))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02366494 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02366494-2024-11-25-360181d94a99`](#source-ctg-observation-nct02366494-2024-11-25-360181d94a99))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02366494-2024-11-25-360181d94a99`](#source-ctg-observation-nct02366494-2024-11-25-360181d94a99))

### Sources

<a id="source-ctg-observation-nct02366494-2024-11-25-360181d94a99"></a>
- **ClinicalTrials.gov record NCT02366494 · retained source version 2024-11-25:360181d94a99beee6b540cc74c78a389318227414b28b9adf71449a30e0843bf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02366494) (`ctg-observation-nct02366494-2024-11-25-360181d94a99`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02366494." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02366494-leuprolide-v1 SHA-256: f830f01189e59f98d83cf959d902f0dc51c0fb650efc05eeaf194a010abd0785.

---

<a id="clinicaltrials-gov-nct02543255-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02543255

> PeptideScanner retained ClinicalTrials.gov record NCT02543255 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02543255-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-01-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02543255-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02543255-leuprolide-v1
- Content SHA-256: `b8c0084a3dcdef471673e43bbebce2f66f9ba51bfe484313a89e528be584b345`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02543255 ([`ctg-observation-nct02543255-2024-01-31-030306fc208e`](#source-ctg-observation-nct02543255-2024-01-31-030306fc208e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02543255 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02543255-2024-01-31-030306fc208e`](#source-ctg-observation-nct02543255-2024-01-31-030306fc208e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02543255 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02543255-2024-01-31-030306fc208e`](#source-ctg-observation-nct02543255-2024-01-31-030306fc208e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02543255-2024-01-31-030306fc208e`](#source-ctg-observation-nct02543255-2024-01-31-030306fc208e))

### Sources

<a id="source-ctg-observation-nct02543255-2024-01-31-030306fc208e"></a>
- **ClinicalTrials.gov record NCT02543255 · retained source version 2024-01-31:030306fc208ee2f7dcd46c19a44355cc811d9f942b2df78e4d5ac783f4430063** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02543255) (`ctg-observation-nct02543255-2024-01-31-030306fc208e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02543255." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02543255-leuprolide-v1 SHA-256: b8c0084a3dcdef471673e43bbebce2f66f9ba51bfe484313a89e528be584b345.

---

<a id="clinicaltrials-gov-nct02685397-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02685397

> PeptideScanner retained ClinicalTrials.gov record NCT02685397 at 2026-07-30T18:37:14.689Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02685397-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-12-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02685397-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02685397-leuprolide-v1
- Content SHA-256: `96da2588faba62eedd046d41edf34ece8f2e4b886210c970f8438951e903edd6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02685397 ([`ctg-observation-nct02685397-2024-12-04-c0e487f59270`](#source-ctg-observation-nct02685397-2024-12-04-c0e487f59270))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02685397 at 2026-07-30T18:37:14.689Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02685397-2024-12-04-c0e487f59270`](#source-ctg-observation-nct02685397-2024-12-04-c0e487f59270))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02685397 at 2026-07-30T18:37:14.689Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02685397-2024-12-04-c0e487f59270`](#source-ctg-observation-nct02685397-2024-12-04-c0e487f59270))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02685397-2024-12-04-c0e487f59270`](#source-ctg-observation-nct02685397-2024-12-04-c0e487f59270))

### Sources

<a id="source-ctg-observation-nct02685397-2024-12-04-c0e487f59270"></a>
- **ClinicalTrials.gov record NCT02685397 · retained source version 2024-12-04:c0e487f59270583c77ae17f3d62c4cb2ae59dbe129c4dfb52e3458467ff75e6d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02685397) (`ctg-observation-nct02685397-2024-12-04-c0e487f59270`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02685397." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02685397-leuprolide-v1 SHA-256: 96da2588faba62eedd046d41edf34ece8f2e4b886210c970f8438951e903edd6.

---

<a id="clinicaltrials-gov-nct02716974-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02716974

> PeptideScanner retained ClinicalTrials.gov record NCT02716974 at 2026-07-30T19:36:31.405Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02716974-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-08-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02716974-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02716974-leuprolide-v1
- Content SHA-256: `6855a34ce3dd9bff1f495b34b4e925f1645b3d29276220a87ada761381ddc3a3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02716974 ([`ctg-observation-nct02716974-2022-08-04-ef6443d8759e`](#source-ctg-observation-nct02716974-2022-08-04-ef6443d8759e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02716974 at 2026-07-30T19:36:31.405Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02716974-2022-08-04-ef6443d8759e`](#source-ctg-observation-nct02716974-2022-08-04-ef6443d8759e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02716974 at 2026-07-30T19:36:31.405Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02716974-2022-08-04-ef6443d8759e`](#source-ctg-observation-nct02716974-2022-08-04-ef6443d8759e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02716974-2022-08-04-ef6443d8759e`](#source-ctg-observation-nct02716974-2022-08-04-ef6443d8759e))

### Sources

<a id="source-ctg-observation-nct02716974-2022-08-04-ef6443d8759e"></a>
- **ClinicalTrials.gov record NCT02716974 · retained source version 2022-08-04:ef6443d8759ead77a6f000503cf1d88249785020fb1fc28885b469b92f47aaa7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02716974) (`ctg-observation-nct02716974-2022-08-04-ef6443d8759e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02716974." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02716974-leuprolide-v1 SHA-256: 6855a34ce3dd9bff1f495b34b4e925f1645b3d29276220a87ada761381ddc3a3.

---

<a id="clinicaltrials-gov-nct02770391-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02770391

> PeptideScanner retained ClinicalTrials.gov record NCT02770391 at 2026-07-30T19:38:43.103Z. Its registry update date was 2022-06-21, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02770391-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-06-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02770391-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02770391-leuprolide-v1
- Content SHA-256: `c6e6651a2e76d4de4a9f840fd2dfe6b59c204900bf4d2fab5c7be7f728c7c5fd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02770391 ([`ctg-observation-nct02770391-2022-06-21-ead131305a5f`](#source-ctg-observation-nct02770391-2022-06-21-ead131305a5f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02770391 at 2026-07-30T19:38:43.103Z. Its registry update date was 2022-06-21, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02770391-2022-06-21-ead131305a5f`](#source-ctg-observation-nct02770391-2022-06-21-ead131305a5f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02770391 at 2026-07-30T19:38:43.103Z. Its registry update date was 2022-06-21, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02770391-2022-06-21-ead131305a5f`](#source-ctg-observation-nct02770391-2022-06-21-ead131305a5f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02770391-2022-06-21-ead131305a5f`](#source-ctg-observation-nct02770391-2022-06-21-ead131305a5f))

### Sources

<a id="source-ctg-observation-nct02770391-2022-06-21-ead131305a5f"></a>
- **ClinicalTrials.gov record NCT02770391 · retained source version 2022-06-21:ead131305a5f413ff45f190c4cc2b8465d0537a50e5af8ddd2ec6109af14cd72** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02770391) (`ctg-observation-nct02770391-2022-06-21-ead131305a5f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02770391." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02770391-leuprolide-v1 SHA-256: c6e6651a2e76d4de4a9f840fd2dfe6b59c204900bf4d2fab5c7be7f728c7c5fd.

---

<a id="clinicaltrials-gov-nct02772588-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02772588

> PeptideScanner retained ClinicalTrials.gov record NCT02772588 at 2026-07-30T16:20:49.312Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02772588-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02772588-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02772588-leuprolide-v1
- Content SHA-256: `4a59fca94d3d7cd976adaa5c2e27de9f30d03c8d5011b17005e31fd170a8a194`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02772588 ([`ctg-observation-nct02772588-2026-04-13-c6550edb4ba4`](#source-ctg-observation-nct02772588-2026-04-13-c6550edb4ba4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02772588 at 2026-07-30T16:20:49.312Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02772588-2026-04-13-c6550edb4ba4`](#source-ctg-observation-nct02772588-2026-04-13-c6550edb4ba4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02772588 at 2026-07-30T16:20:49.312Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02772588-2026-04-13-c6550edb4ba4`](#source-ctg-observation-nct02772588-2026-04-13-c6550edb4ba4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02772588-2026-04-13-c6550edb4ba4`](#source-ctg-observation-nct02772588-2026-04-13-c6550edb4ba4))

### Sources

<a id="source-ctg-observation-nct02772588-2026-04-13-c6550edb4ba4"></a>
- **ClinicalTrials.gov record NCT02772588 · retained source version 2026-04-13:c6550edb4ba4283e488069ecef5616c03e145fcbbfe15ca4e4d299548afbce1c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02772588) (`ctg-observation-nct02772588-2026-04-13-c6550edb4ba4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02772588." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02772588-leuprolide-v1 SHA-256: 4a59fca94d3d7cd976adaa5c2e27de9f30d03c8d5011b17005e31fd170a8a194.

---

<a id="clinicaltrials-gov-nct02903368-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02903368

> PeptideScanner retained ClinicalTrials.gov record NCT02903368 at 2026-07-30T18:26:04.260Z. Its registry update date was 2025-06-13, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02903368-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-06-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02903368-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02903368-leuprolide-v1
- Content SHA-256: `260b758bd90e20a03c94bc171932282dbb2580133dcfa472fdf84be394d323ed`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02903368 ([`ctg-observation-nct02903368-2025-06-13-db8b0313c8d0`](#source-ctg-observation-nct02903368-2025-06-13-db8b0313c8d0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02903368 at 2026-07-30T18:26:04.260Z. Its registry update date was 2025-06-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02903368-2025-06-13-db8b0313c8d0`](#source-ctg-observation-nct02903368-2025-06-13-db8b0313c8d0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02903368 at 2026-07-30T18:26:04.260Z. Its registry update date was 2025-06-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02903368-2025-06-13-db8b0313c8d0`](#source-ctg-observation-nct02903368-2025-06-13-db8b0313c8d0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02903368-2025-06-13-db8b0313c8d0`](#source-ctg-observation-nct02903368-2025-06-13-db8b0313c8d0))

### Sources

<a id="source-ctg-observation-nct02903368-2025-06-13-db8b0313c8d0"></a>
- **ClinicalTrials.gov record NCT02903368 · retained source version 2025-06-13:db8b0313c8d01f5d1de29cf9e9eea9df661c477a44df42b26ee123fc426079f5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02903368) (`ctg-observation-nct02903368-2025-06-13-db8b0313c8d0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02903368." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02903368-leuprolide-v1 SHA-256: 260b758bd90e20a03c94bc171932282dbb2580133dcfa472fdf84be394d323ed.

---

<a id="clinicaltrials-gov-nct02927392-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02927392

> PeptideScanner retained ClinicalTrials.gov record NCT02927392 at 2026-07-30T18:43:56.185Z. Its registry update date was 2024-06-13, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02927392-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-06-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02927392-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02927392-leuprolide-v1
- Content SHA-256: `e196747750888e4a09fb26a1d497397fcea7a5807ac6de23e817541216f3296f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02927392 ([`ctg-observation-nct02927392-2024-06-13-a31107e2cf3b`](#source-ctg-observation-nct02927392-2024-06-13-a31107e2cf3b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02927392 at 2026-07-30T18:43:56.185Z. Its registry update date was 2024-06-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02927392-2024-06-13-a31107e2cf3b`](#source-ctg-observation-nct02927392-2024-06-13-a31107e2cf3b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02927392 at 2026-07-30T18:43:56.185Z. Its registry update date was 2024-06-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02927392-2024-06-13-a31107e2cf3b`](#source-ctg-observation-nct02927392-2024-06-13-a31107e2cf3b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02927392-2024-06-13-a31107e2cf3b`](#source-ctg-observation-nct02927392-2024-06-13-a31107e2cf3b))

### Sources

<a id="source-ctg-observation-nct02927392-2024-06-13-a31107e2cf3b"></a>
- **ClinicalTrials.gov record NCT02927392 · retained source version 2024-06-13:a31107e2cf3b8b2a43af605c6a7508e15fda00278f495be5a9e002b0427697a8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02927392) (`ctg-observation-nct02927392-2024-06-13-a31107e2cf3b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02927392." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02927392-leuprolide-v1 SHA-256: e196747750888e4a09fb26a1d497397fcea7a5807ac6de23e817541216f3296f.

---

<a id="clinicaltrials-gov-nct02960022-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02960022

> PeptideScanner retained ClinicalTrials.gov record NCT02960022 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02960022-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02960022-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02960022-leuprolide-v1
- Content SHA-256: `df09b6d62aa705660530f96770716197e5dc4b11ee8245ff72d5b45c1352a668`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02960022 ([`ctg-observation-nct02960022-2026-04-13-c70b886810ae`](#source-ctg-observation-nct02960022-2026-04-13-c70b886810ae))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02960022 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02960022-2026-04-13-c70b886810ae`](#source-ctg-observation-nct02960022-2026-04-13-c70b886810ae))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02960022 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02960022-2026-04-13-c70b886810ae`](#source-ctg-observation-nct02960022-2026-04-13-c70b886810ae))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02960022-2026-04-13-c70b886810ae`](#source-ctg-observation-nct02960022-2026-04-13-c70b886810ae))

### Sources

<a id="source-ctg-observation-nct02960022-2026-04-13-c70b886810ae"></a>
- **ClinicalTrials.gov record NCT02960022 · retained source version 2026-04-13:c70b886810ae9b54a9c948e5eef3caeba6d2f8269f384271b2b9588c2ff87003** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02960022) (`ctg-observation-nct02960022-2026-04-13-c70b886810ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02960022." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02960022-leuprolide-v1 SHA-256: df09b6d62aa705660530f96770716197e5dc4b11ee8245ff72d5b45c1352a668.

---

<a id="clinicaltrials-gov-nct02969590-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT02969590

> PeptideScanner retained ClinicalTrials.gov record NCT02969590 at 2026-07-30T20:44:36.693Z. Its registry update date was 2019-10-18, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02969590-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-10-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02969590-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02969590-leuprolide-v1
- Content SHA-256: `822fe792018294f1bff38ed75ad7d8d4ad462dbf3174256d6c41dab12975bf40`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02969590 ([`ctg-observation-nct02969590-2019-10-18-41c8046a990e`](#source-ctg-observation-nct02969590-2019-10-18-41c8046a990e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02969590 at 2026-07-30T20:44:36.693Z. Its registry update date was 2019-10-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02969590-2019-10-18-41c8046a990e`](#source-ctg-observation-nct02969590-2019-10-18-41c8046a990e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02969590 at 2026-07-30T20:44:36.693Z. Its registry update date was 2019-10-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02969590-2019-10-18-41c8046a990e`](#source-ctg-observation-nct02969590-2019-10-18-41c8046a990e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02969590-2019-10-18-41c8046a990e`](#source-ctg-observation-nct02969590-2019-10-18-41c8046a990e))

### Sources

<a id="source-ctg-observation-nct02969590-2019-10-18-41c8046a990e"></a>
- **ClinicalTrials.gov record NCT02969590 · retained source version 2019-10-18:41c8046a990eda99771a07b810a7578bbf71a48bd4e79b450f5838a5f8e1ab85** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02969590) (`ctg-observation-nct02969590-2019-10-18-41c8046a990e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02969590." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct02969590-leuprolide-v1 SHA-256: 822fe792018294f1bff38ed75ad7d8d4ad462dbf3174256d6c41dab12975bf40.

---

<a id="clinicaltrials-gov-nct03035032-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT03035032

> PeptideScanner retained ClinicalTrials.gov record NCT03035032 at 2026-07-30T18:38:25.519Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct03035032-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-11-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03035032-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03035032-leuprolide-v1
- Content SHA-256: `0aea4fc2232e37f0b199581943547aec703fd0c219e4b6bcfa6951b22d6755c2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03035032 ([`ctg-observation-nct03035032-2024-11-26-468ab0201a13`](#source-ctg-observation-nct03035032-2024-11-26-468ab0201a13))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03035032 at 2026-07-30T18:38:25.519Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03035032-2024-11-26-468ab0201a13`](#source-ctg-observation-nct03035032-2024-11-26-468ab0201a13))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03035032 at 2026-07-30T18:38:25.519Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03035032-2024-11-26-468ab0201a13`](#source-ctg-observation-nct03035032-2024-11-26-468ab0201a13))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03035032-2024-11-26-468ab0201a13`](#source-ctg-observation-nct03035032-2024-11-26-468ab0201a13))

### Sources

<a id="source-ctg-observation-nct03035032-2024-11-26-468ab0201a13"></a>
- **ClinicalTrials.gov record NCT03035032 · retained source version 2024-11-26:468ab0201a13f57d96692af54646832726fd78f73b8476262f2c85649cb7f01c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03035032) (`ctg-observation-nct03035032-2024-11-26-468ab0201a13`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03035032." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03035032-leuprolide-v1 SHA-256: 0aea4fc2232e37f0b199581943547aec703fd0c219e4b6bcfa6951b22d6755c2.

---

<a id="clinicaltrials-gov-nct03043807-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT03043807

> PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct03043807-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-02-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03043807-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03043807-leuprolide-v1
- Content SHA-256: `19f5e3a7d4a5a66640749878d90fb045994fc4580eb121f01886c32ff3dad450`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03043807 ([`ctg-observation-nct03043807-2023-02-16-badb01aaa4f6`](#source-ctg-observation-nct03043807-2023-02-16-badb01aaa4f6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03043807-2023-02-16-badb01aaa4f6`](#source-ctg-observation-nct03043807-2023-02-16-badb01aaa4f6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03043807-2023-02-16-badb01aaa4f6`](#source-ctg-observation-nct03043807-2023-02-16-badb01aaa4f6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03043807-2023-02-16-badb01aaa4f6`](#source-ctg-observation-nct03043807-2023-02-16-badb01aaa4f6))

### Sources

<a id="source-ctg-observation-nct03043807-2023-02-16-badb01aaa4f6"></a>
- **ClinicalTrials.gov record NCT03043807 · retained source version 2023-02-16:badb01aaa4f67d045b6a2b9af505ed2fc25e645be40213f0402fe8b0d2da0ebe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03043807) (`ctg-observation-nct03043807-2023-02-16-badb01aaa4f6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03043807." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03043807-leuprolide-v1 SHA-256: 19f5e3a7d4a5a66640749878d90fb045994fc4580eb121f01886c32ff3dad450.

---

<a id="clinicaltrials-gov-nct03070886-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT03070886

> PeptideScanner retained ClinicalTrials.gov record NCT03070886 at 2026-07-30T16:19:03.056Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct03070886-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03070886-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03070886-leuprolide-v1
- Content SHA-256: `580a0a2f57ee3fc42986df6f04a17a11784b174f45c2fda4f7d479b1840283bc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03070886 ([`ctg-observation-nct03070886-2026-06-25-73b6ee0c06fe`](#source-ctg-observation-nct03070886-2026-06-25-73b6ee0c06fe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03070886 at 2026-07-30T16:19:03.056Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03070886-2026-06-25-73b6ee0c06fe`](#source-ctg-observation-nct03070886-2026-06-25-73b6ee0c06fe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03070886 at 2026-07-30T16:19:03.056Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03070886-2026-06-25-73b6ee0c06fe`](#source-ctg-observation-nct03070886-2026-06-25-73b6ee0c06fe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03070886-2026-06-25-73b6ee0c06fe`](#source-ctg-observation-nct03070886-2026-06-25-73b6ee0c06fe))

### Sources

<a id="source-ctg-observation-nct03070886-2026-06-25-73b6ee0c06fe"></a>
- **ClinicalTrials.gov record NCT03070886 · retained source version 2026-06-25:73b6ee0c06fe3c9dff9b8bff292852e7ab3dab85f61971d6960883d037021a86** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03070886) (`ctg-observation-nct03070886-2026-06-25-73b6ee0c06fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03070886." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03070886-leuprolide-v1 SHA-256: 580a0a2f57ee3fc42986df6f04a17a11784b174f45c2fda4f7d479b1840283bc.

---

<a id="clinicaltrials-gov-nct03085095-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT03085095

> PeptideScanner retained ClinicalTrials.gov record NCT03085095 at 2026-07-30T19:44:52.972Z. Its registry update date was 2022-01-18, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct03085095-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-01-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03085095-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03085095-leuprolide-v1
- Content SHA-256: `51516b2f9ae0820fdbcc8fe012e698105980cbfa574151ca67c7e3c2c3ad50b8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03085095 ([`ctg-observation-nct03085095-2022-01-18-17f50f6871ff`](#source-ctg-observation-nct03085095-2022-01-18-17f50f6871ff))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03085095 at 2026-07-30T19:44:52.972Z. Its registry update date was 2022-01-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03085095-2022-01-18-17f50f6871ff`](#source-ctg-observation-nct03085095-2022-01-18-17f50f6871ff))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03085095 at 2026-07-30T19:44:52.972Z. Its registry update date was 2022-01-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03085095-2022-01-18-17f50f6871ff`](#source-ctg-observation-nct03085095-2022-01-18-17f50f6871ff))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03085095-2022-01-18-17f50f6871ff`](#source-ctg-observation-nct03085095-2022-01-18-17f50f6871ff))

### Sources

<a id="source-ctg-observation-nct03085095-2022-01-18-17f50f6871ff"></a>
- **ClinicalTrials.gov record NCT03085095 · retained source version 2022-01-18:17f50f6871ff31195de294801b76f0fcb62ccd7fd313539493793c13efaa2d9e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03085095) (`ctg-observation-nct03085095-2022-01-18-17f50f6871ff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03085095." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03085095-leuprolide-v1 SHA-256: 51516b2f9ae0820fdbcc8fe012e698105980cbfa574151ca67c7e3c2c3ad50b8.

---

<a id="clinicaltrials-gov-nct03298087-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT03298087

> PeptideScanner retained ClinicalTrials.gov record NCT03298087 at 2026-07-30T18:23:09.823Z. Its registry update date was 2025-08-01, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct03298087-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03298087-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03298087-leuprolide-v1
- Content SHA-256: `6a17ec2707c1f561fc3c08c31aa651cfba4f88f694edd659108e5c3a905a2075`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03298087 ([`ctg-observation-nct03298087-2025-08-01-1e574250deb9`](#source-ctg-observation-nct03298087-2025-08-01-1e574250deb9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03298087 at 2026-07-30T18:23:09.823Z. Its registry update date was 2025-08-01, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03298087-2025-08-01-1e574250deb9`](#source-ctg-observation-nct03298087-2025-08-01-1e574250deb9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03298087 at 2026-07-30T18:23:09.823Z. Its registry update date was 2025-08-01, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03298087-2025-08-01-1e574250deb9`](#source-ctg-observation-nct03298087-2025-08-01-1e574250deb9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03298087-2025-08-01-1e574250deb9`](#source-ctg-observation-nct03298087-2025-08-01-1e574250deb9))

### Sources

<a id="source-ctg-observation-nct03298087-2025-08-01-1e574250deb9"></a>
- **ClinicalTrials.gov record NCT03298087 · retained source version 2025-08-01:1e574250deb9f71b245a382cae2b22737738a65f97de6f002790051ec6e7b403** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03298087) (`ctg-observation-nct03298087-2025-08-01-1e574250deb9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03298087." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03298087-leuprolide-v1 SHA-256: 6a17ec2707c1f561fc3c08c31aa651cfba4f88f694edd659108e5c3a905a2075.

---

<a id="clinicaltrials-gov-nct03678025-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT03678025

> PeptideScanner retained ClinicalTrials.gov record NCT03678025 at 2026-07-30T18:22:04.918Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct03678025-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03678025-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03678025-leuprolide-v1
- Content SHA-256: `3ca850e882d2b6dfde850d21a46b2ab83c7b72cd2eb7edb0014a98119cd87316`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03678025 ([`ctg-observation-nct03678025-2025-09-11-2d0ba947ec87`](#source-ctg-observation-nct03678025-2025-09-11-2d0ba947ec87))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03678025 at 2026-07-30T18:22:04.918Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03678025-2025-09-11-2d0ba947ec87`](#source-ctg-observation-nct03678025-2025-09-11-2d0ba947ec87))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03678025 at 2026-07-30T18:22:04.918Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03678025-2025-09-11-2d0ba947ec87`](#source-ctg-observation-nct03678025-2025-09-11-2d0ba947ec87))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03678025-2025-09-11-2d0ba947ec87`](#source-ctg-observation-nct03678025-2025-09-11-2d0ba947ec87))

### Sources

<a id="source-ctg-observation-nct03678025-2025-09-11-2d0ba947ec87"></a>
- **ClinicalTrials.gov record NCT03678025 · retained source version 2025-09-11:2d0ba947ec87417f439e82972719bb6f2614d15d250cd1b782b9edaef47d14f6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03678025) (`ctg-observation-nct03678025-2025-09-11-2d0ba947ec87`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03678025." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03678025-leuprolide-v1 SHA-256: 3ca850e882d2b6dfde850d21a46b2ab83c7b72cd2eb7edb0014a98119cd87316.

---

<a id="clinicaltrials-gov-nct03809000-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT03809000

> PeptideScanner retained ClinicalTrials.gov record NCT03809000 at 2026-07-30T18:18:33.523Z. Its registry update date was 2025-12-30, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct03809000-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03809000-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03809000-leuprolide-v1
- Content SHA-256: `c806d580c411a259bb1a52d5a8452e573f30c242e088cc37bfc39281473a5458`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03809000 ([`ctg-observation-nct03809000-2025-12-30-a123230df6e6`](#source-ctg-observation-nct03809000-2025-12-30-a123230df6e6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03809000 at 2026-07-30T18:18:33.523Z. Its registry update date was 2025-12-30, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03809000-2025-12-30-a123230df6e6`](#source-ctg-observation-nct03809000-2025-12-30-a123230df6e6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03809000 at 2026-07-30T18:18:33.523Z. Its registry update date was 2025-12-30, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03809000-2025-12-30-a123230df6e6`](#source-ctg-observation-nct03809000-2025-12-30-a123230df6e6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03809000-2025-12-30-a123230df6e6`](#source-ctg-observation-nct03809000-2025-12-30-a123230df6e6))

### Sources

<a id="source-ctg-observation-nct03809000-2025-12-30-a123230df6e6"></a>
- **ClinicalTrials.gov record NCT03809000 · retained source version 2025-12-30:a123230df6e649ca1fd4967f1f43f2315e5ab063d5c68ce979fd07128b91f3c6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03809000) (`ctg-observation-nct03809000-2025-12-30-a123230df6e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03809000." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03809000-leuprolide-v1 SHA-256: c806d580c411a259bb1a52d5a8452e573f30c242e088cc37bfc39281473a5458.

---

<a id="clinicaltrials-gov-nct03902951-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT03902951

> PeptideScanner retained ClinicalTrials.gov record NCT03902951 at 2026-07-30T16:23:45.660Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct03902951-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03902951-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03902951-leuprolide-v1
- Content SHA-256: `6ff602b32c9f78426f40342fbbb3286a8049e19dae8bed1b25dff446c0d8cff8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03902951 ([`ctg-observation-nct03902951-2026-02-05-b6d1f283a87b`](#source-ctg-observation-nct03902951-2026-02-05-b6d1f283a87b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03902951 at 2026-07-30T16:23:45.660Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03902951-2026-02-05-b6d1f283a87b`](#source-ctg-observation-nct03902951-2026-02-05-b6d1f283a87b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03902951 at 2026-07-30T16:23:45.660Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03902951-2026-02-05-b6d1f283a87b`](#source-ctg-observation-nct03902951-2026-02-05-b6d1f283a87b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03902951-2026-02-05-b6d1f283a87b`](#source-ctg-observation-nct03902951-2026-02-05-b6d1f283a87b))

### Sources

<a id="source-ctg-observation-nct03902951-2026-02-05-b6d1f283a87b"></a>
- **ClinicalTrials.gov record NCT03902951 · retained source version 2026-02-05:b6d1f283a87b56e1da5c1b8b21e861c7655e139d0cfd930015baca145adc43a3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03902951) (`ctg-observation-nct03902951-2026-02-05-b6d1f283a87b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03902951." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03902951-leuprolide-v1 SHA-256: 6ff602b32c9f78426f40342fbbb3286a8049e19dae8bed1b25dff446c0d8cff8.

---

<a id="clinicaltrials-gov-nct03944434-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT03944434

> PeptideScanner retained ClinicalTrials.gov record NCT03944434 at 2026-07-30T18:31:14.558Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct03944434-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-02-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03944434-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03944434-leuprolide-v1
- Content SHA-256: `87f21f970d75451bc32a5696797a52616da48282c11e595a9c7abf264651bb02`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03944434 ([`ctg-observation-nct03944434-2025-02-26-eae98ab7b7f6`](#source-ctg-observation-nct03944434-2025-02-26-eae98ab7b7f6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03944434 at 2026-07-30T18:31:14.558Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03944434-2025-02-26-eae98ab7b7f6`](#source-ctg-observation-nct03944434-2025-02-26-eae98ab7b7f6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03944434 at 2026-07-30T18:31:14.558Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03944434-2025-02-26-eae98ab7b7f6`](#source-ctg-observation-nct03944434-2025-02-26-eae98ab7b7f6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03944434-2025-02-26-eae98ab7b7f6`](#source-ctg-observation-nct03944434-2025-02-26-eae98ab7b7f6))

### Sources

<a id="source-ctg-observation-nct03944434-2025-02-26-eae98ab7b7f6"></a>
- **ClinicalTrials.gov record NCT03944434 · retained source version 2025-02-26:eae98ab7b7f609c708366713d23dbdd886b7dbd924a424af8026961ea30fb2e4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03944434) (`ctg-observation-nct03944434-2025-02-26-eae98ab7b7f6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03944434." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct03944434-leuprolide-v1 SHA-256: 87f21f970d75451bc32a5696797a52616da48282c11e595a9c7abf264651bb02.

---

<a id="clinicaltrials-gov-nct04126070-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT04126070

> PeptideScanner retained ClinicalTrials.gov record NCT04126070 at 2026-07-30T16:19:36.912Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct04126070-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04126070-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04126070-leuprolide-v1
- Content SHA-256: `074d99ec761b7328a0e838fe22c66c6713300e1e554d00ea3564dd170010e51a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04126070 ([`ctg-observation-nct04126070-2026-05-27-acf7514b1813`](#source-ctg-observation-nct04126070-2026-05-27-acf7514b1813))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04126070 at 2026-07-30T16:19:36.912Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04126070-2026-05-27-acf7514b1813`](#source-ctg-observation-nct04126070-2026-05-27-acf7514b1813))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04126070 at 2026-07-30T16:19:36.912Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04126070-2026-05-27-acf7514b1813`](#source-ctg-observation-nct04126070-2026-05-27-acf7514b1813))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04126070-2026-05-27-acf7514b1813`](#source-ctg-observation-nct04126070-2026-05-27-acf7514b1813))

### Sources

<a id="source-ctg-observation-nct04126070-2026-05-27-acf7514b1813"></a>
- **ClinicalTrials.gov record NCT04126070 · retained source version 2026-05-27:acf7514b1813d851d2aaf9053fd8824b54af7b498f6cc86f937ecd3f5be89b6d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04126070) (`ctg-observation-nct04126070-2026-05-27-acf7514b1813`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04126070." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04126070-leuprolide-v1 SHA-256: 074d99ec761b7328a0e838fe22c66c6713300e1e554d00ea3564dd170010e51a.

---

<a id="clinicaltrials-gov-nct04194554-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT04194554

> PeptideScanner retained ClinicalTrials.gov record NCT04194554 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct04194554-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04194554-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04194554-leuprolide-v1
- Content SHA-256: `3a088d9100c9340af620d16209fd8824b16a27756b33c360dc82caf968b1a4f0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04194554 ([`ctg-observation-nct04194554-2026-05-01-3ab71e3724cc`](#source-ctg-observation-nct04194554-2026-05-01-3ab71e3724cc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04194554 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04194554-2026-05-01-3ab71e3724cc`](#source-ctg-observation-nct04194554-2026-05-01-3ab71e3724cc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04194554 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04194554-2026-05-01-3ab71e3724cc`](#source-ctg-observation-nct04194554-2026-05-01-3ab71e3724cc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04194554-2026-05-01-3ab71e3724cc`](#source-ctg-observation-nct04194554-2026-05-01-3ab71e3724cc))

### Sources

<a id="source-ctg-observation-nct04194554-2026-05-01-3ab71e3724cc"></a>
- **ClinicalTrials.gov record NCT04194554 · retained source version 2026-05-01:3ab71e3724ccf10ab4d725f91ccc0c02e1a6677bf1c1ae8d55da47ebd7c9185a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04194554) (`ctg-observation-nct04194554-2026-05-01-3ab71e3724cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04194554." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04194554-leuprolide-v1 SHA-256: 3a088d9100c9340af620d16209fd8824b16a27756b33c360dc82caf968b1a4f0.

---

<a id="clinicaltrials-gov-nct04225221-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT04225221

> PeptideScanner retained ClinicalTrials.gov record NCT04225221 at 2026-07-30T19:37:37.629Z. Its registry update date was 2022-07-26, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct04225221-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-07-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04225221-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04225221-leuprolide-v1
- Content SHA-256: `9362542ba0750fedc132b57cdbb2178010d5387f5e3a7fb368ca7a4ecb9f465e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04225221 ([`ctg-observation-nct04225221-2022-07-26-04bf757033e0`](#source-ctg-observation-nct04225221-2022-07-26-04bf757033e0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04225221 at 2026-07-30T19:37:37.629Z. Its registry update date was 2022-07-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04225221-2022-07-26-04bf757033e0`](#source-ctg-observation-nct04225221-2022-07-26-04bf757033e0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04225221 at 2026-07-30T19:37:37.629Z. Its registry update date was 2022-07-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04225221-2022-07-26-04bf757033e0`](#source-ctg-observation-nct04225221-2022-07-26-04bf757033e0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04225221-2022-07-26-04bf757033e0`](#source-ctg-observation-nct04225221-2022-07-26-04bf757033e0))

### Sources

<a id="source-ctg-observation-nct04225221-2022-07-26-04bf757033e0"></a>
- **ClinicalTrials.gov record NCT04225221 · retained source version 2022-07-26:04bf757033e0b18a86022ef73679491c76b8759929a89f8cc3c9645d8c7d04de** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04225221) (`ctg-observation-nct04225221-2022-07-26-04bf757033e0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04225221." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04225221-leuprolide-v1 SHA-256: 9362542ba0750fedc132b57cdbb2178010d5387f5e3a7fb368ca7a4ecb9f465e.

---

<a id="clinicaltrials-gov-nct04423211-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT04423211

> PeptideScanner retained ClinicalTrials.gov record NCT04423211 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct04423211-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04423211-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04423211-leuprolide-v1
- Content SHA-256: `3586e6cbc94760300763b2999f65ec83da9a77ab8995d42ce8975b0e1c7514b5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04423211 ([`ctg-observation-nct04423211-2026-06-18-6f2cde3ab517`](#source-ctg-observation-nct04423211-2026-06-18-6f2cde3ab517))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04423211 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04423211-2026-06-18-6f2cde3ab517`](#source-ctg-observation-nct04423211-2026-06-18-6f2cde3ab517))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04423211 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04423211-2026-06-18-6f2cde3ab517`](#source-ctg-observation-nct04423211-2026-06-18-6f2cde3ab517))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04423211-2026-06-18-6f2cde3ab517`](#source-ctg-observation-nct04423211-2026-06-18-6f2cde3ab517))

### Sources

<a id="source-ctg-observation-nct04423211-2026-06-18-6f2cde3ab517"></a>
- **ClinicalTrials.gov record NCT04423211 · retained source version 2026-06-18:6f2cde3ab51756553871de9a548a2c0c5338f4078f78ffbe32e5744e249a5c71** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04423211) (`ctg-observation-nct04423211-2026-06-18-6f2cde3ab517`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04423211." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04423211-leuprolide-v1 SHA-256: 3586e6cbc94760300763b2999f65ec83da9a77ab8995d42ce8975b0e1c7514b5.

---

<a id="clinicaltrials-gov-nct04455750-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT04455750

> PeptideScanner retained ClinicalTrials.gov record NCT04455750 at 2026-07-30T16:23:45.647Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct04455750-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04455750-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04455750-leuprolide-v1
- Content SHA-256: `2f06e20e2cc50fe8b4d28325300f2efa601bd769b1c37d84615b29274b8652b5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04455750 ([`ctg-observation-nct04455750-2026-02-05-5c5a09fb5ea1`](#source-ctg-observation-nct04455750-2026-02-05-5c5a09fb5ea1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04455750 at 2026-07-30T16:23:45.647Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04455750-2026-02-05-5c5a09fb5ea1`](#source-ctg-observation-nct04455750-2026-02-05-5c5a09fb5ea1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04455750 at 2026-07-30T16:23:45.647Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04455750-2026-02-05-5c5a09fb5ea1`](#source-ctg-observation-nct04455750-2026-02-05-5c5a09fb5ea1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04455750-2026-02-05-5c5a09fb5ea1`](#source-ctg-observation-nct04455750-2026-02-05-5c5a09fb5ea1))

### Sources

<a id="source-ctg-observation-nct04455750-2026-02-05-5c5a09fb5ea1"></a>
- **ClinicalTrials.gov record NCT04455750 · retained source version 2026-02-05:5c5a09fb5ea1fc894ee4d3c14f546cd2e31f8c5ec97ca27f0e682a95c024c3dc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04455750) (`ctg-observation-nct04455750-2026-02-05-5c5a09fb5ea1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04455750." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04455750-leuprolide-v1 SHA-256: 2f06e20e2cc50fe8b4d28325300f2efa601bd769b1c37d84615b29274b8652b5.

---

<a id="clinicaltrials-gov-nct04484818-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT04484818

> PeptideScanner retained ClinicalTrials.gov record NCT04484818 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct04484818-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04484818-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04484818-leuprolide-v1
- Content SHA-256: `a41b6bd49220f8bf2b072586f17ad3ca188b2d515fd84fcebd3cb4ef27567ba8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04484818 ([`ctg-observation-nct04484818-2026-07-28-cc6f51af5e73`](#source-ctg-observation-nct04484818-2026-07-28-cc6f51af5e73))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04484818 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04484818-2026-07-28-cc6f51af5e73`](#source-ctg-observation-nct04484818-2026-07-28-cc6f51af5e73))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04484818 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04484818-2026-07-28-cc6f51af5e73`](#source-ctg-observation-nct04484818-2026-07-28-cc6f51af5e73))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04484818-2026-07-28-cc6f51af5e73`](#source-ctg-observation-nct04484818-2026-07-28-cc6f51af5e73))

### Sources

<a id="source-ctg-observation-nct04484818-2026-07-28-cc6f51af5e73"></a>
- **ClinicalTrials.gov record NCT04484818 · retained source version 2026-07-28:cc6f51af5e73f6bb604acfb46c8f35f6f8fc20b4b3bb0cdc91ce4b4732674b30** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04484818) (`ctg-observation-nct04484818-2026-07-28-cc6f51af5e73`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04484818." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04484818-leuprolide-v1 SHA-256: a41b6bd49220f8bf2b072586f17ad3ca188b2d515fd84fcebd3cb4ef27567ba8.

---

<a id="clinicaltrials-gov-nct04734730-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT04734730

> PeptideScanner retained ClinicalTrials.gov record NCT04734730 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct04734730-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04734730-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04734730-leuprolide-v1
- Content SHA-256: `947e5ff39286406a926fd07e5c954b385c30d325ce7eb584b765d4150742ff52`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04734730 ([`ctg-observation-nct04734730-2026-01-28-371cd5ffd153`](#source-ctg-observation-nct04734730-2026-01-28-371cd5ffd153))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04734730 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04734730-2026-01-28-371cd5ffd153`](#source-ctg-observation-nct04734730-2026-01-28-371cd5ffd153))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04734730 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04734730-2026-01-28-371cd5ffd153`](#source-ctg-observation-nct04734730-2026-01-28-371cd5ffd153))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04734730-2026-01-28-371cd5ffd153`](#source-ctg-observation-nct04734730-2026-01-28-371cd5ffd153))

### Sources

<a id="source-ctg-observation-nct04734730-2026-01-28-371cd5ffd153"></a>
- **ClinicalTrials.gov record NCT04734730 · retained source version 2026-01-28:371cd5ffd1536aeb267768453ada839f374fc6a92a3707ef2563b4e9b5441b68** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04734730) (`ctg-observation-nct04734730-2026-01-28-371cd5ffd153`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04734730." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04734730-leuprolide-v1 SHA-256: 947e5ff39286406a926fd07e5c954b385c30d325ce7eb584b765d4150742ff52.

---

<a id="clinicaltrials-gov-nct04897958-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT04897958

> PeptideScanner retained ClinicalTrials.gov record NCT04897958 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct04897958-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04897958-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04897958-leuprolide-v1
- Content SHA-256: `d865499f78a8ff0077bcf74b76dd425bc3753e3b570b3582d2784c871110faec`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04897958 ([`ctg-observation-nct04897958-2023-07-27-af2cf16ac04b`](#source-ctg-observation-nct04897958-2023-07-27-af2cf16ac04b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04897958 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04897958-2023-07-27-af2cf16ac04b`](#source-ctg-observation-nct04897958-2023-07-27-af2cf16ac04b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04897958 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04897958-2023-07-27-af2cf16ac04b`](#source-ctg-observation-nct04897958-2023-07-27-af2cf16ac04b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04897958-2023-07-27-af2cf16ac04b`](#source-ctg-observation-nct04897958-2023-07-27-af2cf16ac04b))

### Sources

<a id="source-ctg-observation-nct04897958-2023-07-27-af2cf16ac04b"></a>
- **ClinicalTrials.gov record NCT04897958 · retained source version 2023-07-27:af2cf16ac04b07f0bd120b0121da2723528e68d078e64f2c62d8e62ac8cf4bf3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04897958) (`ctg-observation-nct04897958-2023-07-27-af2cf16ac04b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04897958." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct04897958-leuprolide-v1 SHA-256: d865499f78a8ff0077bcf74b76dd425bc3753e3b570b3582d2784c871110faec.

---

<a id="clinicaltrials-gov-nct05189457-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT05189457

> PeptideScanner retained ClinicalTrials.gov record NCT05189457 at 2026-07-30T18:18:33.510Z. Its registry update date was 2025-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct05189457-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05189457-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05189457-leuprolide-v1
- Content SHA-256: `619aee3cc63cb96c78cdab62a911ad37966d915701ee8bf138112cfb5ac588c0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05189457 ([`ctg-observation-nct05189457-2025-12-04-6ddc10d5ced2`](#source-ctg-observation-nct05189457-2025-12-04-6ddc10d5ced2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05189457 at 2026-07-30T18:18:33.510Z. Its registry update date was 2025-12-04, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05189457-2025-12-04-6ddc10d5ced2`](#source-ctg-observation-nct05189457-2025-12-04-6ddc10d5ced2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05189457 at 2026-07-30T18:18:33.510Z. Its registry update date was 2025-12-04, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05189457-2025-12-04-6ddc10d5ced2`](#source-ctg-observation-nct05189457-2025-12-04-6ddc10d5ced2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05189457-2025-12-04-6ddc10d5ced2`](#source-ctg-observation-nct05189457-2025-12-04-6ddc10d5ced2))

### Sources

<a id="source-ctg-observation-nct05189457-2025-12-04-6ddc10d5ced2"></a>
- **ClinicalTrials.gov record NCT05189457 · retained source version 2025-12-04:6ddc10d5ced2059a7d3bf24736feb090b41775cb304becef7cc0a79c252c6812** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05189457) (`ctg-observation-nct05189457-2025-12-04-6ddc10d5ced2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05189457." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05189457-leuprolide-v1 SHA-256: 619aee3cc63cb96c78cdab62a911ad37966d915701ee8bf138112cfb5ac588c0.

---

<a id="clinicaltrials-gov-nct05320406-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT05320406

> PeptideScanner retained ClinicalTrials.gov record NCT05320406 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct05320406-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05320406-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05320406-leuprolide-v1
- Content SHA-256: `bd2384f33848ab8ed5e0f2908b626ec03674a90c8f8721fd7965312e0b96fddd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05320406 ([`ctg-observation-nct05320406-2026-02-12-5b7c8fc9a5de`](#source-ctg-observation-nct05320406-2026-02-12-5b7c8fc9a5de))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05320406 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05320406-2026-02-12-5b7c8fc9a5de`](#source-ctg-observation-nct05320406-2026-02-12-5b7c8fc9a5de))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05320406 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05320406-2026-02-12-5b7c8fc9a5de`](#source-ctg-observation-nct05320406-2026-02-12-5b7c8fc9a5de))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05320406-2026-02-12-5b7c8fc9a5de`](#source-ctg-observation-nct05320406-2026-02-12-5b7c8fc9a5de))

### Sources

<a id="source-ctg-observation-nct05320406-2026-02-12-5b7c8fc9a5de"></a>
- **ClinicalTrials.gov record NCT05320406 · retained source version 2026-02-12:5b7c8fc9a5de1c11d12cf501b09eb73c03994265728b7c9c62181c1349c9c903** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05320406) (`ctg-observation-nct05320406-2026-02-12-5b7c8fc9a5de`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05320406." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05320406-leuprolide-v1 SHA-256: bd2384f33848ab8ed5e0f2908b626ec03674a90c8f8721fd7965312e0b96fddd.

---

<a id="clinicaltrials-gov-nct05498272-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT05498272

> PeptideScanner retained ClinicalTrials.gov record NCT05498272 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct05498272-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-10
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05498272-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05498272-leuprolide-v1
- Content SHA-256: `0bc456b3a9e63f6d643a40a39187f13378d5a713b366e86e473c672fffff228b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05498272 ([`ctg-observation-nct05498272-2026-07-10-4d02fa3bf216`](#source-ctg-observation-nct05498272-2026-07-10-4d02fa3bf216))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05498272 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05498272-2026-07-10-4d02fa3bf216`](#source-ctg-observation-nct05498272-2026-07-10-4d02fa3bf216))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05498272 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05498272-2026-07-10-4d02fa3bf216`](#source-ctg-observation-nct05498272-2026-07-10-4d02fa3bf216))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05498272-2026-07-10-4d02fa3bf216`](#source-ctg-observation-nct05498272-2026-07-10-4d02fa3bf216))

### Sources

<a id="source-ctg-observation-nct05498272-2026-07-10-4d02fa3bf216"></a>
- **ClinicalTrials.gov record NCT05498272 · retained source version 2026-07-10:4d02fa3bf216bd602c0a3f45c9e6750e2c1aa84cbcfbdd8f7e7e899533c35b3b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05498272) (`ctg-observation-nct05498272-2026-07-10-4d02fa3bf216`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05498272." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05498272-leuprolide-v1 SHA-256: 0bc456b3a9e63f6d643a40a39187f13378d5a713b366e86e473c672fffff228b.

---

<a id="clinicaltrials-gov-nct05605964-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT05605964

> PeptideScanner retained ClinicalTrials.gov record NCT05605964 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct05605964-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05605964-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05605964-leuprolide-v1
- Content SHA-256: `d078ba60bc3b7f80453417b475e6947ab608c07217ab4180404bf6b583d200c4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05605964 ([`ctg-observation-nct05605964-2026-06-15-2ba253d2d727`](#source-ctg-observation-nct05605964-2026-06-15-2ba253d2d727))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05605964 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05605964-2026-06-15-2ba253d2d727`](#source-ctg-observation-nct05605964-2026-06-15-2ba253d2d727))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05605964 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05605964-2026-06-15-2ba253d2d727`](#source-ctg-observation-nct05605964-2026-06-15-2ba253d2d727))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05605964-2026-06-15-2ba253d2d727`](#source-ctg-observation-nct05605964-2026-06-15-2ba253d2d727))

### Sources

<a id="source-ctg-observation-nct05605964-2026-06-15-2ba253d2d727"></a>
- **ClinicalTrials.gov record NCT05605964 · retained source version 2026-06-15:2ba253d2d7274b05b0fc39bd4a34f3b28500cd37e8aaeeae1dff6cac517bfa40** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05605964) (`ctg-observation-nct05605964-2026-06-15-2ba253d2d727`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05605964." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05605964-leuprolide-v1 SHA-256: d078ba60bc3b7f80453417b475e6947ab608c07217ab4180404bf6b583d200c4.

---

<a id="clinicaltrials-gov-nct05669664-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT05669664

> PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct05669664-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05669664-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05669664-leuprolide-v1
- Content SHA-256: `345e1ab970c51f3669bfbd3b3b14bba831af470561d698bb2f5ed868586dfb35`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05669664 ([`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2`](#source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2`](#source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2`](#source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2`](#source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2))

### Sources

<a id="source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2"></a>
- **ClinicalTrials.gov record NCT05669664 · retained source version 2026-06-17:1cc9e92daca2e48442a97e4d66e5a7adcbabfa6fda01a0441097da551cf8d473** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05669664) (`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05669664." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05669664-leuprolide-v1 SHA-256: 345e1ab970c51f3669bfbd3b3b14bba831af470561d698bb2f5ed868586dfb35.

---

<a id="clinicaltrials-gov-nct05669664-leuprolide-v2"></a>

## ClinicalTrials.gov record NCT05669664

> PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct05669664-leuprolide:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05669664-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05669664-leuprolide-v2
- Content SHA-256: `9064e6afbed82fb219349d493fea8acf7c384a183e2782d440437b208fa26056`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05669664 ([`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2`](#source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2`](#source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2`](#source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2`](#source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2))

### Sources

<a id="source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2"></a>
- **ClinicalTrials.gov record NCT05669664 · retained source version 2026-11-16:f51e846025c33d2a6185a83c6915ed112fda6b9b5c9880bd640e171be3a0141c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05669664) (`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2`)

### Correction lineage

updated on 2026-11-16: ClinicalTrials.gov posted a newer version of NCT05669664, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2`](#source-ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05669664." Version 2, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05669664-leuprolide-v2 SHA-256: 9064e6afbed82fb219349d493fea8acf7c384a183e2782d440437b208fa26056.

---

<a id="clinicaltrials-gov-nct05700903-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT05700903

> PeptideScanner retained ClinicalTrials.gov record NCT05700903 at 2026-07-30T16:22:22.343Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct05700903-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05700903-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05700903-leuprolide-v1
- Content SHA-256: `a63180caed0e5d2f0c71fbe42d4611b16c4ca464e9c4b0373e2c3a382dd9b2a7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05700903 ([`ctg-observation-nct05700903-2026-03-02-c7eb5bedb4e3`](#source-ctg-observation-nct05700903-2026-03-02-c7eb5bedb4e3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05700903 at 2026-07-30T16:22:22.343Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05700903-2026-03-02-c7eb5bedb4e3`](#source-ctg-observation-nct05700903-2026-03-02-c7eb5bedb4e3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05700903 at 2026-07-30T16:22:22.343Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05700903-2026-03-02-c7eb5bedb4e3`](#source-ctg-observation-nct05700903-2026-03-02-c7eb5bedb4e3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05700903-2026-03-02-c7eb5bedb4e3`](#source-ctg-observation-nct05700903-2026-03-02-c7eb5bedb4e3))

### Sources

<a id="source-ctg-observation-nct05700903-2026-03-02-c7eb5bedb4e3"></a>
- **ClinicalTrials.gov record NCT05700903 · retained source version 2026-03-02:c7eb5bedb4e34fbdfe48f022cd0f60019a3b7c7e1091d7a7e9db4aa9d7620636** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05700903) (`ctg-observation-nct05700903-2026-03-02-c7eb5bedb4e3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05700903." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05700903-leuprolide-v1 SHA-256: a63180caed0e5d2f0c71fbe42d4611b16c4ca464e9c4b0373e2c3a382dd9b2a7.

---

<a id="clinicaltrials-gov-nct05765500-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT05765500

> PeptideScanner retained ClinicalTrials.gov record NCT05765500 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct05765500-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05765500-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05765500-leuprolide-v1
- Content SHA-256: `fb0178057e314dc81fba45ca841a7021d46b0194e87ee9b7cd88ab3d47d12f82`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05765500 ([`ctg-observation-nct05765500-2026-07-30-0ecdd05db344`](#source-ctg-observation-nct05765500-2026-07-30-0ecdd05db344))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05765500 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05765500-2026-07-30-0ecdd05db344`](#source-ctg-observation-nct05765500-2026-07-30-0ecdd05db344))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05765500 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05765500-2026-07-30-0ecdd05db344`](#source-ctg-observation-nct05765500-2026-07-30-0ecdd05db344))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05765500-2026-07-30-0ecdd05db344`](#source-ctg-observation-nct05765500-2026-07-30-0ecdd05db344))

### Sources

<a id="source-ctg-observation-nct05765500-2026-07-30-0ecdd05db344"></a>
- **ClinicalTrials.gov record NCT05765500 · retained source version 2026-07-30:0ecdd05db34468156b4a8901768a0eeec7bef6489c780aa7b3d19c8ff5cea41e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05765500) (`ctg-observation-nct05765500-2026-07-30-0ecdd05db344`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05765500." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05765500-leuprolide-v1 SHA-256: fb0178057e314dc81fba45ca841a7021d46b0194e87ee9b7cd88ab3d47d12f82.

---

<a id="clinicaltrials-gov-nct05827081-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT05827081

> PeptideScanner retained ClinicalTrials.gov record NCT05827081 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct05827081-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05827081-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05827081-leuprolide-v1
- Content SHA-256: `0ba3d40ab86dcbf25581ec8245a4a6729d603990cf40a2088249ea9c0bc52869`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05827081 ([`ctg-observation-nct05827081-2026-11-13-8d5e139ca7e6`](#source-ctg-observation-nct05827081-2026-11-13-8d5e139ca7e6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05827081 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05827081-2026-11-13-8d5e139ca7e6`](#source-ctg-observation-nct05827081-2026-11-13-8d5e139ca7e6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05827081 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05827081-2026-11-13-8d5e139ca7e6`](#source-ctg-observation-nct05827081-2026-11-13-8d5e139ca7e6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05827081-2026-11-13-8d5e139ca7e6`](#source-ctg-observation-nct05827081-2026-11-13-8d5e139ca7e6))

### Sources

<a id="source-ctg-observation-nct05827081-2026-11-13-8d5e139ca7e6"></a>
- **ClinicalTrials.gov record NCT05827081 · retained source version 2026-11-13:8d5e139ca7e6f99f60e4f37f60dfb7c2e418225882817a66ff8dbd7649f414d9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05827081) (`ctg-observation-nct05827081-2026-11-13-8d5e139ca7e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05827081." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05827081-leuprolide-v1 SHA-256: 0ba3d40ab86dcbf25581ec8245a4a6729d603990cf40a2088249ea9c0bc52869.

---

<a id="clinicaltrials-gov-nct05896293-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT05896293

> PeptideScanner retained ClinicalTrials.gov record NCT05896293 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct05896293-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-13
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05896293-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05896293-leuprolide-v1
- Content SHA-256: `ddfca2a6259158b121884eaf30becb3bdeb37d211a0a14df57ff2b90504f880d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05896293 ([`ctg-observation-nct05896293-2026-07-13-82a522048f17`](#source-ctg-observation-nct05896293-2026-07-13-82a522048f17))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05896293 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05896293-2026-07-13-82a522048f17`](#source-ctg-observation-nct05896293-2026-07-13-82a522048f17))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05896293 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct05896293-2026-07-13-82a522048f17`](#source-ctg-observation-nct05896293-2026-07-13-82a522048f17))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05896293-2026-07-13-82a522048f17`](#source-ctg-observation-nct05896293-2026-07-13-82a522048f17))

### Sources

<a id="source-ctg-observation-nct05896293-2026-07-13-82a522048f17"></a>
- **ClinicalTrials.gov record NCT05896293 · retained source version 2026-07-13:82a522048f17753ae91353613c2b8449075d1ba66f97b8b1be891119d88347e3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05896293) (`ctg-observation-nct05896293-2026-07-13-82a522048f17`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05896293." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct05896293-leuprolide-v1 SHA-256: ddfca2a6259158b121884eaf30becb3bdeb37d211a0a14df57ff2b90504f880d.

---

<a id="clinicaltrials-gov-nct06106932-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT06106932

> PeptideScanner retained ClinicalTrials.gov record NCT06106932 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-30, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct06106932-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-10-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06106932-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06106932-leuprolide-v1
- Content SHA-256: `f410ad0780f7f8d1687067cd95ee2e983f6f617a4c2e0f6520eb22c8b487d3cf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06106932 ([`ctg-observation-nct06106932-2023-10-30-a7d05bdaf9f9`](#source-ctg-observation-nct06106932-2023-10-30-a7d05bdaf9f9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06106932 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-30, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06106932-2023-10-30-a7d05bdaf9f9`](#source-ctg-observation-nct06106932-2023-10-30-a7d05bdaf9f9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06106932 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-30, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06106932-2023-10-30-a7d05bdaf9f9`](#source-ctg-observation-nct06106932-2023-10-30-a7d05bdaf9f9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06106932-2023-10-30-a7d05bdaf9f9`](#source-ctg-observation-nct06106932-2023-10-30-a7d05bdaf9f9))

### Sources

<a id="source-ctg-observation-nct06106932-2023-10-30-a7d05bdaf9f9"></a>
- **ClinicalTrials.gov record NCT06106932 · retained source version 2023-10-30:a7d05bdaf9f91dc990b71dd41e83e2a18a2afd6cbc7a861aff1e9522749916b5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06106932) (`ctg-observation-nct06106932-2023-10-30-a7d05bdaf9f9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06106932." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06106932-leuprolide-v1 SHA-256: f410ad0780f7f8d1687067cd95ee2e983f6f617a4c2e0f6520eb22c8b487d3cf.

---

<a id="clinicaltrials-gov-nct06169124-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT06169124

> PeptideScanner retained ClinicalTrials.gov record NCT06169124 at 2026-08-13T05:56:16.370Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct06169124-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-28
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06169124-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06169124-leuprolide-v1
- Content SHA-256: `a39ef2b9de0c8b2be7e6e735ac61673d0e1af2e4bcb0a27f40dfe864520a26ae`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06169124 ([`ctg-observation-nct06169124-2026-07-28-6c3b425ddeb0`](#source-ctg-observation-nct06169124-2026-07-28-6c3b425ddeb0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06169124 at 2026-08-13T05:56:16.370Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06169124-2026-07-28-6c3b425ddeb0`](#source-ctg-observation-nct06169124-2026-07-28-6c3b425ddeb0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06169124 at 2026-08-13T05:56:16.370Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06169124-2026-07-28-6c3b425ddeb0`](#source-ctg-observation-nct06169124-2026-07-28-6c3b425ddeb0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06169124-2026-07-28-6c3b425ddeb0`](#source-ctg-observation-nct06169124-2026-07-28-6c3b425ddeb0))

### Sources

<a id="source-ctg-observation-nct06169124-2026-07-28-6c3b425ddeb0"></a>
- **ClinicalTrials.gov record NCT06169124 · retained source version 2026-07-28:6c3b425ddeb026c54c72112c465d5cfe41b05f5411aafcf134bde7976360dbe7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06169124) (`ctg-observation-nct06169124-2026-07-28-6c3b425ddeb0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06169124." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06169124-leuprolide-v1 SHA-256: a39ef2b9de0c8b2be7e6e735ac61673d0e1af2e4bcb0a27f40dfe864520a26ae.

---

<a id="clinicaltrials-gov-nct06305598-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT06305598

> PeptideScanner retained ClinicalTrials.gov record NCT06305598 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct06305598-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06305598-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06305598-leuprolide-v1
- Content SHA-256: `82668db4f922137ef8bdf02784a46c0c1cfb1c00edebf2ba3f21f1bcd5083e2b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06305598 ([`ctg-observation-nct06305598-2026-06-10-01908f3269bc`](#source-ctg-observation-nct06305598-2026-06-10-01908f3269bc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06305598 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06305598-2026-06-10-01908f3269bc`](#source-ctg-observation-nct06305598-2026-06-10-01908f3269bc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06305598 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06305598-2026-06-10-01908f3269bc`](#source-ctg-observation-nct06305598-2026-06-10-01908f3269bc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06305598-2026-06-10-01908f3269bc`](#source-ctg-observation-nct06305598-2026-06-10-01908f3269bc))

### Sources

<a id="source-ctg-observation-nct06305598-2026-06-10-01908f3269bc"></a>
- **ClinicalTrials.gov record NCT06305598 · retained source version 2026-06-10:01908f3269bc2e7dc30d5041ed4713e2cd017a5b247ed07849344b4d7da30b4c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06305598) (`ctg-observation-nct06305598-2026-06-10-01908f3269bc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06305598." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06305598-leuprolide-v1 SHA-256: 82668db4f922137ef8bdf02784a46c0c1cfb1c00edebf2ba3f21f1bcd5083e2b.

---

<a id="clinicaltrials-gov-nct06330805-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT06330805

> PeptideScanner retained ClinicalTrials.gov record NCT06330805 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-09, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct06330805-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06330805-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06330805-leuprolide-v1
- Content SHA-256: `c35d22aa987d2ea4c2031078dec79127dda14482ca499444e52d37c879a03881`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06330805 ([`ctg-observation-nct06330805-2026-03-09-d0f483df3d39`](#source-ctg-observation-nct06330805-2026-03-09-d0f483df3d39))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06330805 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-09, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06330805-2026-03-09-d0f483df3d39`](#source-ctg-observation-nct06330805-2026-03-09-d0f483df3d39))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06330805 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-09, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06330805-2026-03-09-d0f483df3d39`](#source-ctg-observation-nct06330805-2026-03-09-d0f483df3d39))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06330805-2026-03-09-d0f483df3d39`](#source-ctg-observation-nct06330805-2026-03-09-d0f483df3d39))

### Sources

<a id="source-ctg-observation-nct06330805-2026-03-09-d0f483df3d39"></a>
- **ClinicalTrials.gov record NCT06330805 · retained source version 2026-03-09:d0f483df3d3955b6e5338d8da4bfaacb065d7e7efc2aa527e8faf5f324ca816a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06330805) (`ctg-observation-nct06330805-2026-03-09-d0f483df3d39`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06330805." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06330805-leuprolide-v1 SHA-256: c35d22aa987d2ea4c2031078dec79127dda14482ca499444e52d37c879a03881.

---

<a id="clinicaltrials-gov-nct06348264-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT06348264

> PeptideScanner retained ClinicalTrials.gov record NCT06348264 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-23, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct06348264-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06348264-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06348264-leuprolide-v1
- Content SHA-256: `c3f4ed418372558fd071a72ff08bea11f2a3e9afcf1c425a3b3db9fd2658aa8f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06348264 ([`ctg-observation-nct06348264-2025-09-23-37f0bb7adf2e`](#source-ctg-observation-nct06348264-2025-09-23-37f0bb7adf2e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06348264 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-23, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06348264-2025-09-23-37f0bb7adf2e`](#source-ctg-observation-nct06348264-2025-09-23-37f0bb7adf2e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06348264 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-23, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06348264-2025-09-23-37f0bb7adf2e`](#source-ctg-observation-nct06348264-2025-09-23-37f0bb7adf2e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06348264-2025-09-23-37f0bb7adf2e`](#source-ctg-observation-nct06348264-2025-09-23-37f0bb7adf2e))

### Sources

<a id="source-ctg-observation-nct06348264-2025-09-23-37f0bb7adf2e"></a>
- **ClinicalTrials.gov record NCT06348264 · retained source version 2025-09-23:37f0bb7adf2e06e712cf5c30973196d05264b47c956da2f30e7761493615a69b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06348264) (`ctg-observation-nct06348264-2025-09-23-37f0bb7adf2e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06348264." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06348264-leuprolide-v1 SHA-256: c3f4ed418372558fd071a72ff08bea11f2a3e9afcf1c425a3b3db9fd2658aa8f.

---

<a id="clinicaltrials-gov-nct06378866-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT06378866

> PeptideScanner retained ClinicalTrials.gov record NCT06378866 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct06378866-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-20
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06378866-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06378866-leuprolide-v1
- Content SHA-256: `cd4851745c500bb82bfbb423802048b5c4e269870a0d5c8f2d74835c4ccac283`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06378866 ([`ctg-observation-nct06378866-2026-07-20-e12fde8f60a5`](#source-ctg-observation-nct06378866-2026-07-20-e12fde8f60a5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06378866 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06378866-2026-07-20-e12fde8f60a5`](#source-ctg-observation-nct06378866-2026-07-20-e12fde8f60a5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06378866 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06378866-2026-07-20-e12fde8f60a5`](#source-ctg-observation-nct06378866-2026-07-20-e12fde8f60a5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06378866-2026-07-20-e12fde8f60a5`](#source-ctg-observation-nct06378866-2026-07-20-e12fde8f60a5))

### Sources

<a id="source-ctg-observation-nct06378866-2026-07-20-e12fde8f60a5"></a>
- **ClinicalTrials.gov record NCT06378866 · retained source version 2026-07-20:e12fde8f60a5ff42e88c43d55a29e621e872c646ac36b35b5ec5ef7c7e3ce37f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06378866) (`ctg-observation-nct06378866-2026-07-20-e12fde8f60a5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06378866." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06378866-leuprolide-v1 SHA-256: cd4851745c500bb82bfbb423802048b5c4e269870a0d5c8f2d74835c4ccac283.

---

<a id="clinicaltrials-gov-nct06734130-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT06734130

> PeptideScanner retained ClinicalTrials.gov record NCT06734130 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct06734130-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06734130-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06734130-leuprolide-v1
- Content SHA-256: `24cd96e6543e904f7172fe5fed19af7c5070210184f0f5e50232cdf0297cdf27`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06734130 ([`ctg-observation-nct06734130-2026-04-01-08927edbf9b7`](#source-ctg-observation-nct06734130-2026-04-01-08927edbf9b7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06734130 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06734130-2026-04-01-08927edbf9b7`](#source-ctg-observation-nct06734130-2026-04-01-08927edbf9b7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06734130 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct06734130-2026-04-01-08927edbf9b7`](#source-ctg-observation-nct06734130-2026-04-01-08927edbf9b7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06734130-2026-04-01-08927edbf9b7`](#source-ctg-observation-nct06734130-2026-04-01-08927edbf9b7))

### Sources

<a id="source-ctg-observation-nct06734130-2026-04-01-08927edbf9b7"></a>
- **ClinicalTrials.gov record NCT06734130 · retained source version 2026-04-01:08927edbf9b7ba2ce6438c18757b5690e24ef8b9db31d44036a7477d9f2afae7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06734130) (`ctg-observation-nct06734130-2026-04-01-08927edbf9b7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06734130." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct06734130-leuprolide-v1 SHA-256: 24cd96e6543e904f7172fe5fed19af7c5070210184f0f5e50232cdf0297cdf27.

---

<a id="clinicaltrials-gov-nct07027124-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT07027124

> PeptideScanner retained ClinicalTrials.gov record NCT07027124 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct07027124-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07027124-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07027124-leuprolide-v1
- Content SHA-256: `65fd5780becee798251efaeae79274787ce2f80f06b6e5e9f83f5abdd8496b82`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07027124 ([`ctg-observation-nct07027124-2026-06-16-2a124ad2ad4c`](#source-ctg-observation-nct07027124-2026-06-16-2a124ad2ad4c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07027124 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07027124-2026-06-16-2a124ad2ad4c`](#source-ctg-observation-nct07027124-2026-06-16-2a124ad2ad4c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07027124 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07027124-2026-06-16-2a124ad2ad4c`](#source-ctg-observation-nct07027124-2026-06-16-2a124ad2ad4c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07027124-2026-06-16-2a124ad2ad4c`](#source-ctg-observation-nct07027124-2026-06-16-2a124ad2ad4c))

### Sources

<a id="source-ctg-observation-nct07027124-2026-06-16-2a124ad2ad4c"></a>
- **ClinicalTrials.gov record NCT07027124 · retained source version 2026-06-16:2a124ad2ad4c66d67b5625de6bb70b4610e11c375a2d1c082fb6fd16679f5747** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07027124) (`ctg-observation-nct07027124-2026-06-16-2a124ad2ad4c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07027124." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07027124-leuprolide-v1 SHA-256: 65fd5780becee798251efaeae79274787ce2f80f06b6e5e9f83f5abdd8496b82.

---

<a id="clinicaltrials-gov-nct07158021-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT07158021

> PeptideScanner retained ClinicalTrials.gov record NCT07158021 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-23, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct07158021-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07158021-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07158021-leuprolide-v1
- Content SHA-256: `92620fbe8e4dad605935248a2590f4f48244e47192b357705d58f0df4506b8ef`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07158021 ([`ctg-observation-nct07158021-2026-06-23-525ed7e4d341`](#source-ctg-observation-nct07158021-2026-06-23-525ed7e4d341))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07158021 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-23, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07158021-2026-06-23-525ed7e4d341`](#source-ctg-observation-nct07158021-2026-06-23-525ed7e4d341))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07158021 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-23, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07158021-2026-06-23-525ed7e4d341`](#source-ctg-observation-nct07158021-2026-06-23-525ed7e4d341))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07158021-2026-06-23-525ed7e4d341`](#source-ctg-observation-nct07158021-2026-06-23-525ed7e4d341))

### Sources

<a id="source-ctg-observation-nct07158021-2026-06-23-525ed7e4d341"></a>
- **ClinicalTrials.gov record NCT07158021 · retained source version 2026-06-23:525ed7e4d341cb9cccd84ef85b477b46dc3478563212e7c6b01665154b3f69a0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07158021) (`ctg-observation-nct07158021-2026-06-23-525ed7e4d341`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07158021." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07158021-leuprolide-v1 SHA-256: 92620fbe8e4dad605935248a2590f4f48244e47192b357705d58f0df4506b8ef.

---

<a id="clinicaltrials-gov-nct07455903-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT07455903

> PeptideScanner retained ClinicalTrials.gov record NCT07455903 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct07455903-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-06
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07455903-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07455903-leuprolide-v1
- Content SHA-256: `ff0c3b7e7c539983c84c1f39c840c31a83c21e13c75b56f30acf42b522f8cf7f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07455903 ([`ctg-observation-nct07455903-2026-08-06-39a5439f2a3a`](#source-ctg-observation-nct07455903-2026-08-06-39a5439f2a3a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07455903 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07455903-2026-08-06-39a5439f2a3a`](#source-ctg-observation-nct07455903-2026-08-06-39a5439f2a3a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07455903 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07455903-2026-08-06-39a5439f2a3a`](#source-ctg-observation-nct07455903-2026-08-06-39a5439f2a3a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07455903-2026-08-06-39a5439f2a3a`](#source-ctg-observation-nct07455903-2026-08-06-39a5439f2a3a))

### Sources

<a id="source-ctg-observation-nct07455903-2026-08-06-39a5439f2a3a"></a>
- **ClinicalTrials.gov record NCT07455903 · retained source version 2026-08-06:39a5439f2a3aeadf3b33be055d5ee15371cedc7c9101976b97c376d38f163e6d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07455903) (`ctg-observation-nct07455903-2026-08-06-39a5439f2a3a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07455903." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07455903-leuprolide-v1 SHA-256: ff0c3b7e7c539983c84c1f39c840c31a83c21e13c75b56f30acf42b522f8cf7f.

---

<a id="clinicaltrials-gov-nct07596212-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT07596212

> PeptideScanner retained ClinicalTrials.gov record NCT07596212 at 2026-09-09T19:17:17.112Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct07596212-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-24
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07596212-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07596212-leuprolide-v1
- Content SHA-256: `5a665cc747489a97292f007f50ec65e2a1a404bd89bafe462a2835f1b6ffaf2d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07596212 ([`ctg-observation-nct07596212-2026-08-24-b1cf0da3b9f4`](#source-ctg-observation-nct07596212-2026-08-24-b1cf0da3b9f4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07596212 at 2026-09-09T19:17:17.112Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07596212-2026-08-24-b1cf0da3b9f4`](#source-ctg-observation-nct07596212-2026-08-24-b1cf0da3b9f4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07596212 at 2026-09-09T19:17:17.112Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07596212-2026-08-24-b1cf0da3b9f4`](#source-ctg-observation-nct07596212-2026-08-24-b1cf0da3b9f4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07596212-2026-08-24-b1cf0da3b9f4`](#source-ctg-observation-nct07596212-2026-08-24-b1cf0da3b9f4))

### Sources

<a id="source-ctg-observation-nct07596212-2026-08-24-b1cf0da3b9f4"></a>
- **ClinicalTrials.gov record NCT07596212 · retained source version 2026-08-24:b1cf0da3b9f42b87561772fda2094b23814be137e0c73499c9e142327dfe0231** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07596212) (`ctg-observation-nct07596212-2026-08-24-b1cf0da3b9f4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07596212." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07596212-leuprolide-v1 SHA-256: 5a665cc747489a97292f007f50ec65e2a1a404bd89bafe462a2835f1b6ffaf2d.

---

<a id="clinicaltrials-gov-nct07650240-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT07650240

> PeptideScanner retained ClinicalTrials.gov record NCT07650240 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct07650240-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07650240-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07650240-leuprolide-v1
- Content SHA-256: `fb36ee149d44afa53aef7ae8db1d0619d94aa08bb5325237c45c04b9907cb4d6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07650240 ([`ctg-observation-nct07650240-2026-06-17-579b482fec19`](#source-ctg-observation-nct07650240-2026-06-17-579b482fec19))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07650240 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07650240-2026-06-17-579b482fec19`](#source-ctg-observation-nct07650240-2026-06-17-579b482fec19))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07650240 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07650240-2026-06-17-579b482fec19`](#source-ctg-observation-nct07650240-2026-06-17-579b482fec19))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07650240-2026-06-17-579b482fec19`](#source-ctg-observation-nct07650240-2026-06-17-579b482fec19))

### Sources

<a id="source-ctg-observation-nct07650240-2026-06-17-579b482fec19"></a>
- **ClinicalTrials.gov record NCT07650240 · retained source version 2026-06-17:579b482fec19a9c8769b6b1ffd878c697f06959f0464baa7334d64d04a646111** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07650240) (`ctg-observation-nct07650240-2026-06-17-579b482fec19`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07650240." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07650240-leuprolide-v1 SHA-256: fb36ee149d44afa53aef7ae8db1d0619d94aa08bb5325237c45c04b9907cb4d6.

---

<a id="clinicaltrials-gov-nct07801664-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT07801664

> PeptideScanner retained ClinicalTrials.gov record NCT07801664 at 2026-09-09T19:17:17.074Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct07801664-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-03
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07801664-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07801664-leuprolide-v1
- Content SHA-256: `6cc950f84e091367c9c3cf7ee7bcd7a61e602241b334cec48c38f7412714151b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07801664 ([`ctg-observation-nct07801664-2026-09-03-f1e4961dc1d9`](#source-ctg-observation-nct07801664-2026-09-03-f1e4961dc1d9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07801664 at 2026-09-09T19:17:17.074Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07801664-2026-09-03-f1e4961dc1d9`](#source-ctg-observation-nct07801664-2026-09-03-f1e4961dc1d9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07801664 at 2026-09-09T19:17:17.074Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07801664-2026-09-03-f1e4961dc1d9`](#source-ctg-observation-nct07801664-2026-09-03-f1e4961dc1d9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07801664-2026-09-03-f1e4961dc1d9`](#source-ctg-observation-nct07801664-2026-09-03-f1e4961dc1d9))

### Sources

<a id="source-ctg-observation-nct07801664-2026-09-03-f1e4961dc1d9"></a>
- **ClinicalTrials.gov record NCT07801664 · retained source version 2026-09-03:f1e4961dc1d9eb70b40395b72318aaaf82106ccf801b22ad4e62e841392cf05f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07801664) (`ctg-observation-nct07801664-2026-09-03-f1e4961dc1d9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07801664." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07801664-leuprolide-v1 SHA-256: 6cc950f84e091367c9c3cf7ee7bcd7a61e602241b334cec48c38f7412714151b.

---

<a id="clinicaltrials-gov-nct07848828-leuprolide-v1"></a>

## ClinicalTrials.gov record NCT07848828

> PeptideScanner retained ClinicalTrials.gov record NCT07848828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct07848828-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-02
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07848828-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07848828-leuprolide-v1
- Content SHA-256: `0d99e786f110691c6aba942d7c75edf917db49ce828fec54c96de03499a15738`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07848828 ([`ctg-observation-nct07848828-2026-11-02-3e1f14d65271`](#source-ctg-observation-nct07848828-2026-11-02-3e1f14d65271))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07848828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07848828-2026-11-02-3e1f14d65271`](#source-ctg-observation-nct07848828-2026-11-02-3e1f14d65271))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07848828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct07848828-2026-11-02-3e1f14d65271`](#source-ctg-observation-nct07848828-2026-11-02-3e1f14d65271))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07848828-2026-11-02-3e1f14d65271`](#source-ctg-observation-nct07848828-2026-11-02-3e1f14d65271))

### Sources

<a id="source-ctg-observation-nct07848828-2026-11-02-3e1f14d65271"></a>
- **ClinicalTrials.gov record NCT07848828 · retained source version 2026-11-02:3e1f14d65271e4757e709eada0b20f671181a217191b604d1e49141d95b07f75** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07848828) (`ctg-observation-nct07848828-2026-11-02-3e1f14d65271`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07848828." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#clinicaltrials-gov-nct07848828-leuprolide-v1 SHA-256: 0d99e786f110691c6aba942d7c75edf917db49ce828fec54c96de03499a15738.

---

<a id="dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-v1"></a>

## Leuprolide DailyMed SPL version 10

> DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2026-07-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10:v1`
- Evidence domain: Regulatory
- Date in source: 2026-07-06
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-v1
- Content SHA-256: `cb0b1d26f085469987fa20621fcd78b55a45499a0e25a12a7124ede3001c163c`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 10 ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-history))

#### Summary

DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2026-07-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2026-07-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-history))

### Sources

<a id="source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-history"></a>
- **DailyMed SPL SET ID 4838c674-044e-46b2-81e7-c691b99d8fa5 · SPL version 10 · published 2026-07-06 · retained ZIP SHA-256 86f3963f5e8c460c7214ef2ac8e45182d3919a279b0fa097bf03eb2c5632471d** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4838c674-044e-46b2-81e7-c691b99d8fa5&version=10) (`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 10." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10-v1 SHA-256: cb0b1d26f085469987fa20621fcd78b55a45499a0e25a12a7124ede3001c163c.

---

<a id="dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-v1"></a>

## Leuprolide DailyMed SPL version 4

> DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2022-11-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4:v1`
- Evidence domain: Regulatory
- Date in source: 2022-11-07
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-v1
- Content SHA-256: `962c17a3b5a15ac60250c094cdf70b088bb9055216d6f76b9863ddb31bf722aa`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 4 ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-history))

#### Summary

DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2022-11-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2022-11-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-history))

### Sources

<a id="source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-history"></a>
- **DailyMed SPL SET ID 4838c674-044e-46b2-81e7-c691b99d8fa5 · SPL version 4 · published 2022-11-07 · retained ZIP SHA-256 5a050b4de56cee3e6d10cc827f70ec63708e7d854a144b19b7fc0522bcd3827e** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4838c674-044e-46b2-81e7-c691b99d8fa5&version=4) (`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 4." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v4-v1 SHA-256: 962c17a3b5a15ac60250c094cdf70b088bb9055216d6f76b9863ddb31bf722aa.

---

<a id="dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-v1"></a>

## Leuprolide DailyMed SPL version 5

> DailyMed lists Structured Product Labeling version 5 for the reviewed Leuprolide label family with a published date of 2023-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5:v1`
- Evidence domain: Regulatory
- Date in source: 2023-03-07
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-v1
- Content SHA-256: `d39343f10ed6f90bec95d3e7e9a58c6e2b4a2e983f17735be996ee34f23a6c5c`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 5 ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-history))

#### Summary

DailyMed lists Structured Product Labeling version 5 for the reviewed Leuprolide label family with a published date of 2023-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 5 for the reviewed Leuprolide label family with a published date of 2023-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-history))

### Sources

<a id="source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-history"></a>
- **DailyMed SPL SET ID 4838c674-044e-46b2-81e7-c691b99d8fa5 · SPL version 5 · published 2023-03-07 · retained ZIP SHA-256 7e51494e11e4ef4a39083b94e7647dac4b73d6dc69c72885adc60f5bedfab23d** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4838c674-044e-46b2-81e7-c691b99d8fa5&version=5) (`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 5." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v5-v1 SHA-256: d39343f10ed6f90bec95d3e7e9a58c6e2b4a2e983f17735be996ee34f23a6c5c.

---

<a id="dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-v1"></a>

## Leuprolide DailyMed SPL version 6

> DailyMed lists Structured Product Labeling version 6 for the reviewed Leuprolide label family with a published date of 2024-11-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6:v1`
- Evidence domain: Regulatory
- Date in source: 2024-11-18
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-v1
- Content SHA-256: `084a73f3abbbae4956cf93d94809a6d2b8d9d909cb35f35d5f9d4dbe03a2f99f`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 6 ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-history))

#### Summary

DailyMed lists Structured Product Labeling version 6 for the reviewed Leuprolide label family with a published date of 2024-11-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 6 for the reviewed Leuprolide label family with a published date of 2024-11-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-history))

### Sources

<a id="source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-history"></a>
- **DailyMed SPL SET ID 4838c674-044e-46b2-81e7-c691b99d8fa5 · SPL version 6 · published 2024-11-18 · retained ZIP SHA-256 65b040e4ce1b6e96c1c1787f884d2115f8ee2c31a07fb2d3b20271667acfeb5d** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4838c674-044e-46b2-81e7-c691b99d8fa5&version=6) (`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 6." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v6-v1 SHA-256: 084a73f3abbbae4956cf93d94809a6d2b8d9d909cb35f35d5f9d4dbe03a2f99f.

---

<a id="dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-v1"></a>

## Leuprolide DailyMed SPL version 7

> DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2025-04-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7:v1`
- Evidence domain: Regulatory
- Date in source: 2025-04-28
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-v1
- Content SHA-256: `f4fa3f0693cb0c26e55d1b4c7652a8069a10c1020c488a8b53acf8daf996fc59`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 7 ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-history))

#### Summary

DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2025-04-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2025-04-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-history))

### Sources

<a id="source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-history"></a>
- **DailyMed SPL SET ID 4838c674-044e-46b2-81e7-c691b99d8fa5 · SPL version 7 · published 2025-04-28 · retained ZIP SHA-256 282a2d471703411b7bb43b203b11b92c7f2a29258077455ab5f152d2843771d2** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4838c674-044e-46b2-81e7-c691b99d8fa5&version=7) (`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 7." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v7-v1 SHA-256: f4fa3f0693cb0c26e55d1b4c7652a8069a10c1020c488a8b53acf8daf996fc59.

---

<a id="dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-v1"></a>

## Leuprolide DailyMed SPL version 9

> DailyMed lists Structured Product Labeling version 9 for the reviewed Leuprolide label family with a published date of 2025-12-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9:v1`
- Evidence domain: Regulatory
- Date in source: 2025-12-29
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-v1
- Content SHA-256: `f633e98f7a816225d452be7bb36cbe2656e51b6f8b2529e07d2f0838decb6187`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 9 ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-history))

#### Summary

DailyMed lists Structured Product Labeling version 9 for the reviewed Leuprolide label family with a published date of 2025-12-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 9 for the reviewed Leuprolide label family with a published date of 2025-12-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-history`](#source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-history))

### Sources

<a id="source-dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-history"></a>
- **DailyMed SPL SET ID 4838c674-044e-46b2-81e7-c691b99d8fa5 · SPL version 9 · published 2025-12-29 · retained ZIP SHA-256 c979d44225f41242fa150c30a8d09418878cf265a519985a1f8fec5efd9a821f** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4838c674-044e-46b2-81e7-c691b99d8fa5&version=9) (`dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 9." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v9-v1 SHA-256: f633e98f7a816225d452be7bb36cbe2656e51b6f8b2529e07d2f0838decb6187.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-v1"></a>

## Leuprolide DailyMed SPL version 10

> DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2024-01-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10:v1`
- Evidence domain: Regulatory
- Date in source: 2024-01-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-v1
- Content SHA-256: `1a8d79ff1a354c95961fe31a3c259808a95cba33ebda798112b7e86b1330bfdb`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 10 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-history))

#### Summary

DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2024-01-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2024-01-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 10 · published 2024-01-22 · retained ZIP SHA-256 393aad182f69f71dc35a2658f2f4fe33026af8c29b21f3a794bc7be9dba0ab12** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=10) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 10." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v10-v1 SHA-256: 1a8d79ff1a354c95961fe31a3c259808a95cba33ebda798112b7e86b1330bfdb.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-v1"></a>

## Leuprolide DailyMed SPL version 11

> DailyMed lists Structured Product Labeling version 11 for the reviewed Leuprolide label family with a published date of 2024-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11:v1`
- Evidence domain: Regulatory
- Date in source: 2024-02-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-v1
- Content SHA-256: `7225a2c2eeb5aa8f67e2eb8852f924a20d8e8eddfa41c77311ed2b9b237b62bc`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 11 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-history))

#### Summary

DailyMed lists Structured Product Labeling version 11 for the reviewed Leuprolide label family with a published date of 2024-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 11 for the reviewed Leuprolide label family with a published date of 2024-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 11 · published 2024-02-12 · retained ZIP SHA-256 335f62078b5060411174630f4746a2da7cb7cc1f1d7a17ec70a4505832dfa6c1** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=11) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 11." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v11-v1 SHA-256: 7225a2c2eeb5aa8f67e2eb8852f924a20d8e8eddfa41c77311ed2b9b237b62bc.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-v1"></a>

## Leuprolide DailyMed SPL version 13

> DailyMed lists Structured Product Labeling version 13 for the reviewed Leuprolide label family with a published date of 2024-06-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13:v1`
- Evidence domain: Regulatory
- Date in source: 2024-06-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-v1
- Content SHA-256: `2fbc72d8f02dd93ed29caa245ce3dead6be0856316a5cb2616b31ed4ee87bc6c`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 13 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-history))

#### Summary

DailyMed lists Structured Product Labeling version 13 for the reviewed Leuprolide label family with a published date of 2024-06-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 13 for the reviewed Leuprolide label family with a published date of 2024-06-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 13 · published 2024-06-03 · retained ZIP SHA-256 9e7b2ff39aa51fc8af2aed87a26eed42ed7d5ab451e9c1191a944d1eeb56e901** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=13) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 13." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v13-v1 SHA-256: 2fbc72d8f02dd93ed29caa245ce3dead6be0856316a5cb2616b31ed4ee87bc6c.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-v1"></a>

## Leuprolide DailyMed SPL version 14

> DailyMed lists Structured Product Labeling version 14 for the reviewed Leuprolide label family with a published date of 2024-08-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14:v1`
- Evidence domain: Regulatory
- Date in source: 2024-08-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-v1
- Content SHA-256: `1822499a1c69427f345fea4b4be99a37f982ebc8338b5a9325615fd4d25f4520`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 14 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-history))

#### Summary

DailyMed lists Structured Product Labeling version 14 for the reviewed Leuprolide label family with a published date of 2024-08-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 14 for the reviewed Leuprolide label family with a published date of 2024-08-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 14 · published 2024-08-30 · retained ZIP SHA-256 7ec8788caec06ec5fab5ae15dbd06317985cf5f1f1b0615607a52fe507903999** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=14) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 14." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v14-v1 SHA-256: 1822499a1c69427f345fea4b4be99a37f982ebc8338b5a9325615fd4d25f4520.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-v1"></a>

## Leuprolide DailyMed SPL version 16

> DailyMed lists Structured Product Labeling version 16 for the reviewed Leuprolide label family with a published date of 2024-12-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16:v1`
- Evidence domain: Regulatory
- Date in source: 2024-12-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-v1
- Content SHA-256: `cbee11f86d495e7e393d2619abc4411ab9ffee2bb5a1b352fd2b9928d53a7623`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 16 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-history))

#### Summary

DailyMed lists Structured Product Labeling version 16 for the reviewed Leuprolide label family with a published date of 2024-12-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 16 for the reviewed Leuprolide label family with a published date of 2024-12-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 16 · published 2024-12-13 · retained ZIP SHA-256 561f6284f514e9fb45a912d80fc750485bfa1447fd9ef02addb5fbae219134ba** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=16) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 16." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v16-v1 SHA-256: cbee11f86d495e7e393d2619abc4411ab9ffee2bb5a1b352fd2b9928d53a7623.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-v1"></a>

## Leuprolide DailyMed SPL version 17

> DailyMed lists Structured Product Labeling version 17 for the reviewed Leuprolide label family with a published date of 2025-02-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17:v1`
- Evidence domain: Regulatory
- Date in source: 2025-02-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-v1
- Content SHA-256: `4588c6c3614a5050b5f6429366a136491ab2b94e574c163ce6dede9722ed8d5a`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 17 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-history))

#### Summary

DailyMed lists Structured Product Labeling version 17 for the reviewed Leuprolide label family with a published date of 2025-02-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 17 for the reviewed Leuprolide label family with a published date of 2025-02-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 17 · published 2025-02-17 · retained ZIP SHA-256 6af270df786d784a1cff455d02c30eed1bb5028ed2826b89a1cedf2b51a100c4** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=17) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 17." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v17-v1 SHA-256: 4588c6c3614a5050b5f6429366a136491ab2b94e574c163ce6dede9722ed8d5a.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-v1"></a>

## Leuprolide DailyMed SPL version 18

> DailyMed lists Structured Product Labeling version 18 for the reviewed Leuprolide label family with a published date of 2025-02-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18:v1`
- Evidence domain: Regulatory
- Date in source: 2025-02-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-v1
- Content SHA-256: `ebfed6140a4381ebcecbe14c1d73208cf2424c5217a5c772d99e15153d9d339d`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 18 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-history))

#### Summary

DailyMed lists Structured Product Labeling version 18 for the reviewed Leuprolide label family with a published date of 2025-02-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 18 for the reviewed Leuprolide label family with a published date of 2025-02-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 18 · published 2025-02-28 · retained ZIP SHA-256 67f61e0778e9f2ecbe836e8f061eae4a083c434d5690cf11a2bac756cfa99c41** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=18) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 18." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v18-v1 SHA-256: ebfed6140a4381ebcecbe14c1d73208cf2424c5217a5c772d99e15153d9d339d.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-v1"></a>

## Leuprolide DailyMed SPL version 19

> DailyMed lists Structured Product Labeling version 19 for the reviewed Leuprolide label family with a published date of 2026-05-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19:v1`
- Evidence domain: Regulatory
- Date in source: 2026-05-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-v1
- Content SHA-256: `fc2990cb92009be35f7a776b5c22cb6df170bffe36e0618d16293b37891d8081`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 19 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-history))

#### Summary

DailyMed lists Structured Product Labeling version 19 for the reviewed Leuprolide label family with a published date of 2026-05-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 19 for the reviewed Leuprolide label family with a published date of 2026-05-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 19 · published 2026-05-11 · retained ZIP SHA-256 e08a1c26251d2db47180407faaf2e74660c8798bec8fce2d22c67face8e7904b** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=19) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 19." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19-v1 SHA-256: fc2990cb92009be35f7a776b5c22cb6df170bffe36e0618d16293b37891d8081.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-v1"></a>

## Leuprolide DailyMed SPL version 1

> DailyMed lists Structured Product Labeling version 1 for the reviewed Leuprolide label family with a published date of 2023-09-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1:v1`
- Evidence domain: Regulatory
- Date in source: 2023-09-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-v1
- Content SHA-256: `62036157aa5df35ec6c533307d4e2a261dd4ad034b30c6e757fc9606bedac9ca`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 1 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-history))

#### Summary

DailyMed lists Structured Product Labeling version 1 for the reviewed Leuprolide label family with a published date of 2023-09-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Leuprolide label family with a published date of 2023-09-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 1 · published 2023-09-01 · retained ZIP SHA-256 dafccff7ecfb38c3478156edfcfd1e67dc7452920ed7907d20aa41754b2c55b8** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=1) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 1." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v1-v1 SHA-256: 62036157aa5df35ec6c533307d4e2a261dd4ad034b30c6e757fc9606bedac9ca.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-v1"></a>

## Leuprolide DailyMed SPL version 4

> DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2023-09-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4:v1`
- Evidence domain: Regulatory
- Date in source: 2023-09-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-v1
- Content SHA-256: `bfb41b2e983e032e80aae4bb146a2ef5c454fe92728a84404c121a37dacfe210`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 4 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-history))

#### Summary

DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2023-09-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2023-09-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 4 · published 2023-09-15 · retained ZIP SHA-256 8be79a8d8c89a0a78b942060fe3aef1eb3039fd9a68a784e0baa96c87d711a35** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=4) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 4." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v4-v1 SHA-256: bfb41b2e983e032e80aae4bb146a2ef5c454fe92728a84404c121a37dacfe210.

---

<a id="dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-v1"></a>

## Leuprolide DailyMed SPL version 7

> DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2023-12-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7:v1`
- Evidence domain: Regulatory
- Date in source: 2023-12-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-v1
- Content SHA-256: `20b80a29f1205ffd1bb779c71f30ff784118d3e6adf6f15da541a623ff82084f`

### Claims and source pins

#### Headline

Leuprolide DailyMed SPL version 7 ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-history))

#### Summary

DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2023-12-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2023-12-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-history`](#source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-history))

### Sources

<a id="source-dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-history"></a>
- **DailyMed SPL SET ID b7b679a9-6823-4ef8-8d31-3ab5058ffcfc · SPL version 7 · published 2023-12-18 · retained ZIP SHA-256 59d7c7de86fcb818282d33eef653ea192c85549d67b2a07e7e0cb0bd39885c4f** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=7) (`dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide DailyMed SPL version 7." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#dailymed-label-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v7-v1 SHA-256: 20b80a29f1205ffd1bb779c71f30ff784118d3e6adf6f15da541a623ff82084f.

---

<a id="fda-drugs-anda074728-v1"></a>

## Drugs@FDA application ANDA074728

> The official Drugs@FDA dataset lists original submission 1 for ANDA 074728 with status AP dated 1998-08-04, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda074728:v1`
- Evidence domain: Regulatory
- Date in source: 1998-08-04
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda074728/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda074728-v1
- Content SHA-256: `7d8eb85462e0ac81b7aba74a3c44772bddccf74466dc29c2fca03e48d8f88d86`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA074728 ([`fda-drugs-anda074728-1998-08-04-50e6a8729b7d`](#source-fda-drugs-anda074728-1998-08-04-50e6a8729b7d))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 074728 with status AP dated 1998-08-04, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda074728-1998-08-04-50e6a8729b7d`](#source-fda-drugs-anda074728-1998-08-04-50e6a8729b7d))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 074728 with status AP dated 1998-08-04, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda074728-1998-08-04-50e6a8729b7d`](#source-fda-drugs-anda074728-1998-08-04-50e6a8729b7d))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda074728-1998-08-04-50e6a8729b7d`](#source-fda-drugs-anda074728-1998-08-04-50e6a8729b7d))

### Sources

<a id="source-fda-drugs-anda074728-1998-08-04-50e6a8729b7d"></a>
- **Drugs@FDA application ANDA074728 · original submission status AP · 1998-08-04 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA074728%22&limit=1) (`fda-drugs-anda074728-1998-08-04-50e6a8729b7d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA074728." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda074728-v1 SHA-256: 7d8eb85462e0ac81b7aba74a3c44772bddccf74466dc29c2fca03e48d8f88d86.

---

<a id="fda-drugs-anda075471-v1"></a>

## Drugs@FDA application ANDA075471

> The official Drugs@FDA dataset lists original submission 1 for ANDA 075471 with status AP dated 2000-10-25, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda075471:v1`
- Evidence domain: Regulatory
- Date in source: 2000-10-25
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda075471/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda075471-v1
- Content SHA-256: `cb0153922291d59cdb17910ce2d053a8639e7dba25c8b6b91dd9faaacb807004`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA075471 ([`fda-drugs-anda075471-2000-10-25-c222d1a4a3e4`](#source-fda-drugs-anda075471-2000-10-25-c222d1a4a3e4))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 075471 with status AP dated 2000-10-25, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda075471-2000-10-25-c222d1a4a3e4`](#source-fda-drugs-anda075471-2000-10-25-c222d1a4a3e4))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 075471 with status AP dated 2000-10-25, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda075471-2000-10-25-c222d1a4a3e4`](#source-fda-drugs-anda075471-2000-10-25-c222d1a4a3e4))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda075471-2000-10-25-c222d1a4a3e4`](#source-fda-drugs-anda075471-2000-10-25-c222d1a4a3e4))

### Sources

<a id="source-fda-drugs-anda075471-2000-10-25-c222d1a4a3e4"></a>
- **Drugs@FDA application ANDA075471 · original submission status AP · 2000-10-25 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA075471%22&limit=1) (`fda-drugs-anda075471-2000-10-25-c222d1a4a3e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA075471." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda075471-v1 SHA-256: cb0153922291d59cdb17910ce2d053a8639e7dba25c8b6b91dd9faaacb807004.

---

<a id="fda-drugs-anda075721-v1"></a>

## Drugs@FDA application ANDA075721

> The official Drugs@FDA dataset lists original submission 1 for ANDA 075721 with status AP dated 2001-11-29, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda075721:v1`
- Evidence domain: Regulatory
- Date in source: 2001-11-29
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda075721/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda075721-v1
- Content SHA-256: `ec60abeab00a44ba43dadb7c6600fda8eba9f4d973221b2f919b6d00627b8457`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA075721 ([`fda-drugs-anda075721-2001-11-29-6e44354439bb`](#source-fda-drugs-anda075721-2001-11-29-6e44354439bb))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 075721 with status AP dated 2001-11-29, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda075721-2001-11-29-6e44354439bb`](#source-fda-drugs-anda075721-2001-11-29-6e44354439bb))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 075721 with status AP dated 2001-11-29, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda075721-2001-11-29-6e44354439bb`](#source-fda-drugs-anda075721-2001-11-29-6e44354439bb))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda075721-2001-11-29-6e44354439bb`](#source-fda-drugs-anda075721-2001-11-29-6e44354439bb))

### Sources

<a id="source-fda-drugs-anda075721-2001-11-29-6e44354439bb"></a>
- **Drugs@FDA application ANDA075721 · original submission status AP · 2001-11-29 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA075721%22&limit=1) (`fda-drugs-anda075721-2001-11-29-6e44354439bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA075721." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda075721-v1 SHA-256: ec60abeab00a44ba43dadb7c6600fda8eba9f4d973221b2f919b6d00627b8457.

---

<a id="fda-drugs-anda078885-v1"></a>

## Drugs@FDA application ANDA078885

> The official Drugs@FDA dataset lists original submission 1 for ANDA 078885 with status AP dated 2009-03-09, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda078885:v1`
- Evidence domain: Regulatory
- Date in source: 2009-03-09
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda078885/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda078885-v1
- Content SHA-256: `a3f4d9de7cc4b6e74dc707f5c5643629c1ac982f66566849599a3e09ebdc2420`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA078885 ([`fda-drugs-anda078885-2009-03-09-f5013ced1b5a`](#source-fda-drugs-anda078885-2009-03-09-f5013ced1b5a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 078885 with status AP dated 2009-03-09, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda078885-2009-03-09-f5013ced1b5a`](#source-fda-drugs-anda078885-2009-03-09-f5013ced1b5a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 078885 with status AP dated 2009-03-09, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda078885-2009-03-09-f5013ced1b5a`](#source-fda-drugs-anda078885-2009-03-09-f5013ced1b5a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda078885-2009-03-09-f5013ced1b5a`](#source-fda-drugs-anda078885-2009-03-09-f5013ced1b5a))

### Sources

<a id="source-fda-drugs-anda078885-2009-03-09-f5013ced1b5a"></a>
- **Drugs@FDA application ANDA078885 · original submission status AP · 2009-03-09 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA078885%22&limit=1) (`fda-drugs-anda078885-2009-03-09-f5013ced1b5a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA078885." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda078885-v1 SHA-256: a3f4d9de7cc4b6e74dc707f5c5643629c1ac982f66566849599a3e09ebdc2420.

---

<a id="fda-drugs-anda212963-v1"></a>

## Drugs@FDA application ANDA212963

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212963 with status AP dated 2022-06-06, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212963:v1`
- Evidence domain: Regulatory
- Date in source: 2022-06-06
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212963/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda212963-v1
- Content SHA-256: `005b0a04742ecff1f6c356a20d98c790b50d2a9ef9239e7cf9f08f8ec026d857`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212963 ([`fda-drugs-anda212963-2022-06-06-76078963da00`](#source-fda-drugs-anda212963-2022-06-06-76078963da00))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212963 with status AP dated 2022-06-06, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda212963-2022-06-06-76078963da00`](#source-fda-drugs-anda212963-2022-06-06-76078963da00))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212963 with status AP dated 2022-06-06, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda212963-2022-06-06-76078963da00`](#source-fda-drugs-anda212963-2022-06-06-76078963da00))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212963-2022-06-06-76078963da00`](#source-fda-drugs-anda212963-2022-06-06-76078963da00))

### Sources

<a id="source-fda-drugs-anda212963-2022-06-06-76078963da00"></a>
- **Drugs@FDA application ANDA212963 · original submission status AP · 2022-06-06 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212963%22&limit=1) (`fda-drugs-anda212963-2022-06-06-76078963da00`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212963." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda212963-v1 SHA-256: 005b0a04742ecff1f6c356a20d98c790b50d2a9ef9239e7cf9f08f8ec026d857.

---

<a id="fda-drugs-anda213829-v1"></a>

## Drugs@FDA application ANDA213829

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213829 with status AP dated 2021-08-13, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213829:v1`
- Evidence domain: Regulatory
- Date in source: 2021-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213829/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda213829-v1
- Content SHA-256: `72a659ad4641f3dd768f1437d1f18891d5d25c66cf1aca3e30152e3647b6ddc1`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213829 ([`fda-drugs-anda213829-2021-08-13-de3816b22ef8`](#source-fda-drugs-anda213829-2021-08-13-de3816b22ef8))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213829 with status AP dated 2021-08-13, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda213829-2021-08-13-de3816b22ef8`](#source-fda-drugs-anda213829-2021-08-13-de3816b22ef8))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213829 with status AP dated 2021-08-13, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda213829-2021-08-13-de3816b22ef8`](#source-fda-drugs-anda213829-2021-08-13-de3816b22ef8))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213829-2021-08-13-de3816b22ef8`](#source-fda-drugs-anda213829-2021-08-13-de3816b22ef8))

### Sources

<a id="source-fda-drugs-anda213829-2021-08-13-de3816b22ef8"></a>
- **Drugs@FDA application ANDA213829 · original submission status AP · 2021-08-13 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213829%22&limit=1) (`fda-drugs-anda213829-2021-08-13-de3816b22ef8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213829." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda213829-v1 SHA-256: 72a659ad4641f3dd768f1437d1f18891d5d25c66cf1aca3e30152e3647b6ddc1.

---

<a id="fda-drugs-anda215336-v1"></a>

## Drugs@FDA application ANDA215336

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215336 with status AP dated 2022-10-28, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215336:v1`
- Evidence domain: Regulatory
- Date in source: 2022-10-28
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215336/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda215336-v1
- Content SHA-256: `7f6ed3f667f441c0099b707e81569f8f6c5eb1524427fd80d76ac99cecee1ddb`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215336 ([`fda-drugs-anda215336-2022-10-28-9c04f2a2d514`](#source-fda-drugs-anda215336-2022-10-28-9c04f2a2d514))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215336 with status AP dated 2022-10-28, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda215336-2022-10-28-9c04f2a2d514`](#source-fda-drugs-anda215336-2022-10-28-9c04f2a2d514))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215336 with status AP dated 2022-10-28, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda215336-2022-10-28-9c04f2a2d514`](#source-fda-drugs-anda215336-2022-10-28-9c04f2a2d514))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215336-2022-10-28-9c04f2a2d514`](#source-fda-drugs-anda215336-2022-10-28-9c04f2a2d514))

### Sources

<a id="source-fda-drugs-anda215336-2022-10-28-9c04f2a2d514"></a>
- **Drugs@FDA application ANDA215336 · original submission status AP · 2022-10-28 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215336%22&limit=1) (`fda-drugs-anda215336-2022-10-28-9c04f2a2d514`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215336." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda215336-v1 SHA-256: 7f6ed3f667f441c0099b707e81569f8f6c5eb1524427fd80d76ac99cecee1ddb.

---

<a id="fda-drugs-anda215826-v1"></a>

## Drugs@FDA application ANDA215826

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215826 with status AP dated 2025-11-13, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215826:v1`
- Evidence domain: Regulatory
- Date in source: 2025-11-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215826/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda215826-v1
- Content SHA-256: `ce98c83ed568a487728e9263928b1dc71ceae640ca9b84dc79687190f32dcaf2`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215826 ([`fda-drugs-anda215826-2025-11-13-fbfb41aeebc9`](#source-fda-drugs-anda215826-2025-11-13-fbfb41aeebc9))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215826 with status AP dated 2025-11-13, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda215826-2025-11-13-fbfb41aeebc9`](#source-fda-drugs-anda215826-2025-11-13-fbfb41aeebc9))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215826 with status AP dated 2025-11-13, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda215826-2025-11-13-fbfb41aeebc9`](#source-fda-drugs-anda215826-2025-11-13-fbfb41aeebc9))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215826-2025-11-13-fbfb41aeebc9`](#source-fda-drugs-anda215826-2025-11-13-fbfb41aeebc9))

### Sources

<a id="source-fda-drugs-anda215826-2025-11-13-fbfb41aeebc9"></a>
- **Drugs@FDA application ANDA215826 · original submission status AP · 2025-11-13 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215826%22&limit=1) (`fda-drugs-anda215826-2025-11-13-fbfb41aeebc9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215826." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda215826-v1 SHA-256: ce98c83ed568a487728e9263928b1dc71ceae640ca9b84dc79687190f32dcaf2.

---

<a id="fda-drugs-anda217437-v1"></a>

## Drugs@FDA application ANDA217437

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217437 with status AP dated 2025-06-09, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217437:v1`
- Evidence domain: Regulatory
- Date in source: 2025-06-09
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217437/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda217437-v1
- Content SHA-256: `bdfd2808b21d2631b83f1ccf7f55824d0e3008f3176359a6396672ba53d570e4`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217437 ([`fda-drugs-anda217437-2025-06-09-26b05b64a91f`](#source-fda-drugs-anda217437-2025-06-09-26b05b64a91f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217437 with status AP dated 2025-06-09, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda217437-2025-06-09-26b05b64a91f`](#source-fda-drugs-anda217437-2025-06-09-26b05b64a91f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217437 with status AP dated 2025-06-09, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda217437-2025-06-09-26b05b64a91f`](#source-fda-drugs-anda217437-2025-06-09-26b05b64a91f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217437-2025-06-09-26b05b64a91f`](#source-fda-drugs-anda217437-2025-06-09-26b05b64a91f))

### Sources

<a id="source-fda-drugs-anda217437-2025-06-09-26b05b64a91f"></a>
- **Drugs@FDA application ANDA217437 · original submission status AP · 2025-06-09 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217437%22&limit=1) (`fda-drugs-anda217437-2025-06-09-26b05b64a91f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217437." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda217437-v1 SHA-256: bdfd2808b21d2631b83f1ccf7f55824d0e3008f3176359a6396672ba53d570e4.

---

<a id="fda-drugs-anda217957-v1"></a>

## Drugs@FDA application ANDA217957

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217957 with status AP dated 2024-10-17, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217957:v1`
- Evidence domain: Regulatory
- Date in source: 2024-10-17
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217957/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda217957-v1
- Content SHA-256: `22266579f35ce1a8f80cdcc9dff6e681b1249025dff61fef3aa485db0f0295b6`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217957 ([`fda-drugs-anda217957-2024-10-17-cd7cff595b8e`](#source-fda-drugs-anda217957-2024-10-17-cd7cff595b8e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217957 with status AP dated 2024-10-17, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda217957-2024-10-17-cd7cff595b8e`](#source-fda-drugs-anda217957-2024-10-17-cd7cff595b8e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217957 with status AP dated 2024-10-17, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-anda217957-2024-10-17-cd7cff595b8e`](#source-fda-drugs-anda217957-2024-10-17-cd7cff595b8e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217957-2024-10-17-cd7cff595b8e`](#source-fda-drugs-anda217957-2024-10-17-cd7cff595b8e))

### Sources

<a id="source-fda-drugs-anda217957-2024-10-17-cd7cff595b8e"></a>
- **Drugs@FDA application ANDA217957 · original submission status AP · 2024-10-17 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217957%22&limit=1) (`fda-drugs-anda217957-2024-10-17-cd7cff595b8e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217957." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-anda217957-v1 SHA-256: 22266579f35ce1a8f80cdcc9dff6e681b1249025dff61fef3aa485db0f0295b6.

---

<a id="fda-drugs-nda019010-v1"></a>

## Drugs@FDA application NDA019010

> The official Drugs@FDA dataset lists original submission 1 for NDA 019010 with status AP dated 1985-04-09, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019010:v1`
- Evidence domain: Regulatory
- Date in source: 1985-04-09
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019010/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda019010-v1
- Content SHA-256: `7bab964a29ce145d62d3dee0fa91f2c4a156f8b4edd5b2b946dc247a813e913b`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019010 ([`fda-drugs-nda019010-1985-04-09-d97355079c93`](#source-fda-drugs-nda019010-1985-04-09-d97355079c93))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019010 with status AP dated 1985-04-09, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda019010-1985-04-09-d97355079c93`](#source-fda-drugs-nda019010-1985-04-09-d97355079c93))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019010 with status AP dated 1985-04-09, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda019010-1985-04-09-d97355079c93`](#source-fda-drugs-nda019010-1985-04-09-d97355079c93))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019010-1985-04-09-d97355079c93`](#source-fda-drugs-nda019010-1985-04-09-d97355079c93))

### Sources

<a id="source-fda-drugs-nda019010-1985-04-09-d97355079c93"></a>
- **Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019010%22&limit=1) (`fda-drugs-nda019010-1985-04-09-d97355079c93`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019010." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda019010-v1 SHA-256: 7bab964a29ce145d62d3dee0fa91f2c4a156f8b4edd5b2b946dc247a813e913b.

---

<a id="fda-drugs-nda019732-v1"></a>

## Drugs@FDA application NDA019732

> The official Drugs@FDA dataset lists original submission 1 for NDA 019732 with status AP dated 1989-01-26, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019732:v1`
- Evidence domain: Regulatory
- Date in source: 1989-01-26
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019732/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda019732-v1
- Content SHA-256: `c239bfeff344d522bb4cba49c4e447df8eab135609ab5f007bbe6ae1fd1cd756`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019732 ([`fda-drugs-nda019732-1989-01-26-f4233297ff5a`](#source-fda-drugs-nda019732-1989-01-26-f4233297ff5a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019732 with status AP dated 1989-01-26, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda019732-1989-01-26-f4233297ff5a`](#source-fda-drugs-nda019732-1989-01-26-f4233297ff5a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019732 with status AP dated 1989-01-26, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda019732-1989-01-26-f4233297ff5a`](#source-fda-drugs-nda019732-1989-01-26-f4233297ff5a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019732-1989-01-26-f4233297ff5a`](#source-fda-drugs-nda019732-1989-01-26-f4233297ff5a))

### Sources

<a id="source-fda-drugs-nda019732-1989-01-26-f4233297ff5a"></a>
- **Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019732%22&limit=1) (`fda-drugs-nda019732-1989-01-26-f4233297ff5a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019732." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda019732-v1 SHA-256: c239bfeff344d522bb4cba49c4e447df8eab135609ab5f007bbe6ae1fd1cd756.

---

<a id="fda-drugs-nda019943-v1"></a>

## Drugs@FDA application NDA019943

> The official Drugs@FDA dataset lists original submission 1 for NDA 019943 with status AP dated 1995-03-30, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019943:v1`
- Evidence domain: Regulatory
- Date in source: 1995-03-30
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019943/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda019943-v1
- Content SHA-256: `34900320b16c00ee8512d122d6ac0f010ef495fc66dca06683ceca0d4d8876d1`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019943 ([`fda-drugs-nda019943-1995-03-30-2e6a8a0509d6`](#source-fda-drugs-nda019943-1995-03-30-2e6a8a0509d6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019943 with status AP dated 1995-03-30, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda019943-1995-03-30-2e6a8a0509d6`](#source-fda-drugs-nda019943-1995-03-30-2e6a8a0509d6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019943 with status AP dated 1995-03-30, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda019943-1995-03-30-2e6a8a0509d6`](#source-fda-drugs-nda019943-1995-03-30-2e6a8a0509d6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019943-1995-03-30-2e6a8a0509d6`](#source-fda-drugs-nda019943-1995-03-30-2e6a8a0509d6))

### Sources

<a id="source-fda-drugs-nda019943-1995-03-30-2e6a8a0509d6"></a>
- **Drugs@FDA application NDA019943 · original submission status AP · 1995-03-30 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019943%22&limit=1) (`fda-drugs-nda019943-1995-03-30-2e6a8a0509d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019943." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda019943-v1 SHA-256: 34900320b16c00ee8512d122d6ac0f010ef495fc66dca06683ceca0d4d8876d1.

---

<a id="fda-drugs-nda020011-v1"></a>

## Drugs@FDA application NDA020011

> The official Drugs@FDA dataset lists original submission 1 for NDA 020011 with status AP dated 1990-10-22, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020011:v1`
- Evidence domain: Regulatory
- Date in source: 1990-10-22
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020011/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda020011-v1
- Content SHA-256: `1a54d8e682e0c8b53c42e1fe888acb6f26695115e009e4e84466c698cc876808`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020011 ([`fda-drugs-nda020011-1990-10-22-1d2e6bafe266`](#source-fda-drugs-nda020011-1990-10-22-1d2e6bafe266))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020011 with status AP dated 1990-10-22, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda020011-1990-10-22-1d2e6bafe266`](#source-fda-drugs-nda020011-1990-10-22-1d2e6bafe266))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020011 with status AP dated 1990-10-22, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda020011-1990-10-22-1d2e6bafe266`](#source-fda-drugs-nda020011-1990-10-22-1d2e6bafe266))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020011-1990-10-22-1d2e6bafe266`](#source-fda-drugs-nda020011-1990-10-22-1d2e6bafe266))

### Sources

<a id="source-fda-drugs-nda020011-1990-10-22-1d2e6bafe266"></a>
- **Drugs@FDA application NDA020011 · original submission status AP · 1990-10-22 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020011%22&limit=1) (`fda-drugs-nda020011-1990-10-22-1d2e6bafe266`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020011." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda020011-v1 SHA-256: 1a54d8e682e0c8b53c42e1fe888acb6f26695115e009e4e84466c698cc876808.

---

<a id="fda-drugs-nda020263-v1"></a>

## Drugs@FDA application NDA020263

> The official Drugs@FDA dataset lists original submission 1 for NDA 020263 with status AP dated 1993-04-16, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020263:v1`
- Evidence domain: Regulatory
- Date in source: 1993-04-16
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020263/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda020263-v1
- Content SHA-256: `368443a7ad989d6d90fc0d5c2cc3f2039e07db17738f80be495b1a8c444cb841`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020263 ([`fda-drugs-nda020263-1993-04-16-d5ec3f5822e0`](#source-fda-drugs-nda020263-1993-04-16-d5ec3f5822e0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020263 with status AP dated 1993-04-16, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda020263-1993-04-16-d5ec3f5822e0`](#source-fda-drugs-nda020263-1993-04-16-d5ec3f5822e0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020263 with status AP dated 1993-04-16, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda020263-1993-04-16-d5ec3f5822e0`](#source-fda-drugs-nda020263-1993-04-16-d5ec3f5822e0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020263-1993-04-16-d5ec3f5822e0`](#source-fda-drugs-nda020263-1993-04-16-d5ec3f5822e0))

### Sources

<a id="source-fda-drugs-nda020263-1993-04-16-d5ec3f5822e0"></a>
- **Drugs@FDA application NDA020263 · original submission status AP · 1993-04-16 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020263%22&limit=1) (`fda-drugs-nda020263-1993-04-16-d5ec3f5822e0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020263." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda020263-v1 SHA-256: 368443a7ad989d6d90fc0d5c2cc3f2039e07db17738f80be495b1a8c444cb841.

---

<a id="fda-drugs-nda020517-v1"></a>

## Drugs@FDA application NDA020517

> The official Drugs@FDA dataset lists original submission 1 for NDA 020517 with status AP dated 1995-12-22, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020517:v1`
- Evidence domain: Regulatory
- Date in source: 1995-12-22
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020517/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda020517-v1
- Content SHA-256: `7329652b2045cbd60b239f10973801b4b350e27bf1a710706bf01e4cc7590dd3`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020517 ([`fda-drugs-nda020517-1995-12-22-ab96f9c2937c`](#source-fda-drugs-nda020517-1995-12-22-ab96f9c2937c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020517 with status AP dated 1995-12-22, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda020517-1995-12-22-ab96f9c2937c`](#source-fda-drugs-nda020517-1995-12-22-ab96f9c2937c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020517 with status AP dated 1995-12-22, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda020517-1995-12-22-ab96f9c2937c`](#source-fda-drugs-nda020517-1995-12-22-ab96f9c2937c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020517-1995-12-22-ab96f9c2937c`](#source-fda-drugs-nda020517-1995-12-22-ab96f9c2937c))

### Sources

<a id="source-fda-drugs-nda020517-1995-12-22-ab96f9c2937c"></a>
- **Drugs@FDA application NDA020517 · original submission status AP · 1995-12-22 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020517%22&limit=1) (`fda-drugs-nda020517-1995-12-22-ab96f9c2937c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020517." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda020517-v1 SHA-256: 7329652b2045cbd60b239f10973801b4b350e27bf1a710706bf01e4cc7590dd3.

---

<a id="fda-drugs-nda020708-v1"></a>

## Drugs@FDA application NDA020708

> The official Drugs@FDA dataset lists original submission 1 for NDA 020708 with status AP dated 1997-03-07, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020708:v1`
- Evidence domain: Regulatory
- Date in source: 1997-03-07
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020708/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda020708-v1
- Content SHA-256: `1533f57b4aaf09245acdad554ff3c9cf1ea1c0317441c0dcbaf4613a08c534f0`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020708 ([`fda-drugs-nda020708-1997-03-07-67e5f0a5a0fc`](#source-fda-drugs-nda020708-1997-03-07-67e5f0a5a0fc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020708 with status AP dated 1997-03-07, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda020708-1997-03-07-67e5f0a5a0fc`](#source-fda-drugs-nda020708-1997-03-07-67e5f0a5a0fc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020708 with status AP dated 1997-03-07, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda020708-1997-03-07-67e5f0a5a0fc`](#source-fda-drugs-nda020708-1997-03-07-67e5f0a5a0fc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020708-1997-03-07-67e5f0a5a0fc`](#source-fda-drugs-nda020708-1997-03-07-67e5f0a5a0fc))

### Sources

<a id="source-fda-drugs-nda020708-1997-03-07-67e5f0a5a0fc"></a>
- **Drugs@FDA application NDA020708 · original submission status AP · 1997-03-07 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020708%22&limit=1) (`fda-drugs-nda020708-1997-03-07-67e5f0a5a0fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020708." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda020708-v1 SHA-256: 1533f57b4aaf09245acdad554ff3c9cf1ea1c0317441c0dcbaf4613a08c534f0.

---

<a id="fda-drugs-nda021088-v1"></a>

## Drugs@FDA application NDA021088

> The official Drugs@FDA dataset lists original submission 1 for NDA 021088 with status AP dated 2000-03-03, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021088:v1`
- Evidence domain: Regulatory
- Date in source: 2000-03-03
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021088/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda021088-v1
- Content SHA-256: `3f83e9cc898e8ccd4a21708436914781ad4720f44fe3d7404d807bfe29575147`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021088 ([`fda-drugs-nda021088-2000-03-03-045b4c286c95`](#source-fda-drugs-nda021088-2000-03-03-045b4c286c95))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021088 with status AP dated 2000-03-03, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda021088-2000-03-03-045b4c286c95`](#source-fda-drugs-nda021088-2000-03-03-045b4c286c95))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021088 with status AP dated 2000-03-03, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda021088-2000-03-03-045b4c286c95`](#source-fda-drugs-nda021088-2000-03-03-045b4c286c95))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021088-2000-03-03-045b4c286c95`](#source-fda-drugs-nda021088-2000-03-03-045b4c286c95))

### Sources

<a id="source-fda-drugs-nda021088-2000-03-03-045b4c286c95"></a>
- **Drugs@FDA application NDA021088 · original submission status AP · 2000-03-03 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021088%22&limit=1) (`fda-drugs-nda021088-2000-03-03-045b4c286c95`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021088." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda021088-v1 SHA-256: 3f83e9cc898e8ccd4a21708436914781ad4720f44fe3d7404d807bfe29575147.

---

<a id="fda-drugs-nda021343-v1"></a>

## Drugs@FDA application NDA021343

> The official Drugs@FDA dataset lists original submission 1 for NDA 021343 with status AP dated 2002-01-23, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021343:v1`
- Evidence domain: Regulatory
- Date in source: 2002-01-23
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021343/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda021343-v1
- Content SHA-256: `b995c583bd0b52c1dba1dbb535a8b2b96b6f6cb078604a4d034662a850e810b0`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021343 ([`fda-drugs-nda021343-2002-01-23-f17a5edda965`](#source-fda-drugs-nda021343-2002-01-23-f17a5edda965))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021343 with status AP dated 2002-01-23, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda021343-2002-01-23-f17a5edda965`](#source-fda-drugs-nda021343-2002-01-23-f17a5edda965))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021343 with status AP dated 2002-01-23, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda021343-2002-01-23-f17a5edda965`](#source-fda-drugs-nda021343-2002-01-23-f17a5edda965))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021343-2002-01-23-f17a5edda965`](#source-fda-drugs-nda021343-2002-01-23-f17a5edda965))

### Sources

<a id="source-fda-drugs-nda021343-2002-01-23-f17a5edda965"></a>
- **Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021343%22&limit=1) (`fda-drugs-nda021343-2002-01-23-f17a5edda965`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021343." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda021343-v1 SHA-256: b995c583bd0b52c1dba1dbb535a8b2b96b6f6cb078604a4d034662a850e810b0.

---

<a id="fda-drugs-nda021379-v1"></a>

## Drugs@FDA application NDA021379

> The official Drugs@FDA dataset lists original submission 1 for NDA 021379 with status AP dated 2002-07-24, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021379:v1`
- Evidence domain: Regulatory
- Date in source: 2002-07-24
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021379/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda021379-v1
- Content SHA-256: `1d7ebe85f35eacbd4ff91776fd3e115918edce82ec448af30897ff3b5015e0d3`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021379 ([`fda-drugs-nda021379-2002-07-24-fa5842bb4bb7`](#source-fda-drugs-nda021379-2002-07-24-fa5842bb4bb7))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021379 with status AP dated 2002-07-24, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda021379-2002-07-24-fa5842bb4bb7`](#source-fda-drugs-nda021379-2002-07-24-fa5842bb4bb7))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021379 with status AP dated 2002-07-24, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda021379-2002-07-24-fa5842bb4bb7`](#source-fda-drugs-nda021379-2002-07-24-fa5842bb4bb7))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021379-2002-07-24-fa5842bb4bb7`](#source-fda-drugs-nda021379-2002-07-24-fa5842bb4bb7))

### Sources

<a id="source-fda-drugs-nda021379-2002-07-24-fa5842bb4bb7"></a>
- **Drugs@FDA application NDA021379 · original submission status AP · 2002-07-24 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021379%22&limit=1) (`fda-drugs-nda021379-2002-07-24-fa5842bb4bb7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021379." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda021379-v1 SHA-256: 1d7ebe85f35eacbd4ff91776fd3e115918edce82ec448af30897ff3b5015e0d3.

---

<a id="fda-drugs-nda021488-v1"></a>

## Drugs@FDA application NDA021488

> The official Drugs@FDA dataset lists original submission 1 for NDA 021488 with status AP dated 2003-02-13, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021488:v1`
- Evidence domain: Regulatory
- Date in source: 2003-02-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021488/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda021488-v1
- Content SHA-256: `080e64bb4e595bd98a7ee0fe8dfd6f6fd1ca7755ecfdf84f4a3a97175205be91`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021488 ([`fda-drugs-nda021488-2003-02-13-6c917bc07c27`](#source-fda-drugs-nda021488-2003-02-13-6c917bc07c27))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021488 with status AP dated 2003-02-13, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda021488-2003-02-13-6c917bc07c27`](#source-fda-drugs-nda021488-2003-02-13-6c917bc07c27))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021488 with status AP dated 2003-02-13, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda021488-2003-02-13-6c917bc07c27`](#source-fda-drugs-nda021488-2003-02-13-6c917bc07c27))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021488-2003-02-13-6c917bc07c27`](#source-fda-drugs-nda021488-2003-02-13-6c917bc07c27))

### Sources

<a id="source-fda-drugs-nda021488-2003-02-13-6c917bc07c27"></a>
- **Drugs@FDA application NDA021488 · original submission status AP · 2003-02-13 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021488%22&limit=1) (`fda-drugs-nda021488-2003-02-13-6c917bc07c27`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021488." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda021488-v1 SHA-256: 080e64bb4e595bd98a7ee0fe8dfd6f6fd1ca7755ecfdf84f4a3a97175205be91.

---

<a id="fda-drugs-nda021731-v1"></a>

## Drugs@FDA application NDA021731

> The official Drugs@FDA dataset lists original submission 1 for NDA 021731 with status AP dated 2004-12-14, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021731:v1`
- Evidence domain: Regulatory
- Date in source: 2004-12-14
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021731/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda021731-v1
- Content SHA-256: `9235d491ba4eb63d1dc414aab545a8ae92a1e5c0d17933a7abd3ade29cabb502`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021731 ([`fda-drugs-nda021731-2004-12-14-38622ec75dd0`](#source-fda-drugs-nda021731-2004-12-14-38622ec75dd0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021731 with status AP dated 2004-12-14, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda021731-2004-12-14-38622ec75dd0`](#source-fda-drugs-nda021731-2004-12-14-38622ec75dd0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021731 with status AP dated 2004-12-14, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda021731-2004-12-14-38622ec75dd0`](#source-fda-drugs-nda021731-2004-12-14-38622ec75dd0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021731-2004-12-14-38622ec75dd0`](#source-fda-drugs-nda021731-2004-12-14-38622ec75dd0))

### Sources

<a id="source-fda-drugs-nda021731-2004-12-14-38622ec75dd0"></a>
- **Drugs@FDA application NDA021731 · original submission status AP · 2004-12-14 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021731%22&limit=1) (`fda-drugs-nda021731-2004-12-14-38622ec75dd0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021731." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda021731-v1 SHA-256: 9235d491ba4eb63d1dc414aab545a8ae92a1e5c0d17933a7abd3ade29cabb502.

---

<a id="fda-drugs-nda205054-v1"></a>

## Drugs@FDA application NDA205054

> The official Drugs@FDA dataset lists original submission 1 for NDA 205054 with status AP dated 2018-08-28, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda205054:v1`
- Evidence domain: Regulatory
- Date in source: 2018-08-28
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda205054/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda205054-v1
- Content SHA-256: `e092ac9a883c5dc06de0ce91404c42bd5660cb0750197cbb6bc93f7ee75cb144`

### Claims and source pins

#### Headline

Drugs@FDA application NDA205054 ([`fda-drugs-nda205054-2018-08-28-d3de69f79957`](#source-fda-drugs-nda205054-2018-08-28-d3de69f79957))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 205054 with status AP dated 2018-08-28, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda205054-2018-08-28-d3de69f79957`](#source-fda-drugs-nda205054-2018-08-28-d3de69f79957))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 205054 with status AP dated 2018-08-28, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda205054-2018-08-28-d3de69f79957`](#source-fda-drugs-nda205054-2018-08-28-d3de69f79957))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda205054-2018-08-28-d3de69f79957`](#source-fda-drugs-nda205054-2018-08-28-d3de69f79957))

### Sources

<a id="source-fda-drugs-nda205054-2018-08-28-d3de69f79957"></a>
- **Drugs@FDA application NDA205054 · original submission status AP · 2018-08-28 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA205054%22&limit=1) (`fda-drugs-nda205054-2018-08-28-d3de69f79957`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA205054." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda205054-v1 SHA-256: e092ac9a883c5dc06de0ce91404c42bd5660cb0750197cbb6bc93f7ee75cb144.

---

<a id="fda-drugs-nda213150-v1"></a>

## Drugs@FDA application NDA213150

> The official Drugs@FDA dataset lists original submission 1 for NDA 213150 with status AP dated 2020-05-01, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda213150:v1`
- Evidence domain: Regulatory
- Date in source: 2020-05-01
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda213150/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda213150-v1
- Content SHA-256: `ad382cd56f8b502f3d72c1324f7cd5bf1c2943bb5e493859082fd084bd262b1c`

### Claims and source pins

#### Headline

Drugs@FDA application NDA213150 ([`fda-drugs-nda213150-2020-05-01-40513bba6c48`](#source-fda-drugs-nda213150-2020-05-01-40513bba6c48))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 213150 with status AP dated 2020-05-01, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda213150-2020-05-01-40513bba6c48`](#source-fda-drugs-nda213150-2020-05-01-40513bba6c48))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 213150 with status AP dated 2020-05-01, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda213150-2020-05-01-40513bba6c48`](#source-fda-drugs-nda213150-2020-05-01-40513bba6c48))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda213150-2020-05-01-40513bba6c48`](#source-fda-drugs-nda213150-2020-05-01-40513bba6c48))

### Sources

<a id="source-fda-drugs-nda213150-2020-05-01-40513bba6c48"></a>
- **Drugs@FDA application NDA213150 · original submission status AP · 2020-05-01 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA213150%22&limit=1) (`fda-drugs-nda213150-2020-05-01-40513bba6c48`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA213150." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda213150-v1 SHA-256: ad382cd56f8b502f3d72c1324f7cd5bf1c2943bb5e493859082fd084bd262b1c.

---

<a id="fda-drugs-nda213225-v1"></a>

## Drugs@FDA application NDA213225

> The official Drugs@FDA dataset lists original submission 1 for NDA 213225 with status AP dated 2026-08-26, and names leuprolide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda213225:v1`
- Evidence domain: Regulatory
- Date in source: 2026-08-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda213225/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda213225-v1
- Content SHA-256: `764e78e1c1e75e149486c243c71a14e51b6516156ce7d71d81a94e0b67b5c36e`

### Claims and source pins

#### Headline

Drugs@FDA application NDA213225 ([`fda-drugs-nda213225-2026-08-26-94e1fef9b739`](#source-fda-drugs-nda213225-2026-08-26-94e1fef9b739))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 213225 with status AP dated 2026-08-26, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda213225-2026-08-26-94e1fef9b739`](#source-fda-drugs-nda213225-2026-08-26-94e1fef9b739))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 213225 with status AP dated 2026-08-26, and names leuprolide acetate among the application record's active ingredients. ([`fda-drugs-nda213225-2026-08-26-94e1fef9b739`](#source-fda-drugs-nda213225-2026-08-26-94e1fef9b739))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda213225-2026-08-26-94e1fef9b739`](#source-fda-drugs-nda213225-2026-08-26-94e1fef9b739))

### Sources

<a id="source-fda-drugs-nda213225-2026-08-26-94e1fef9b739"></a>
- **Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA213225%22&limit=1) (`fda-drugs-nda213225-2026-08-26-94e1fef9b739`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA213225." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-drugs-nda213225-v1 SHA-256: 764e78e1c1e75e149486c243c71a14e51b6516156ce7d71d81a94e0b67b5c36e.

---

<a id="fda-enforcement-d-1178-2023-v1"></a>

## FDA enforcement report D-1178-2023

> FDA's dated enforcement report D-1178-2023 lists Class III and source status Terminated for Tolmar, Inc. PeptideScanner connects the report to reviewed application NDA021379 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-1178-2023:v1`
- Evidence domain: Safety
- Date in source: 2023-10-04
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-1178-2023/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1178-2023-v1
- Content SHA-256: `2e78e1529b1d469485e964b1d2bebc255a4f817b0fdb0e49a17c7fbc5be65892`

### Claims and source pins

#### Headline

FDA enforcement report D-1178-2023 ([`fda-enforcement-d-1178-2023-62ec8c01e26e`](#source-fda-enforcement-d-1178-2023-62ec8c01e26e))

#### Summary

FDA's dated enforcement report D-1178-2023 lists Class III and source status Terminated for Tolmar, Inc. PeptideScanner connects the report to reviewed application NDA021379 through exact openFDA application-number annotations. ([`fda-enforcement-d-1178-2023-62ec8c01e26e`](#source-fda-enforcement-d-1178-2023-62ec8c01e26e))

#### Paragraph 1

FDA's dated enforcement report D-1178-2023 lists Class III and source status Terminated for Tolmar, Inc. PeptideScanner connects the report to reviewed application NDA021379 through exact openFDA application-number annotations. ([`fda-enforcement-d-1178-2023-62ec8c01e26e`](#source-fda-enforcement-d-1178-2023-62ec8c01e26e))

#### Paragraph 2

FDA's source-reported reason is: Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product. ([`fda-enforcement-d-1178-2023-62ec8c01e26e`](#source-fda-enforcement-d-1178-2023-62ec8c01e26e))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-1178-2023-62ec8c01e26e`](#source-fda-enforcement-d-1178-2023-62ec8c01e26e))

### Sources

<a id="source-fda-enforcement-d-1178-2023-62ec8c01e26e"></a>
- **FDA enforcement report D-1178-2023 · Class III · report date 2023-10-04 · source status Terminated** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1178-2023%22&limit=1) (`fda-enforcement-d-1178-2023-62ec8c01e26e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-1178-2023." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1178-2023-v1 SHA-256: 2e78e1529b1d469485e964b1d2bebc255a4f817b0fdb0e49a17c7fbc5be65892.

---

<a id="fda-enforcement-d-1287-2014-v1"></a>

## FDA enforcement report D-1287-2014

> FDA's dated enforcement report D-1287-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-1287-2014:v1`
- Evidence domain: Safety
- Date in source: 2014-05-07
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-1287-2014/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1287-2014-v1
- Content SHA-256: `d1fb7ce839afcbf5a2e69b7e6d3a1e9c1537efefbba44233475dd815016ea244`

### Claims and source pins

#### Headline

FDA enforcement report D-1287-2014 ([`fda-enforcement-d-1287-2014-d2ccaca025bc`](#source-fda-enforcement-d-1287-2014-d2ccaca025bc))

#### Summary

FDA's dated enforcement report D-1287-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations. ([`fda-enforcement-d-1287-2014-d2ccaca025bc`](#source-fda-enforcement-d-1287-2014-d2ccaca025bc))

#### Paragraph 1

FDA's dated enforcement report D-1287-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations. ([`fda-enforcement-d-1287-2014-d2ccaca025bc`](#source-fda-enforcement-d-1287-2014-d2ccaca025bc))

#### Paragraph 2

FDA's source-reported reason is: Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device. ([`fda-enforcement-d-1287-2014-d2ccaca025bc`](#source-fda-enforcement-d-1287-2014-d2ccaca025bc))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-1287-2014-d2ccaca025bc`](#source-fda-enforcement-d-1287-2014-d2ccaca025bc))

### Sources

<a id="source-fda-enforcement-d-1287-2014-d2ccaca025bc"></a>
- **FDA enforcement report D-1287-2014 · Class II · report date 2014-05-07 · source status Terminated** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1287-2014%22&limit=1) (`fda-enforcement-d-1287-2014-d2ccaca025bc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-1287-2014." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1287-2014-v1 SHA-256: d1fb7ce839afcbf5a2e69b7e6d3a1e9c1537efefbba44233475dd815016ea244.

---

<a id="fda-enforcement-d-1288-2014-v1"></a>

## FDA enforcement report D-1288-2014

> FDA's dated enforcement report D-1288-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-1288-2014:v1`
- Evidence domain: Safety
- Date in source: 2014-05-07
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-1288-2014/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1288-2014-v1
- Content SHA-256: `da2242a00d29ba0465b65a77cd1c50888b5af0cf751bc774f5245c4a8f1ea50e`

### Claims and source pins

#### Headline

FDA enforcement report D-1288-2014 ([`fda-enforcement-d-1288-2014-03719cd660a8`](#source-fda-enforcement-d-1288-2014-03719cd660a8))

#### Summary

FDA's dated enforcement report D-1288-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations. ([`fda-enforcement-d-1288-2014-03719cd660a8`](#source-fda-enforcement-d-1288-2014-03719cd660a8))

#### Paragraph 1

FDA's dated enforcement report D-1288-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations. ([`fda-enforcement-d-1288-2014-03719cd660a8`](#source-fda-enforcement-d-1288-2014-03719cd660a8))

#### Paragraph 2

FDA's source-reported reason is: Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device. ([`fda-enforcement-d-1288-2014-03719cd660a8`](#source-fda-enforcement-d-1288-2014-03719cd660a8))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-1288-2014-03719cd660a8`](#source-fda-enforcement-d-1288-2014-03719cd660a8))

### Sources

<a id="source-fda-enforcement-d-1288-2014-03719cd660a8"></a>
- **FDA enforcement report D-1288-2014 · Class II · report date 2014-05-07 · source status Terminated** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1288-2014%22&limit=1) (`fda-enforcement-d-1288-2014-03719cd660a8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-1288-2014." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1288-2014-v1 SHA-256: da2242a00d29ba0465b65a77cd1c50888b5af0cf751bc774f5245c4a8f1ea50e.

---

<a id="fda-enforcement-d-1289-2014-v1"></a>

## FDA enforcement report D-1289-2014

> FDA's dated enforcement report D-1289-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020263 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-1289-2014:v1`
- Evidence domain: Safety
- Date in source: 2014-05-07
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-1289-2014/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1289-2014-v1
- Content SHA-256: `39a52c4da6a5da50120562a082c7ebdf549643c21358f2569f38d194a9c26b4c`

### Claims and source pins

#### Headline

FDA enforcement report D-1289-2014 ([`fda-enforcement-d-1289-2014-8c6d14481452`](#source-fda-enforcement-d-1289-2014-8c6d14481452))

#### Summary

FDA's dated enforcement report D-1289-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020263 through exact openFDA application-number annotations. ([`fda-enforcement-d-1289-2014-8c6d14481452`](#source-fda-enforcement-d-1289-2014-8c6d14481452))

#### Paragraph 1

FDA's dated enforcement report D-1289-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020263 through exact openFDA application-number annotations. ([`fda-enforcement-d-1289-2014-8c6d14481452`](#source-fda-enforcement-d-1289-2014-8c6d14481452))

#### Paragraph 2

FDA's source-reported reason is: Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device. ([`fda-enforcement-d-1289-2014-8c6d14481452`](#source-fda-enforcement-d-1289-2014-8c6d14481452))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-1289-2014-8c6d14481452`](#source-fda-enforcement-d-1289-2014-8c6d14481452))

### Sources

<a id="source-fda-enforcement-d-1289-2014-8c6d14481452"></a>
- **FDA enforcement report D-1289-2014 · Class II · report date 2014-05-07 · source status Terminated** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1289-2014%22&limit=1) (`fda-enforcement-d-1289-2014-8c6d14481452`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-1289-2014." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1289-2014-v1 SHA-256: 39a52c4da6a5da50120562a082c7ebdf549643c21358f2569f38d194a9c26b4c.

---

<a id="fda-enforcement-d-1290-2014-v1"></a>

## FDA enforcement report D-1290-2014

> FDA's dated enforcement report D-1290-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020708 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-1290-2014:v1`
- Evidence domain: Safety
- Date in source: 2014-05-07
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-1290-2014/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1290-2014-v1
- Content SHA-256: `788dd7a5f5d070738f8107500fd1c0e01c9a5a462d4af43afc09fad3ed3174c0`

### Claims and source pins

#### Headline

FDA enforcement report D-1290-2014 ([`fda-enforcement-d-1290-2014-d39d745a3a16`](#source-fda-enforcement-d-1290-2014-d39d745a3a16))

#### Summary

FDA's dated enforcement report D-1290-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020708 through exact openFDA application-number annotations. ([`fda-enforcement-d-1290-2014-d39d745a3a16`](#source-fda-enforcement-d-1290-2014-d39d745a3a16))

#### Paragraph 1

FDA's dated enforcement report D-1290-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020708 through exact openFDA application-number annotations. ([`fda-enforcement-d-1290-2014-d39d745a3a16`](#source-fda-enforcement-d-1290-2014-d39d745a3a16))

#### Paragraph 2

FDA's source-reported reason is: Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device. ([`fda-enforcement-d-1290-2014-d39d745a3a16`](#source-fda-enforcement-d-1290-2014-d39d745a3a16))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-1290-2014-d39d745a3a16`](#source-fda-enforcement-d-1290-2014-d39d745a3a16))

### Sources

<a id="source-fda-enforcement-d-1290-2014-d39d745a3a16"></a>
- **FDA enforcement report D-1290-2014 · Class II · report date 2014-05-07 · source status Terminated** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1290-2014%22&limit=1) (`fda-enforcement-d-1290-2014-d39d745a3a16`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-1290-2014." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1290-2014-v1 SHA-256: 788dd7a5f5d070738f8107500fd1c0e01c9a5a462d4af43afc09fad3ed3174c0.

---

<a id="fda-enforcement-d-1291-2014-v1"></a>

## FDA enforcement report D-1291-2014

> FDA's dated enforcement report D-1291-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-1291-2014:v1`
- Evidence domain: Safety
- Date in source: 2014-05-07
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-1291-2014/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1291-2014-v1
- Content SHA-256: `9412d5c0cb9538e2d8a18692f4f9cc687599cb69ad6da4c847153a718c18ad70`

### Claims and source pins

#### Headline

FDA enforcement report D-1291-2014 ([`fda-enforcement-d-1291-2014-b8bdd22d41b8`](#source-fda-enforcement-d-1291-2014-b8bdd22d41b8))

#### Summary

FDA's dated enforcement report D-1291-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations. ([`fda-enforcement-d-1291-2014-b8bdd22d41b8`](#source-fda-enforcement-d-1291-2014-b8bdd22d41b8))

#### Paragraph 1

FDA's dated enforcement report D-1291-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations. ([`fda-enforcement-d-1291-2014-b8bdd22d41b8`](#source-fda-enforcement-d-1291-2014-b8bdd22d41b8))

#### Paragraph 2

FDA's source-reported reason is: Defective Delivery System: Some Lupron Depot Kits may containin a syringe with a potentially defective LuproLoc needle stick protection device. ([`fda-enforcement-d-1291-2014-b8bdd22d41b8`](#source-fda-enforcement-d-1291-2014-b8bdd22d41b8))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-1291-2014-b8bdd22d41b8`](#source-fda-enforcement-d-1291-2014-b8bdd22d41b8))

### Sources

<a id="source-fda-enforcement-d-1291-2014-b8bdd22d41b8"></a>
- **FDA enforcement report D-1291-2014 · Class II · report date 2014-05-07 · source status Terminated** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1291-2014%22&limit=1) (`fda-enforcement-d-1291-2014-b8bdd22d41b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-1291-2014." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#fda-enforcement-d-1291-2014-v1 SHA-256: 9412d5c0cb9538e2d8a18692f4f9cc687599cb69ad6da4c847153a718c18ad70.

---

<a id="federal-register-05-20301-v1"></a>

## Federal Register notice 05-20301

> The Federal Register published notice 05-20301, attributed to FDA and its parent HHS department, on 2005-10-07. Its official title is “Solicitation of Public Review and Comment on Research Protocol: Gonadotropin-releasing Hormone Agonist Test in Disorders of Puberty,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-05-20301:v1`
- Evidence domain: Regulatory
- Date in source: 2005-10-07
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-05-20301/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-05-20301-v1
- Content SHA-256: `4acb0d2955de471c7a9cd378be1481878093d9114c84d70db30e2b88ce8e30cb`

### Claims and source pins

#### Headline

Federal Register notice 05-20301 ([`federal-register-05-20301-6059b21e522c`](#source-federal-register-05-20301-6059b21e522c))

#### Summary

The Federal Register published notice 05-20301, attributed to FDA and its parent HHS department, on 2005-10-07. Its official title is “Solicitation of Public Review and Comment on Research Protocol: Gonadotropin-releasing Hormone Agonist Test in Disorders of Puberty,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-05-20301-6059b21e522c`](#source-federal-register-05-20301-6059b21e522c))

#### Paragraph 1

The Federal Register published notice 05-20301, attributed to FDA and its parent HHS department, on 2005-10-07. Its official title is “Solicitation of Public Review and Comment on Research Protocol: Gonadotropin-releasing Hormone Agonist Test in Disorders of Puberty,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-05-20301-6059b21e522c`](#source-federal-register-05-20301-6059b21e522c))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-05-20301-6059b21e522c`](#source-federal-register-05-20301-6059b21e522c))

### Sources

<a id="source-federal-register-05-20301-6059b21e522c"></a>
- **Federal Register notice 05-20301 · published 2005-10-07 · Solicitation of Public Review and Comment on Research Protocol: Gonadotropin-releasing Hormone Agonist Test in Disorders of Puberty** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2005-10-07/pdf/05-20301.pdf) (`federal-register-05-20301-6059b21e522c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 05-20301." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-05-20301-v1 SHA-256: 4acb0d2955de471c7a9cd378be1481878093d9114c84d70db30e2b88ce8e30cb.

---

<a id="federal-register-05-20302-v1"></a>

## Federal Register notice 05-20302

> The Federal Register published notice 05-20302, attributed to FDA and its parent HHS department, on 2005-10-07. Its official title is “Pediatric Ethics Subcommittee of the Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-05-20302:v1`
- Evidence domain: Regulatory
- Date in source: 2005-10-07
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-05-20302/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-05-20302-v1
- Content SHA-256: `8b5b33e1bf60ce01284ad397d8766cb7e597c60df91e2a3a2de14d824f17d6fa`

### Claims and source pins

#### Headline

Federal Register notice 05-20302 ([`federal-register-05-20302-055c18a87f67`](#source-federal-register-05-20302-055c18a87f67))

#### Summary

The Federal Register published notice 05-20302, attributed to FDA and its parent HHS department, on 2005-10-07. Its official title is “Pediatric Ethics Subcommittee of the Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-05-20302-055c18a87f67`](#source-federal-register-05-20302-055c18a87f67))

#### Paragraph 1

The Federal Register published notice 05-20302, attributed to FDA and its parent HHS department, on 2005-10-07. Its official title is “Pediatric Ethics Subcommittee of the Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-05-20302-055c18a87f67`](#source-federal-register-05-20302-055c18a87f67))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-05-20302-055c18a87f67`](#source-federal-register-05-20302-055c18a87f67))

### Sources

<a id="source-federal-register-05-20302-055c18a87f67"></a>
- **Federal Register notice 05-20302 · published 2005-10-07 · Pediatric Ethics Subcommittee of the Pediatric Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2005-10-07/pdf/05-20302.pdf) (`federal-register-05-20302-055c18a87f67`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 05-20302." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-05-20302-v1 SHA-256: 8b5b33e1bf60ce01284ad397d8766cb7e597c60df91e2a3a2de14d824f17d6fa.

---

<a id="federal-register-2011-14164-v1"></a>

## Federal Register notice 2011-14164

> The Federal Register published notice 2011-14164, attributed to FDA and its parent HHS department, on 2011-06-08. Its official title is “Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-2011-14164:v1`
- Evidence domain: Regulatory
- Date in source: 2011-06-08
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2011-14164/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2011-14164-v1
- Content SHA-256: `9b3918c1b35e34d23614d740e85c6a480fb782af152d9f7b3bba1abb0f0d0004`

### Claims and source pins

#### Headline

Federal Register notice 2011-14164 ([`federal-register-2011-14164-c595ae1b481a`](#source-federal-register-2011-14164-c595ae1b481a))

#### Summary

The Federal Register published notice 2011-14164, attributed to FDA and its parent HHS department, on 2011-06-08. Its official title is “Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2011-14164-c595ae1b481a`](#source-federal-register-2011-14164-c595ae1b481a))

#### Paragraph 1

The Federal Register published notice 2011-14164, attributed to FDA and its parent HHS department, on 2011-06-08. Its official title is “Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2011-14164-c595ae1b481a`](#source-federal-register-2011-14164-c595ae1b481a))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2011-14164-c595ae1b481a`](#source-federal-register-2011-14164-c595ae1b481a))

### Sources

<a id="source-federal-register-2011-14164-c595ae1b481a"></a>
- **Federal Register notice 2011-14164 · published 2011-06-08 · Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2011-06-08/pdf/2011-14164.pdf) (`federal-register-2011-14164-c595ae1b481a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2011-14164." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2011-14164-v1 SHA-256: 9b3918c1b35e34d23614d740e85c6a480fb782af152d9f7b3bba1abb0f0d0004.

---

<a id="federal-register-2012-1433-v1"></a>

## Federal Register notice 2012-1433

> The Federal Register published notice 2012-1433, attributed to FDA and its parent HHS department, on 2012-01-25. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

- Evidence object: `story:federal-register-2012-1433:v1`
- Evidence domain: Regulatory
- Date in source: 2012-01-25
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-1433/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2012-1433-v1
- Content SHA-256: `32ec40bfaa0188c601077092b3f13bc1a20e19e5ad115d7422e3e4e6b01dea92`

### Claims and source pins

#### Headline

Federal Register notice 2012-1433 ([`federal-register-2012-1433-764ac8def52e`](#source-federal-register-2012-1433-764ac8def52e))

#### Summary

The Federal Register published notice 2012-1433, attributed to FDA and its parent HHS department, on 2012-01-25. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide. ([`federal-register-2012-1433-764ac8def52e`](#source-federal-register-2012-1433-764ac8def52e))

#### Paragraph 1

The Federal Register published notice 2012-1433, attributed to FDA and its parent HHS department, on 2012-01-25. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide. ([`federal-register-2012-1433-764ac8def52e`](#source-federal-register-2012-1433-764ac8def52e))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-1433-764ac8def52e`](#source-federal-register-2012-1433-764ac8def52e))

### Sources

<a id="source-federal-register-2012-1433-764ac8def52e"></a>
- **Federal Register notice 2012-1433 · published 2012-01-25 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-01-25/pdf/2012-1433.pdf) (`federal-register-2012-1433-764ac8def52e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2012-1433." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2012-1433-v1 SHA-256: 32ec40bfaa0188c601077092b3f13bc1a20e19e5ad115d7422e3e4e6b01dea92.

---

<a id="federal-register-2014-07330-v1"></a>

## Federal Register notice 2014-07330

> The Federal Register published notice 2014-07330, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

- Evidence object: `story:federal-register-2014-07330:v1`
- Evidence domain: Regulatory
- Date in source: 2014-04-02
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-07330/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2014-07330-v1
- Content SHA-256: `3c39179487c3b834dc4bc24bb927627ea6dd41249a99fe7fa01b33b34ba21bd3`

### Claims and source pins

#### Headline

Federal Register notice 2014-07330 ([`federal-register-2014-07330-d4e2abb7abdb`](#source-federal-register-2014-07330-d4e2abb7abdb))

#### Summary

The Federal Register published notice 2014-07330, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide. ([`federal-register-2014-07330-d4e2abb7abdb`](#source-federal-register-2014-07330-d4e2abb7abdb))

#### Paragraph 1

The Federal Register published notice 2014-07330, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide. ([`federal-register-2014-07330-d4e2abb7abdb`](#source-federal-register-2014-07330-d4e2abb7abdb))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-07330-d4e2abb7abdb`](#source-federal-register-2014-07330-d4e2abb7abdb))

### Sources

<a id="source-federal-register-2014-07330-d4e2abb7abdb"></a>
- **Federal Register notice 2014-07330 · published 2014-04-02 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07330.pdf) (`federal-register-2014-07330-d4e2abb7abdb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2014-07330." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2014-07330-v1 SHA-256: 3c39179487c3b834dc4bc24bb927627ea6dd41249a99fe7fa01b33b34ba21bd3.

---

<a id="federal-register-2014-19713-v1"></a>

## Federal Register notice 2014-19713

> The Federal Register published notice 2014-19713, attributed to FDA and its parent HHS department, on 2014-08-20. Its official title is “Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-2014-19713:v1`
- Evidence domain: Regulatory
- Date in source: 2014-08-20
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-19713/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2014-19713-v1
- Content SHA-256: `c062f77a890b85ce0a5cd7e650415838b58dda7e323a51c9fc6e8d9f2f35d8f3`

### Claims and source pins

#### Headline

Federal Register notice 2014-19713 ([`federal-register-2014-19713-8c38ede7a118`](#source-federal-register-2014-19713-8c38ede7a118))

#### Summary

The Federal Register published notice 2014-19713, attributed to FDA and its parent HHS department, on 2014-08-20. Its official title is “Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2014-19713-8c38ede7a118`](#source-federal-register-2014-19713-8c38ede7a118))

#### Paragraph 1

The Federal Register published notice 2014-19713, attributed to FDA and its parent HHS department, on 2014-08-20. Its official title is “Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2014-19713-8c38ede7a118`](#source-federal-register-2014-19713-8c38ede7a118))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-19713-8c38ede7a118`](#source-federal-register-2014-19713-8c38ede7a118))

### Sources

<a id="source-federal-register-2014-19713-8c38ede7a118"></a>
- **Federal Register notice 2014-19713 · published 2014-08-20 · Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-08-20/pdf/2014-19713.pdf) (`federal-register-2014-19713-8c38ede7a118`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2014-19713." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2014-19713-v1 SHA-256: c062f77a890b85ce0a5cd7e650415838b58dda7e323a51c9fc6e8d9f2f35d8f3.

---

<a id="federal-register-2014-23961-v1"></a>

## Federal Register notice 2014-23961

> The Federal Register published notice 2014-23961, attributed to FDA and its parent HHS department, on 2014-10-08. Its official title is “Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-2014-23961:v1`
- Evidence domain: Regulatory
- Date in source: 2014-10-08
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-23961/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2014-23961-v1
- Content SHA-256: `9f002e0a4e0cb0ab6aafa749c9ab4d3735841bcd92f08d59a8d38db326d76e86`

### Claims and source pins

#### Headline

Federal Register notice 2014-23961 ([`federal-register-2014-23961-97a9930e6662`](#source-federal-register-2014-23961-97a9930e6662))

#### Summary

The Federal Register published notice 2014-23961, attributed to FDA and its parent HHS department, on 2014-10-08. Its official title is “Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2014-23961-97a9930e6662`](#source-federal-register-2014-23961-97a9930e6662))

#### Paragraph 1

The Federal Register published notice 2014-23961, attributed to FDA and its parent HHS department, on 2014-10-08. Its official title is “Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2014-23961-97a9930e6662`](#source-federal-register-2014-23961-97a9930e6662))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-23961-97a9930e6662`](#source-federal-register-2014-23961-97a9930e6662))

### Sources

<a id="source-federal-register-2014-23961-97a9930e6662"></a>
- **Federal Register notice 2014-23961 · published 2014-10-08 · Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-10-08/pdf/2014-23961.pdf) (`federal-register-2014-23961-97a9930e6662`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2014-23961." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2014-23961-v1 SHA-256: 9f002e0a4e0cb0ab6aafa749c9ab4d3735841bcd92f08d59a8d38db326d76e86.

---

<a id="federal-register-2017-12908-v1"></a>

## Federal Register notice 2017-12908

> The Federal Register published notice 2017-12908, attributed to FDA and its parent HHS department, on 2017-06-21. Its official title is “Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

- Evidence object: `story:federal-register-2017-12908:v1`
- Evidence domain: Regulatory
- Date in source: 2017-06-21
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2017-12908/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2017-12908-v1
- Content SHA-256: `7b60d743a6132d1d4d6f250d9be98af0b7e94ef3ad93dbb8cd36d75587131323`

### Claims and source pins

#### Headline

Federal Register notice 2017-12908 ([`federal-register-2017-12908-ed15c5980142`](#source-federal-register-2017-12908-ed15c5980142))

#### Summary

The Federal Register published notice 2017-12908, attributed to FDA and its parent HHS department, on 2017-06-21. Its official title is “Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide. ([`federal-register-2017-12908-ed15c5980142`](#source-federal-register-2017-12908-ed15c5980142))

#### Paragraph 1

The Federal Register published notice 2017-12908, attributed to FDA and its parent HHS department, on 2017-06-21. Its official title is “Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide. ([`federal-register-2017-12908-ed15c5980142`](#source-federal-register-2017-12908-ed15c5980142))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2017-12908-ed15c5980142`](#source-federal-register-2017-12908-ed15c5980142))

### Sources

<a id="source-federal-register-2017-12908-ed15c5980142"></a>
- **Federal Register notice 2017-12908 · published 2017-06-21 · Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2017-06-21/pdf/2017-12908.pdf) (`federal-register-2017-12908-ed15c5980142`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2017-12908." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2017-12908-v1 SHA-256: 7b60d743a6132d1d4d6f250d9be98af0b7e94ef3ad93dbb8cd36d75587131323.

---

<a id="federal-register-2018-02667-v1"></a>

## Federal Register notice 2018-02667

> The Federal Register published notice 2018-02667, attributed to FDA and its parent HHS department, on 2018-02-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-2018-02667:v1`
- Evidence domain: Regulatory
- Date in source: 2018-02-09
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2018-02667/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2018-02667-v1
- Content SHA-256: `f2bb1c77be8d14bb189a4ffd385f0982118f6f7d3f4388806677f9d75d466792`

### Claims and source pins

#### Headline

Federal Register notice 2018-02667 ([`federal-register-2018-02667-1af51a9879d2`](#source-federal-register-2018-02667-1af51a9879d2))

#### Summary

The Federal Register published notice 2018-02667, attributed to FDA and its parent HHS department, on 2018-02-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2018-02667-1af51a9879d2`](#source-federal-register-2018-02667-1af51a9879d2))

#### Paragraph 1

The Federal Register published notice 2018-02667, attributed to FDA and its parent HHS department, on 2018-02-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2018-02667-1af51a9879d2`](#source-federal-register-2018-02667-1af51a9879d2))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2018-02667-1af51a9879d2`](#source-federal-register-2018-02667-1af51a9879d2))

### Sources

<a id="source-federal-register-2018-02667-1af51a9879d2"></a>
- **Federal Register notice 2018-02667 · published 2018-02-09 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02667.pdf) (`federal-register-2018-02667-1af51a9879d2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2018-02667." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2018-02667-v1 SHA-256: f2bb1c77be8d14bb189a4ffd385f0982118f6f7d3f4388806677f9d75d466792.

---

<a id="federal-register-2019-11243-v1"></a>

## Federal Register notice 2019-11243

> The Federal Register published notice 2019-11243, attributed to FDA and its parent HHS department, on 2019-05-30. Its official title is “Determination That LUPRON (Leuprolide Acetate) Injection, 1 Milligram/0.2 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-2019-11243:v1`
- Evidence domain: Regulatory
- Date in source: 2019-05-30
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2019-11243/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2019-11243-v1
- Content SHA-256: `93dd17bb5a4fe03fe8cde0ca7199b8bfeef008dafec8adcca1404979145ce1d2`

### Claims and source pins

#### Headline

Federal Register notice 2019-11243 ([`federal-register-2019-11243-ad3c64e46626`](#source-federal-register-2019-11243-ad3c64e46626))

#### Summary

The Federal Register published notice 2019-11243, attributed to FDA and its parent HHS department, on 2019-05-30. Its official title is “Determination That LUPRON (Leuprolide Acetate) Injection, 1 Milligram/0.2 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2019-11243-ad3c64e46626`](#source-federal-register-2019-11243-ad3c64e46626))

#### Paragraph 1

The Federal Register published notice 2019-11243, attributed to FDA and its parent HHS department, on 2019-05-30. Its official title is “Determination That LUPRON (Leuprolide Acetate) Injection, 1 Milligram/0.2 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2019-11243-ad3c64e46626`](#source-federal-register-2019-11243-ad3c64e46626))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2019-11243-ad3c64e46626`](#source-federal-register-2019-11243-ad3c64e46626))

### Sources

<a id="source-federal-register-2019-11243-ad3c64e46626"></a>
- **Federal Register notice 2019-11243 · published 2019-05-30 · Determination That LUPRON (Leuprolide Acetate) Injection, 1 Milligram/0.2 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2019-05-30/pdf/2019-11243.pdf) (`federal-register-2019-11243-ad3c64e46626`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2019-11243." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2019-11243-v1 SHA-256: 93dd17bb5a4fe03fe8cde0ca7199b8bfeef008dafec8adcca1404979145ce1d2.

---

<a id="federal-register-2021-18072-v1"></a>

## Federal Register notice 2021-18072

> The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide.

- Evidence object: `story:federal-register-2021-18072:v1`
- Evidence domain: Regulatory
- Date in source: 2021-08-23
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2021-18072/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2021-18072-v1
- Content SHA-256: `b22535a229c943eaae5423cffce53c238350b13034e4702334d11435297860d5`

### Claims and source pins

#### Headline

Federal Register notice 2021-18072 ([`federal-register-2021-18072-ab8c99bb7f57`](#source-federal-register-2021-18072-ab8c99bb7f57))

#### Summary

The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide. ([`federal-register-2021-18072-ab8c99bb7f57`](#source-federal-register-2021-18072-ab8c99bb7f57))

#### Paragraph 1

The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide. ([`federal-register-2021-18072-ab8c99bb7f57`](#source-federal-register-2021-18072-ab8c99bb7f57))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2021-18072-ab8c99bb7f57`](#source-federal-register-2021-18072-ab8c99bb7f57))

### Sources

<a id="source-federal-register-2021-18072-ab8c99bb7f57"></a>
- **Federal Register notice 2021-18072 · published 2021-08-23 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2021-08-23/pdf/2021-18072.pdf) (`federal-register-2021-18072-ab8c99bb7f57`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2021-18072." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2021-18072-v1 SHA-256: b22535a229c943eaae5423cffce53c238350b13034e4702334d11435297860d5.

---

<a id="federal-register-2022-03248-v1"></a>

## Federal Register notice 2022-03248

> The Federal Register published notice 2022-03248, attributed to FDA and its parent HHS department, on 2022-02-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-2022-03248:v1`
- Evidence domain: Regulatory
- Date in source: 2022-02-18
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2022-03248/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2022-03248-v1
- Content SHA-256: `407b2967ff954a9e380bc1a16ea5fd1af2b4ffd617b52c364cb546b0ef53d61b`

### Claims and source pins

#### Headline

Federal Register notice 2022-03248 ([`federal-register-2022-03248-c77a008b26a0`](#source-federal-register-2022-03248-c77a008b26a0))

#### Summary

The Federal Register published notice 2022-03248, attributed to FDA and its parent HHS department, on 2022-02-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2022-03248-c77a008b26a0`](#source-federal-register-2022-03248-c77a008b26a0))

#### Paragraph 1

The Federal Register published notice 2022-03248, attributed to FDA and its parent HHS department, on 2022-02-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2022-03248-c77a008b26a0`](#source-federal-register-2022-03248-c77a008b26a0))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2022-03248-c77a008b26a0`](#source-federal-register-2022-03248-c77a008b26a0))

### Sources

<a id="source-federal-register-2022-03248-c77a008b26a0"></a>
- **Federal Register notice 2022-03248 · published 2022-02-18 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2022-02-18/pdf/2022-03248.pdf) (`federal-register-2022-03248-c77a008b26a0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2022-03248." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2022-03248-v1 SHA-256: 407b2967ff954a9e380bc1a16ea5fd1af2b4ffd617b52c364cb546b0ef53d61b.

---

<a id="federal-register-2024-04218-v1"></a>

## Federal Register notice 2024-04218

> The Federal Register published notice 2024-04218, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CAMCEVI,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-2024-04218:v1`
- Evidence domain: Regulatory
- Date in source: 2024-02-29
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-04218/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2024-04218-v1
- Content SHA-256: `713bed7f8842d504182951693874880ded2eced525ece8918fbb3429ea2f0fb3`

### Claims and source pins

#### Headline

Federal Register notice 2024-04218 ([`federal-register-2024-04218-acb75806c6b1`](#source-federal-register-2024-04218-acb75806c6b1))

#### Summary

The Federal Register published notice 2024-04218, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CAMCEVI,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2024-04218-acb75806c6b1`](#source-federal-register-2024-04218-acb75806c6b1))

#### Paragraph 1

The Federal Register published notice 2024-04218, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CAMCEVI,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2024-04218-acb75806c6b1`](#source-federal-register-2024-04218-acb75806c6b1))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-04218-acb75806c6b1`](#source-federal-register-2024-04218-acb75806c6b1))

### Sources

<a id="source-federal-register-2024-04218-acb75806c6b1"></a>
- **Federal Register notice 2024-04218 · published 2024-02-29 · Determination of Regulatory Review Period for Purposes of Patent Extension; CAMCEVI** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04218.pdf) (`federal-register-2024-04218-acb75806c6b1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-04218." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2024-04218-v1 SHA-256: 713bed7f8842d504182951693874880ded2eced525ece8918fbb3429ea2f0fb3.

---

<a id="federal-register-2024-08657-v1"></a>

## Federal Register notice 2024-08657

> The Federal Register published notice 2024-08657, attributed to FDA and its parent HHS department, on 2024-04-23. Its official title is “PAI Holdings, LLC DBA Pharmaceutical Associates, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-2024-08657:v1`
- Evidence domain: Regulatory
- Date in source: 2024-04-23
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-08657/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2024-08657-v1
- Content SHA-256: `53ab047b6545ab7ed0fe576fb0b1d5e36c0540add8dd9f0c224f8c209bf94c51`

### Claims and source pins

#### Headline

Federal Register notice 2024-08657 ([`federal-register-2024-08657-08381a0fe84b`](#source-federal-register-2024-08657-08381a0fe84b))

#### Summary

The Federal Register published notice 2024-08657, attributed to FDA and its parent HHS department, on 2024-04-23. Its official title is “PAI Holdings, LLC DBA Pharmaceutical Associates, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2024-08657-08381a0fe84b`](#source-federal-register-2024-08657-08381a0fe84b))

#### Paragraph 1

The Federal Register published notice 2024-08657, attributed to FDA and its parent HHS department, on 2024-04-23. Its official title is “PAI Holdings, LLC DBA Pharmaceutical Associates, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-2024-08657-08381a0fe84b`](#source-federal-register-2024-08657-08381a0fe84b))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-08657-08381a0fe84b`](#source-federal-register-2024-08657-08381a0fe84b))

### Sources

<a id="source-federal-register-2024-08657-08381a0fe84b"></a>
- **Federal Register notice 2024-08657 · published 2024-04-23 · PAI Holdings, LLC DBA Pharmaceutical Associates, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-04-23/pdf/2024-08657.pdf) (`federal-register-2024-08657-08381a0fe84b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-08657." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2024-08657-v1 SHA-256: 53ab047b6545ab7ed0fe576fb0b1d5e36c0540add8dd9f0c224f8c209bf94c51.

---

<a id="federal-register-2026-17222-v1"></a>

## Federal Register notice 2026-17222

> The Federal Register published notice 2026-17222, attributed to FDA and its parent HHS department, on 2026-08-24. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

- Evidence object: `story:federal-register-2026-17222:v1`
- Evidence domain: Regulatory
- Date in source: 2026-08-24
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/federal-register-2026-17222/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2026-17222-v1
- Content SHA-256: `6a9f92376a8aeac5d30da59d623c9ee327f0ea20f05c1ff7ce053b9b0bb8580f`

### Claims and source pins

#### Headline

Federal Register notice 2026-17222 ([`federal-register-2026-17222-233bfb4ecf80`](#source-federal-register-2026-17222-233bfb4ecf80))

#### Summary

The Federal Register published notice 2026-17222, attributed to FDA and its parent HHS department, on 2026-08-24. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide. ([`federal-register-2026-17222-233bfb4ecf80`](#source-federal-register-2026-17222-233bfb4ecf80))

#### Paragraph 1

The Federal Register published notice 2026-17222, attributed to FDA and its parent HHS department, on 2026-08-24. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide. ([`federal-register-2026-17222-233bfb4ecf80`](#source-federal-register-2026-17222-233bfb4ecf80))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2026-17222-233bfb4ecf80`](#source-federal-register-2026-17222-233bfb4ecf80))

### Sources

<a id="source-federal-register-2026-17222-233bfb4ecf80"></a>
- **Federal Register notice 2026-17222 · published 2026-08-24 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2026-08-24/pdf/2026-17222.pdf) (`federal-register-2026-17222-233bfb4ecf80`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2026-17222." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-2026-17222-v1 SHA-256: 6a9f92376a8aeac5d30da59d623c9ee327f0ea20f05c1ff7ce053b9b0bb8580f.

---

<a id="federal-register-98-13045-v1"></a>

## Federal Register notice 98-13045

> The Federal Register published notice 98-13045, attributed to FDA and its parent HHS department, on 1998-05-18. Its official title is “Environmental Assessments and Findings of No Significant Impact,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-98-13045:v1`
- Evidence domain: Regulatory
- Date in source: 1998-05-18
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-98-13045/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-98-13045-v1
- Content SHA-256: `deebedd41609bf607d3395e9d29f896aca9e6663170a227a26aa6464aac11d3c`

### Claims and source pins

#### Headline

Federal Register notice 98-13045 ([`federal-register-98-13045-6aae5f1cb450`](#source-federal-register-98-13045-6aae5f1cb450))

#### Summary

The Federal Register published notice 98-13045, attributed to FDA and its parent HHS department, on 1998-05-18. Its official title is “Environmental Assessments and Findings of No Significant Impact,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-98-13045-6aae5f1cb450`](#source-federal-register-98-13045-6aae5f1cb450))

#### Paragraph 1

The Federal Register published notice 98-13045, attributed to FDA and its parent HHS department, on 1998-05-18. Its official title is “Environmental Assessments and Findings of No Significant Impact,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-98-13045-6aae5f1cb450`](#source-federal-register-98-13045-6aae5f1cb450))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-98-13045-6aae5f1cb450`](#source-federal-register-98-13045-6aae5f1cb450))

### Sources

<a id="source-federal-register-98-13045-6aae5f1cb450"></a>
- **Federal Register notice 98-13045 · published 1998-05-18 · Environmental Assessments and Findings of No Significant Impact** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1998-05-18/pdf/98-13045.pdf) (`federal-register-98-13045-6aae5f1cb450`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 98-13045." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-98-13045-v1 SHA-256: deebedd41609bf607d3395e9d29f896aca9e6663170a227a26aa6464aac11d3c.

---

<a id="federal-register-e9-13272-v1"></a>

## Federal Register notice E9-13272

> The Federal Register published notice E9-13272, attributed to FDA and its parent HHS department, on 2009-06-08. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

- Evidence object: `story:federal-register-e9-13272:v1`
- Evidence domain: Regulatory
- Date in source: 2009-06-08
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-e9-13272/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-e9-13272-v1
- Content SHA-256: `73f1cdcefa98f0be938cc020776ecd47bb53e36f506ecdc2edf1aad73053df78`

### Claims and source pins

#### Headline

Federal Register notice E9-13272 ([`federal-register-e9-13272-48a81f26d2a2`](#source-federal-register-e9-13272-48a81f26d2a2))

#### Summary

The Federal Register published notice E9-13272, attributed to FDA and its parent HHS department, on 2009-06-08. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-e9-13272-48a81f26d2a2`](#source-federal-register-e9-13272-48a81f26d2a2))

#### Paragraph 1

The Federal Register published notice E9-13272, attributed to FDA and its parent HHS department, on 2009-06-08. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide. ([`federal-register-e9-13272-48a81f26d2a2`](#source-federal-register-e9-13272-48a81f26d2a2))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e9-13272-48a81f26d2a2`](#source-federal-register-e9-13272-48a81f26d2a2))

### Sources

<a id="source-federal-register-e9-13272-48a81f26d2a2"></a>
- **Federal Register notice E9-13272 · published 2009-06-08 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2009-06-08/pdf/E9-13272.pdf) (`federal-register-e9-13272-48a81f26d2a2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E9-13272." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#federal-register-e9-13272-v1 SHA-256: 73f1cdcefa98f0be938cc020776ecd47bb53e36f506ecdc2edf1aad73053df78.

---

<a id="pubmed-pmid-10321505-leuprolide-v1"></a>

## Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients.

> PubMed lists PMID 10321505 in Cancer chemotherapy and pharmacology as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999 (year precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10321505-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10321505-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-10321505-leuprolide-v1
- Content SHA-256: `f968dfb41ea1fb7047e0eb3d082b826632bbc56e0aacec684a97b7a28db704ed`

### Claims and source pins

#### Headline

Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. ([`pubmed-observation-pmid-10321505-2013-11-21-1c913976d8d6`](#source-pubmed-observation-pmid-10321505-2013-11-21-1c913976d8d6))

#### Summary

PubMed lists PMID 10321505 in Cancer chemotherapy and pharmacology as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999 (year precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10321505-2013-11-21-1c913976d8d6`](#source-pubmed-observation-pmid-10321505-2013-11-21-1c913976d8d6))

#### Paragraph 1

PubMed lists PMID 10321505 in Cancer chemotherapy and pharmacology as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999 (year precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10321505-2013-11-21-1c913976d8d6`](#source-pubmed-observation-pmid-10321505-2013-11-21-1c913976d8d6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10321505-2013-11-21-1c913976d8d6`](#source-pubmed-observation-pmid-10321505-2013-11-21-1c913976d8d6))

### Sources

<a id="source-pubmed-observation-pmid-10321505-2013-11-21-1c913976d8d6"></a>
- **Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. · retained source version 1:2013-11-21:current:1c913976d8d6775d1d89d108b469f0b7ef9ebed0383ad400e0175f543122e510** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10321505/) (`pubmed-observation-pmid-10321505-2013-11-21-1c913976d8d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-10321505-leuprolide-v1 SHA-256: f968dfb41ea1fb7047e0eb3d082b826632bbc56e0aacec684a97b7a28db704ed.

---

<a id="pubmed-pmid-11998504-leuprolide-v1"></a>

## Managing advanced prostate cancer with Viadur (leuprolide acetate implant).

> PubMed lists PMID 11998504 in Urologic nursing as Journal Article, Review, with publication-date metadata of 2001-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11998504-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11998504-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-11998504-leuprolide-v1
- Content SHA-256: `687f02dd3c4e4ddc125d400bc39c5a3749b523dab541b08f4799841ebb9c1332`

### Claims and source pins

#### Headline

Managing advanced prostate cancer with Viadur (leuprolide acetate implant). ([`pubmed-observation-pmid-11998504-2013-11-21-3adabdf22c4f`](#source-pubmed-observation-pmid-11998504-2013-11-21-3adabdf22c4f))

#### Summary

PubMed lists PMID 11998504 in Urologic nursing as Journal Article, Review, with publication-date metadata of 2001-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11998504-2013-11-21-3adabdf22c4f`](#source-pubmed-observation-pmid-11998504-2013-11-21-3adabdf22c4f))

#### Paragraph 1

PubMed lists PMID 11998504 in Urologic nursing as Journal Article, Review, with publication-date metadata of 2001-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11998504-2013-11-21-3adabdf22c4f`](#source-pubmed-observation-pmid-11998504-2013-11-21-3adabdf22c4f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11998504-2013-11-21-3adabdf22c4f`](#source-pubmed-observation-pmid-11998504-2013-11-21-3adabdf22c4f))

### Sources

<a id="source-pubmed-observation-pmid-11998504-2013-11-21-3adabdf22c4f"></a>
- **Managing advanced prostate cancer with Viadur (leuprolide acetate implant). · retained source version 1:2013-11-21:current:3adabdf22c4f0074878ebf878a390990d29a9ce5c084ca9b645f1c772165b15c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11998504/) (`pubmed-observation-pmid-11998504-2013-11-21-3adabdf22c4f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Managing advanced prostate cancer with Viadur (leuprolide acetate implant)." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-11998504-leuprolide-v1 SHA-256: 687f02dd3c4e4ddc125d400bc39c5a3749b523dab541b08f4799841ebb9c1332.

---

<a id="pubmed-pmid-1349596-leuprolide-v1"></a>

## PubMed record PMID 1349596

> PeptideScanner retained PubMed bibliographic metadata for PMID 1349596 at 2026-07-30T21:56:46.926Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-03-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-1349596-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1349596-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1349596-leuprolide-v1
- Content SHA-256: `2945b46a1ee72683d25df818339409237abe809ffba85a519d3bd35a1df10dae`

### Claims and source pins

#### Headline

PubMed record PMID 1349596 ([`pubmed-observation-pmid-1349596-2013-11-21-ce9340f7bb6e`](#source-pubmed-observation-pmid-1349596-2013-11-21-ce9340f7bb6e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 1349596 at 2026-07-30T21:56:46.926Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-03-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1349596-2013-11-21-ce9340f7bb6e`](#source-pubmed-observation-pmid-1349596-2013-11-21-ce9340f7bb6e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 1349596 at 2026-07-30T21:56:46.926Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-03-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1349596-2013-11-21-ce9340f7bb6e`](#source-pubmed-observation-pmid-1349596-2013-11-21-ce9340f7bb6e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1349596-2013-11-21-ce9340f7bb6e`](#source-pubmed-observation-pmid-1349596-2013-11-21-ce9340f7bb6e))

### Sources

<a id="source-pubmed-observation-pmid-1349596-2013-11-21-ce9340f7bb6e"></a>
- **PubMed record PMID 1349596 · retained source version 1:2013-11-21:current:ce9340f7bb6eb3aa053de22113588f98e3c02692992acd54e281eb5084ffce99** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1349596/) (`pubmed-observation-pmid-1349596-2013-11-21-ce9340f7bb6e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 1349596." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1349596-leuprolide-v1 SHA-256: 2945b46a1ee72683d25df818339409237abe809ffba85a519d3bd35a1df10dae.

---

<a id="pubmed-pmid-1407643-leuprolide-v1"></a>

## PubMed record PMID 1407643

> PeptideScanner retained PubMed bibliographic metadata for PMID 1407643 at 2026-07-30T21:56:46.929Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-07-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-1407643-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1407643-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1407643-leuprolide-v1
- Content SHA-256: `864eb23282ceee8040eab2fa3898ac5f1eb3df8487d32b246ad0a738d29a7e93`

### Claims and source pins

#### Headline

PubMed record PMID 1407643 ([`pubmed-observation-pmid-1407643-2013-11-21-dc682fb60f40`](#source-pubmed-observation-pmid-1407643-2013-11-21-dc682fb60f40))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 1407643 at 2026-07-30T21:56:46.929Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-07-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1407643-2013-11-21-dc682fb60f40`](#source-pubmed-observation-pmid-1407643-2013-11-21-dc682fb60f40))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 1407643 at 2026-07-30T21:56:46.929Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-07-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1407643-2013-11-21-dc682fb60f40`](#source-pubmed-observation-pmid-1407643-2013-11-21-dc682fb60f40))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1407643-2013-11-21-dc682fb60f40`](#source-pubmed-observation-pmid-1407643-2013-11-21-dc682fb60f40))

### Sources

<a id="source-pubmed-observation-pmid-1407643-2013-11-21-dc682fb60f40"></a>
- **PubMed record PMID 1407643 · retained source version 1:2013-11-21:current:dc682fb60f40b68609ee1b37f201bb36b5acf77d5e8d223dfe7e1cf5bb88e7e0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1407643/) (`pubmed-observation-pmid-1407643-2013-11-21-dc682fb60f40`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 1407643." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1407643-leuprolide-v1 SHA-256: 864eb23282ceee8040eab2fa3898ac5f1eb3df8487d32b246ad0a738d29a7e93.

---

<a id="pubmed-pmid-1407904-leuprolide-v1"></a>

## PubMed record PMID 1407904

> PeptideScanner retained PubMed bibliographic metadata for PMID 1407904 at 2026-07-30T21:56:46.929Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-10-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-1407904-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1407904-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1407904-leuprolide-v1
- Content SHA-256: `d705a06a3220b0814fffad1c4f3b2f2054a9e2fb2a598e55726413cdaac4ff91`

### Claims and source pins

#### Headline

PubMed record PMID 1407904 ([`pubmed-observation-pmid-1407904-2013-11-21-cd885ec9ca45`](#source-pubmed-observation-pmid-1407904-2013-11-21-cd885ec9ca45))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 1407904 at 2026-07-30T21:56:46.929Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-10-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1407904-2013-11-21-cd885ec9ca45`](#source-pubmed-observation-pmid-1407904-2013-11-21-cd885ec9ca45))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 1407904 at 2026-07-30T21:56:46.929Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-10-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1407904-2013-11-21-cd885ec9ca45`](#source-pubmed-observation-pmid-1407904-2013-11-21-cd885ec9ca45))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1407904-2013-11-21-cd885ec9ca45`](#source-pubmed-observation-pmid-1407904-2013-11-21-cd885ec9ca45))

### Sources

<a id="source-pubmed-observation-pmid-1407904-2013-11-21-cd885ec9ca45"></a>
- **PubMed record PMID 1407904 · retained source version 1:2013-11-21:current:cd885ec9ca4508cf6489a8b36aedbc8e76314ef03cb9e75a8e0f19df6f98b983** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1407904/) (`pubmed-observation-pmid-1407904-2013-11-21-cd885ec9ca45`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 1407904." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1407904-leuprolide-v1 SHA-256: d705a06a3220b0814fffad1c4f3b2f2054a9e2fb2a598e55726413cdaac4ff91.

---

<a id="pubmed-pmid-15245886-leuprolide-v1"></a>

## In vitro transdermal iontophoretic delivery of leuprolide under constant current application.

> PubMed lists PMID 15245886 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, with publication-date metadata of 2004-07-23 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15245886-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15245886-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-15245886-leuprolide-v1
- Content SHA-256: `6b7056a8c83caa2f7e888f8800074e540f30d6f538c3d17dbfd4dd4ddb94f32d`

### Claims and source pins

#### Headline

In vitro transdermal iontophoretic delivery of leuprolide under constant current application. ([`pubmed-observation-pmid-15245886-2013-11-21-4fbed636b719`](#source-pubmed-observation-pmid-15245886-2013-11-21-4fbed636b719))

#### Summary

PubMed lists PMID 15245886 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, with publication-date metadata of 2004-07-23 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15245886-2013-11-21-4fbed636b719`](#source-pubmed-observation-pmid-15245886-2013-11-21-4fbed636b719))

#### Paragraph 1

PubMed lists PMID 15245886 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, with publication-date metadata of 2004-07-23 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15245886-2013-11-21-4fbed636b719`](#source-pubmed-observation-pmid-15245886-2013-11-21-4fbed636b719))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15245886-2013-11-21-4fbed636b719`](#source-pubmed-observation-pmid-15245886-2013-11-21-4fbed636b719))

### Sources

<a id="source-pubmed-observation-pmid-15245886-2013-11-21-4fbed636b719"></a>
- **In vitro transdermal iontophoretic delivery of leuprolide under constant current application. · retained source version 1:2013-11-21:current:4fbed636b7192fd01e19aa649d4eaf6b591955dc123a067a659defa5839003ed** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15245886/) (`pubmed-observation-pmid-15245886-2013-11-21-4fbed636b719`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "In vitro transdermal iontophoretic delivery of leuprolide under constant current application." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-15245886-leuprolide-v1 SHA-256: 6b7056a8c83caa2f7e888f8800074e540f30d6f538c3d17dbfd4dd4ddb94f32d.

---

<a id="pubmed-pmid-1533022-leuprolide-v1"></a>

## PubMed record PMID 1533022

> PeptideScanner retained PubMed bibliographic metadata for PMID 1533022 at 2026-07-30T21:56:46.935Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-05-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-1533022-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1533022-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1533022-leuprolide-v1
- Content SHA-256: `bfc8c1da91d7f984931448addb14e0aff40f95b58a73f2365ea608b5b6879aad`

### Claims and source pins

#### Headline

PubMed record PMID 1533022 ([`pubmed-observation-pmid-1533022-2013-11-21-7d3e15e575d1`](#source-pubmed-observation-pmid-1533022-2013-11-21-7d3e15e575d1))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 1533022 at 2026-07-30T21:56:46.935Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-05-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1533022-2013-11-21-7d3e15e575d1`](#source-pubmed-observation-pmid-1533022-2013-11-21-7d3e15e575d1))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 1533022 at 2026-07-30T21:56:46.935Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-05-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1533022-2013-11-21-7d3e15e575d1`](#source-pubmed-observation-pmid-1533022-2013-11-21-7d3e15e575d1))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1533022-2013-11-21-7d3e15e575d1`](#source-pubmed-observation-pmid-1533022-2013-11-21-7d3e15e575d1))

### Sources

<a id="source-pubmed-observation-pmid-1533022-2013-11-21-7d3e15e575d1"></a>
- **PubMed record PMID 1533022 · retained source version 1:2013-11-21:current:7d3e15e575d19c85346afdb391a9cf6956726651aa51e77346cf8024a17695bf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1533022/) (`pubmed-observation-pmid-1533022-2013-11-21-7d3e15e575d1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 1533022." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1533022-leuprolide-v1 SHA-256: bfc8c1da91d7f984931448addb14e0aff40f95b58a73f2365ea608b5b6879aad.

---

<a id="pubmed-pmid-15685898-leuprolide-v1"></a>

## Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations.

> PubMed lists PMID 15685898 in The Netherlands journal of medicine as Case Reports, Journal Article, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15685898-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15685898-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-15685898-leuprolide-v1
- Content SHA-256: `0ba1b1b60b2275c1b6f608786a93079c16e7fd321253843d1c7c6b29e64d636d`

### Claims and source pins

#### Headline

Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations. ([`pubmed-observation-pmid-15685898-2013-11-21-7317a09b5798`](#source-pubmed-observation-pmid-15685898-2013-11-21-7317a09b5798))

#### Summary

PubMed lists PMID 15685898 in The Netherlands journal of medicine as Case Reports, Journal Article, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15685898-2013-11-21-7317a09b5798`](#source-pubmed-observation-pmid-15685898-2013-11-21-7317a09b5798))

#### Paragraph 1

PubMed lists PMID 15685898 in The Netherlands journal of medicine as Case Reports, Journal Article, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15685898-2013-11-21-7317a09b5798`](#source-pubmed-observation-pmid-15685898-2013-11-21-7317a09b5798))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15685898-2013-11-21-7317a09b5798`](#source-pubmed-observation-pmid-15685898-2013-11-21-7317a09b5798))

### Sources

<a id="source-pubmed-observation-pmid-15685898-2013-11-21-7317a09b5798"></a>
- **Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations. · retained source version 1:2013-11-21:current:7317a09b57987c88642c99ee6106559e619fe7cb4297d1357526853a11180d81** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15685898/) (`pubmed-observation-pmid-15685898-2013-11-21-7317a09b5798`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-15685898-leuprolide-v1 SHA-256: 0ba1b1b60b2275c1b6f608786a93079c16e7fd321253843d1c7c6b29e64d636d.

---

<a id="pubmed-pmid-15689930-leuprolide-v1"></a>

## The role of leuprolide acetate therapy in triggering auto-immune thyroiditis.

> PubMed lists PMID 15689930 in The Journal of pediatrics as Comment, Letter, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15689930-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15689930-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-15689930-leuprolide-v1
- Content SHA-256: `7bf8d9be1f69fc8a91854b270f50d223099f6915970e0df074f31fb98b4b6074`

### Claims and source pins

#### Headline

The role of leuprolide acetate therapy in triggering auto-immune thyroiditis. ([`pubmed-observation-pmid-15689930-2013-11-21-11fe0a5a0ce3`](#source-pubmed-observation-pmid-15689930-2013-11-21-11fe0a5a0ce3))

#### Summary

PubMed lists PMID 15689930 in The Journal of pediatrics as Comment, Letter, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15689930-2013-11-21-11fe0a5a0ce3`](#source-pubmed-observation-pmid-15689930-2013-11-21-11fe0a5a0ce3))

#### Paragraph 1

PubMed lists PMID 15689930 in The Journal of pediatrics as Comment, Letter, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15689930-2013-11-21-11fe0a5a0ce3`](#source-pubmed-observation-pmid-15689930-2013-11-21-11fe0a5a0ce3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15689930-2013-11-21-11fe0a5a0ce3`](#source-pubmed-observation-pmid-15689930-2013-11-21-11fe0a5a0ce3))

### Sources

<a id="source-pubmed-observation-pmid-15689930-2013-11-21-11fe0a5a0ce3"></a>
- **The role of leuprolide acetate therapy in triggering auto-immune thyroiditis. · retained source version 1:2013-11-21:current:11fe0a5a0ce3979597574872b629ff384e8a105d1a3e1a8aa3fc416ab47600cc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15689930/) (`pubmed-observation-pmid-15689930-2013-11-21-11fe0a5a0ce3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The role of leuprolide acetate therapy in triggering auto-immune thyroiditis." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-15689930-leuprolide-v1 SHA-256: 7bf8d9be1f69fc8a91854b270f50d223099f6915970e0df074f31fb98b4b6074.

---

<a id="pubmed-pmid-15862697-leuprolide-v1"></a>

## LC determination of leuprolide component amino acids in injectable solution by phanquinone pre-column derivatization labelling procedure.

> PubMed lists PMID 15862697 in Journal of pharmaceutical and biomedical analysis as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-04-29 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15862697-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15862697-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-15862697-leuprolide-v1
- Content SHA-256: `04b5de120471abfb29325f8a01403380f3820ceb2cdcbcad22781ee9294974e5`

### Claims and source pins

#### Headline

LC determination of leuprolide component amino acids in injectable solution by phanquinone pre-column derivatization labelling procedure. ([`pubmed-observation-pmid-15862697-2013-11-21-725bdcf8020a`](#source-pubmed-observation-pmid-15862697-2013-11-21-725bdcf8020a))

#### Summary

PubMed lists PMID 15862697 in Journal of pharmaceutical and biomedical analysis as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-04-29 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15862697-2013-11-21-725bdcf8020a`](#source-pubmed-observation-pmid-15862697-2013-11-21-725bdcf8020a))

#### Paragraph 1

PubMed lists PMID 15862697 in Journal of pharmaceutical and biomedical analysis as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-04-29 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15862697-2013-11-21-725bdcf8020a`](#source-pubmed-observation-pmid-15862697-2013-11-21-725bdcf8020a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15862697-2013-11-21-725bdcf8020a`](#source-pubmed-observation-pmid-15862697-2013-11-21-725bdcf8020a))

### Sources

<a id="source-pubmed-observation-pmid-15862697-2013-11-21-725bdcf8020a"></a>
- **LC determination of leuprolide component amino acids in injectable solution by phanquinone pre-column derivatization labelling procedure. · retained source version 1:2013-11-21:current:725bdcf8020a382696a66082142f6d1a93c862a99244cd53ffa509c9440aeb60** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15862697/) (`pubmed-observation-pmid-15862697-2013-11-21-725bdcf8020a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "LC determination of leuprolide component amino acids in injectable solution by phanquinone pre-column derivatization labelling procedure." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-15862697-leuprolide-v1 SHA-256: 04b5de120471abfb29325f8a01403380f3820ceb2cdcbcad22781ee9294974e5.

---

<a id="pubmed-pmid-16111462-leuprolide-v1"></a>

## Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?

> PubMed lists PMID 16111462 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16111462-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16111462-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-16111462-leuprolide-v1
- Content SHA-256: `4eb30ee95836b3e409fdf449ee6aa0d0e9459881d7854cb6c1cbf76ee2885793`

### Claims and source pins

#### Headline

Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? ([`pubmed-observation-pmid-16111462-2013-11-21-4cd935df829f`](#source-pubmed-observation-pmid-16111462-2013-11-21-4cd935df829f))

#### Summary

PubMed lists PMID 16111462 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16111462-2013-11-21-4cd935df829f`](#source-pubmed-observation-pmid-16111462-2013-11-21-4cd935df829f))

#### Paragraph 1

PubMed lists PMID 16111462 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16111462-2013-11-21-4cd935df829f`](#source-pubmed-observation-pmid-16111462-2013-11-21-4cd935df829f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16111462-2013-11-21-4cd935df829f`](#source-pubmed-observation-pmid-16111462-2013-11-21-4cd935df829f))

### Sources

<a id="source-pubmed-observation-pmid-16111462-2013-11-21-4cd935df829f"></a>
- **Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? · retained source version 1:2013-11-21:current:4cd935df829f8bd1543e09360bee2bc753596571b55a92754a40fddafc9def16** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16111462/) (`pubmed-observation-pmid-16111462-2013-11-21-4cd935df829f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?" Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-16111462-leuprolide-v1 SHA-256: 4eb30ee95836b3e409fdf449ee6aa0d0e9459881d7854cb6c1cbf76ee2885793.

---

<a id="pubmed-pmid-1621201-leuprolide-v1"></a>

## PubMed record PMID 1621201

> PeptideScanner retained PubMed bibliographic metadata for PMID 1621201 at 2026-07-30T21:56:46.937Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-07-11. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-1621201-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1621201-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1621201-leuprolide-v1
- Content SHA-256: `65843a3b1792a29d0d1586535626f3184881c50e54563f824576c1d26fc0d530`

### Claims and source pins

#### Headline

PubMed record PMID 1621201 ([`pubmed-observation-pmid-1621201-2013-11-21-2af2f52a8b36`](#source-pubmed-observation-pmid-1621201-2013-11-21-2af2f52a8b36))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 1621201 at 2026-07-30T21:56:46.937Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-07-11. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1621201-2013-11-21-2af2f52a8b36`](#source-pubmed-observation-pmid-1621201-2013-11-21-2af2f52a8b36))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 1621201 at 2026-07-30T21:56:46.937Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1992-07-11. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1621201-2013-11-21-2af2f52a8b36`](#source-pubmed-observation-pmid-1621201-2013-11-21-2af2f52a8b36))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1621201-2013-11-21-2af2f52a8b36`](#source-pubmed-observation-pmid-1621201-2013-11-21-2af2f52a8b36))

### Sources

<a id="source-pubmed-observation-pmid-1621201-2013-11-21-2af2f52a8b36"></a>
- **PubMed record PMID 1621201 · retained source version 1:2013-11-21:current:2af2f52a8b363beb2f0aee9c16db7cb714a8b49b937b557e8d28ed12f39a2863** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1621201/) (`pubmed-observation-pmid-1621201-2013-11-21-2af2f52a8b36`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 1621201." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1621201-leuprolide-v1 SHA-256: 65843a3b1792a29d0d1586535626f3184881c50e54563f824576c1d26fc0d530.

---

<a id="pubmed-pmid-16312848-leuprolide-v1"></a>

## Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).

> PubMed lists PMID 16312848 in Journal of chemotherapy (Florence, Italy) as Journal Article, with publication-date metadata of 1989-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16312848-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16312848-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-16312848-leuprolide-v1
- Content SHA-256: `1afc02014f37d9bd14cd2724cb73367b00f6f506aa9e432f929a40e9857d1bb3`

### Claims and source pins

#### Headline

Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide). ([`pubmed-observation-pmid-16312848-2013-11-21-2290e5574383`](#source-pubmed-observation-pmid-16312848-2013-11-21-2290e5574383))

#### Summary

PubMed lists PMID 16312848 in Journal of chemotherapy (Florence, Italy) as Journal Article, with publication-date metadata of 1989-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16312848-2013-11-21-2290e5574383`](#source-pubmed-observation-pmid-16312848-2013-11-21-2290e5574383))

#### Paragraph 1

PubMed lists PMID 16312848 in Journal of chemotherapy (Florence, Italy) as Journal Article, with publication-date metadata of 1989-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16312848-2013-11-21-2290e5574383`](#source-pubmed-observation-pmid-16312848-2013-11-21-2290e5574383))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16312848-2013-11-21-2290e5574383`](#source-pubmed-observation-pmid-16312848-2013-11-21-2290e5574383))

### Sources

<a id="source-pubmed-observation-pmid-16312848-2013-11-21-2290e5574383"></a>
- **Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide). · retained source version 1:2013-11-21:current:2290e5574383619557754336864f60d972e0c36c633119bf5829a895bf4edf71** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16312848/) (`pubmed-observation-pmid-16312848-2013-11-21-2290e5574383`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide)." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-16312848-leuprolide-v1 SHA-256: 1afc02014f37d9bd14cd2724cb73367b00f6f506aa9e432f929a40e9857d1bb3.

---

<a id="pubmed-pmid-16314038-leuprolide-v1"></a>

## Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.

> PubMed lists PMID 16314038 in European urology as Journal Article, with publication-date metadata of 2005-11-15 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16314038-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16314038-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-16314038-leuprolide-v1
- Content SHA-256: `ef7ca4932adfcd2b3f8816169d1871b70bf116370b9820fc06582079c71d6600`

### Claims and source pins

#### Headline

Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. ([`pubmed-observation-pmid-16314038-2013-11-21-58a3029d9444`](#source-pubmed-observation-pmid-16314038-2013-11-21-58a3029d9444))

#### Summary

PubMed lists PMID 16314038 in European urology as Journal Article, with publication-date metadata of 2005-11-15 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16314038-2013-11-21-58a3029d9444`](#source-pubmed-observation-pmid-16314038-2013-11-21-58a3029d9444))

#### Paragraph 1

PubMed lists PMID 16314038 in European urology as Journal Article, with publication-date metadata of 2005-11-15 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16314038-2013-11-21-58a3029d9444`](#source-pubmed-observation-pmid-16314038-2013-11-21-58a3029d9444))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16314038-2013-11-21-58a3029d9444`](#source-pubmed-observation-pmid-16314038-2013-11-21-58a3029d9444))

### Sources

<a id="source-pubmed-observation-pmid-16314038-2013-11-21-58a3029d9444"></a>
- **Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. · retained source version 1:2013-11-21:current:58a3029d944477bff460e7f6c408e3ad4b7f55f87550013fba128f0f958b808d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16314038/) (`pubmed-observation-pmid-16314038-2013-11-21-58a3029d9444`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-16314038-leuprolide-v1 SHA-256: ef7ca4932adfcd2b3f8816169d1871b70bf116370b9820fc06582079c71d6600.

---

<a id="pubmed-pmid-1666142-leuprolide-v1"></a>

## PubMed record PMID 1666142

> PeptideScanner retained PubMed bibliographic metadata for PMID 1666142 at 2026-07-30T21:56:47.772Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-10-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-1666142-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1666142-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1666142-leuprolide-v1
- Content SHA-256: `648a0d90b9926884531bd7f526760adbe0665568283dad8887f252d61fab206c`

### Claims and source pins

#### Headline

PubMed record PMID 1666142 ([`pubmed-observation-pmid-1666142-2013-11-21-bfdf62acd042`](#source-pubmed-observation-pmid-1666142-2013-11-21-bfdf62acd042))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 1666142 at 2026-07-30T21:56:47.772Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-10-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1666142-2013-11-21-bfdf62acd042`](#source-pubmed-observation-pmid-1666142-2013-11-21-bfdf62acd042))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 1666142 at 2026-07-30T21:56:47.772Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-10-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1666142-2013-11-21-bfdf62acd042`](#source-pubmed-observation-pmid-1666142-2013-11-21-bfdf62acd042))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1666142-2013-11-21-bfdf62acd042`](#source-pubmed-observation-pmid-1666142-2013-11-21-bfdf62acd042))

### Sources

<a id="source-pubmed-observation-pmid-1666142-2013-11-21-bfdf62acd042"></a>
- **PubMed record PMID 1666142 · retained source version 1:2013-11-21:current:bfdf62acd042caae469b908236de50e12556640eee364827afa9610e71e6a896** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1666142/) (`pubmed-observation-pmid-1666142-2013-11-21-bfdf62acd042`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 1666142." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1666142-leuprolide-v1 SHA-256: 648a0d90b9926884531bd7f526760adbe0665568283dad8887f252d61fab206c.

---

<a id="pubmed-pmid-16727932-leuprolide-v1"></a>

## PubMed record PMID 16727932

> PeptideScanner retained PubMed bibliographic metadata for PMID 16727932 at 2026-07-30T22:50:21.669Z. PubMed recorded a metadata revision date of 2006-05-26 and an Entrez history date of 1996-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-16727932-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2006-05-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16727932-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-16727932-leuprolide-v1
- Content SHA-256: `29c8c7a97744811dd1ef0ba0e58caa9d537e7433f7361468db29a302602a9709`

### Claims and source pins

#### Headline

PubMed record PMID 16727932 ([`pubmed-observation-pmid-16727932-2006-05-26-6c53df61bb39`](#source-pubmed-observation-pmid-16727932-2006-05-26-6c53df61bb39))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 16727932 at 2026-07-30T22:50:21.669Z. PubMed recorded a metadata revision date of 2006-05-26 and an Entrez history date of 1996-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-16727932-2006-05-26-6c53df61bb39`](#source-pubmed-observation-pmid-16727932-2006-05-26-6c53df61bb39))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 16727932 at 2026-07-30T22:50:21.669Z. PubMed recorded a metadata revision date of 2006-05-26 and an Entrez history date of 1996-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-16727932-2006-05-26-6c53df61bb39`](#source-pubmed-observation-pmid-16727932-2006-05-26-6c53df61bb39))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16727932-2006-05-26-6c53df61bb39`](#source-pubmed-observation-pmid-16727932-2006-05-26-6c53df61bb39))

### Sources

<a id="source-pubmed-observation-pmid-16727932-2006-05-26-6c53df61bb39"></a>
- **PubMed record PMID 16727932 · retained source version 1:2006-05-26:current:6c53df61bb39a567b59fa53ce4e9f7b3af83fb99c76c14b652d61aa6e290f1a7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16727932/) (`pubmed-observation-pmid-16727932-2006-05-26-6c53df61bb39`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 16727932." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-16727932-leuprolide-v1 SHA-256: 29c8c7a97744811dd1ef0ba0e58caa9d537e7433f7361468db29a302602a9709.

---

<a id="pubmed-pmid-1748007-leuprolide-v1"></a>

## PubMed record PMID 1748007

> PeptideScanner retained PubMed bibliographic metadata for PMID 1748007 at 2026-07-30T21:56:47.777Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-1748007-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1748007-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1748007-leuprolide-v1
- Content SHA-256: `a19c37aedf209bfb327ef1a5c942babff99934cbb7b47cf972891fca417dfc6e`

### Claims and source pins

#### Headline

PubMed record PMID 1748007 ([`pubmed-observation-pmid-1748007-2013-11-21-37077a498ef2`](#source-pubmed-observation-pmid-1748007-2013-11-21-37077a498ef2))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 1748007 at 2026-07-30T21:56:47.777Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1748007-2013-11-21-37077a498ef2`](#source-pubmed-observation-pmid-1748007-2013-11-21-37077a498ef2))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 1748007 at 2026-07-30T21:56:47.777Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1748007-2013-11-21-37077a498ef2`](#source-pubmed-observation-pmid-1748007-2013-11-21-37077a498ef2))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1748007-2013-11-21-37077a498ef2`](#source-pubmed-observation-pmid-1748007-2013-11-21-37077a498ef2))

### Sources

<a id="source-pubmed-observation-pmid-1748007-2013-11-21-37077a498ef2"></a>
- **PubMed record PMID 1748007 · retained source version 1:2013-11-21:current:37077a498ef2dba1e03533b0ec30747cde62fafdd391f228b08024a66b20939f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1748007/) (`pubmed-observation-pmid-1748007-2013-11-21-37077a498ef2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 1748007." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1748007-leuprolide-v1 SHA-256: a19c37aedf209bfb327ef1a5c942babff99934cbb7b47cf972891fca417dfc6e.

---

<a id="pubmed-pmid-1835275-leuprolide-v1"></a>

## PubMed record PMID 1835275

> PeptideScanner retained PubMed bibliographic metadata for PMID 1835275 at 2026-07-30T21:56:47.778Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-1835275-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1835275-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1835275-leuprolide-v1
- Content SHA-256: `065aee911dec3989fe5b2459996e03a2a3bbae5e03b215b763020aac39fc5c9d`

### Claims and source pins

#### Headline

PubMed record PMID 1835275 ([`pubmed-observation-pmid-1835275-2013-11-21-4109deb7aeb5`](#source-pubmed-observation-pmid-1835275-2013-11-21-4109deb7aeb5))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 1835275 at 2026-07-30T21:56:47.778Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1835275-2013-11-21-4109deb7aeb5`](#source-pubmed-observation-pmid-1835275-2013-11-21-4109deb7aeb5))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 1835275 at 2026-07-30T21:56:47.778Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1835275-2013-11-21-4109deb7aeb5`](#source-pubmed-observation-pmid-1835275-2013-11-21-4109deb7aeb5))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1835275-2013-11-21-4109deb7aeb5`](#source-pubmed-observation-pmid-1835275-2013-11-21-4109deb7aeb5))

### Sources

<a id="source-pubmed-observation-pmid-1835275-2013-11-21-4109deb7aeb5"></a>
- **PubMed record PMID 1835275 · retained source version 1:2013-11-21:current:4109deb7aeb5b8ed310cc68b0be576988ff4b237aa162c475f9c91c012c98bbd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1835275/) (`pubmed-observation-pmid-1835275-2013-11-21-4109deb7aeb5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 1835275." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1835275-leuprolide-v1 SHA-256: 065aee911dec3989fe5b2459996e03a2a3bbae5e03b215b763020aac39fc5c9d.

---

<a id="pubmed-pmid-1941784-leuprolide-v1"></a>

## PubMed record PMID 1941784

> PeptideScanner retained PubMed bibliographic metadata for PMID 1941784 at 2026-07-30T21:56:47.780Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-07-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-1941784-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1941784-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1941784-leuprolide-v1
- Content SHA-256: `e9a18db939877a04635ab5d14fe83ac7cd0a03c8892774eeec9b97f5ff9e551f`

### Claims and source pins

#### Headline

PubMed record PMID 1941784 ([`pubmed-observation-pmid-1941784-2013-11-21-7cd9029c21bb`](#source-pubmed-observation-pmid-1941784-2013-11-21-7cd9029c21bb))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 1941784 at 2026-07-30T21:56:47.780Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-07-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1941784-2013-11-21-7cd9029c21bb`](#source-pubmed-observation-pmid-1941784-2013-11-21-7cd9029c21bb))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 1941784 at 2026-07-30T21:56:47.780Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1991-07-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1941784-2013-11-21-7cd9029c21bb`](#source-pubmed-observation-pmid-1941784-2013-11-21-7cd9029c21bb))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1941784-2013-11-21-7cd9029c21bb`](#source-pubmed-observation-pmid-1941784-2013-11-21-7cd9029c21bb))

### Sources

<a id="source-pubmed-observation-pmid-1941784-2013-11-21-7cd9029c21bb"></a>
- **PubMed record PMID 1941784 · retained source version 1:2013-11-21:current:7cd9029c21bb3f35852a853257123ed8a9b9d472f32d2b6233cff650449e02ce** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1941784/) (`pubmed-observation-pmid-1941784-2013-11-21-7cd9029c21bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 1941784." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1941784-leuprolide-v1 SHA-256: e9a18db939877a04635ab5d14fe83ac7cd0a03c8892774eeec9b97f5ff9e551f.

---

<a id="pubmed-pmid-1981209-leuprolide-v1"></a>

## PubMed record PMID 1981209

> PeptideScanner retained PubMed bibliographic metadata for PMID 1981209 at 2026-07-30T21:56:47.782Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-1981209-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1981209-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1981209-leuprolide-v1
- Content SHA-256: `dd3043c0079940f00a626de1d992112987336d785b2d927f78276e6124efc63b`

### Claims and source pins

#### Headline

PubMed record PMID 1981209 ([`pubmed-observation-pmid-1981209-2013-11-21-24775ba4f809`](#source-pubmed-observation-pmid-1981209-2013-11-21-24775ba4f809))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 1981209 at 2026-07-30T21:56:47.782Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1981209-2013-11-21-24775ba4f809`](#source-pubmed-observation-pmid-1981209-2013-11-21-24775ba4f809))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 1981209 at 2026-07-30T21:56:47.782Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-1981209-2013-11-21-24775ba4f809`](#source-pubmed-observation-pmid-1981209-2013-11-21-24775ba4f809))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1981209-2013-11-21-24775ba4f809`](#source-pubmed-observation-pmid-1981209-2013-11-21-24775ba4f809))

### Sources

<a id="source-pubmed-observation-pmid-1981209-2013-11-21-24775ba4f809"></a>
- **PubMed record PMID 1981209 · retained source version 1:2013-11-21:current:24775ba4f8092d5764ee78d870d33a8d2910d80e340703ef64ff4bdbb83a307c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1981209/) (`pubmed-observation-pmid-1981209-2013-11-21-24775ba4f809`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 1981209." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-1981209-leuprolide-v1 SHA-256: dd3043c0079940f00a626de1d992112987336d785b2d927f78276e6124efc63b.

---

<a id="pubmed-pmid-2106145-leuprolide-v1"></a>

## PubMed record PMID 2106145

> PeptideScanner retained PubMed bibliographic metadata for PMID 2106145 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-01-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-2106145-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2106145-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2106145-leuprolide-v1
- Content SHA-256: `3621429446008334d40839fcc4b6897e5c98dbfda3a379679d3173b349ea0d7f`

### Claims and source pins

#### Headline

PubMed record PMID 2106145 ([`pubmed-observation-pmid-2106145-2013-11-21-de1cf2eefc8c`](#source-pubmed-observation-pmid-2106145-2013-11-21-de1cf2eefc8c))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 2106145 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-01-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2106145-2013-11-21-de1cf2eefc8c`](#source-pubmed-observation-pmid-2106145-2013-11-21-de1cf2eefc8c))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 2106145 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-01-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2106145-2013-11-21-de1cf2eefc8c`](#source-pubmed-observation-pmid-2106145-2013-11-21-de1cf2eefc8c))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2106145-2013-11-21-de1cf2eefc8c`](#source-pubmed-observation-pmid-2106145-2013-11-21-de1cf2eefc8c))

### Sources

<a id="source-pubmed-observation-pmid-2106145-2013-11-21-de1cf2eefc8c"></a>
- **PubMed record PMID 2106145 · retained source version 1:2013-11-21:current:de1cf2eefc8cc09c40927413826d8e56a24d940d8f804dd237d962032d2fbb9e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2106145/) (`pubmed-observation-pmid-2106145-2013-11-21-de1cf2eefc8c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 2106145." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2106145-leuprolide-v1 SHA-256: 3621429446008334d40839fcc4b6897e5c98dbfda3a379679d3173b349ea0d7f.

---

<a id="pubmed-pmid-2115128-leuprolide-v1"></a>

## PubMed record PMID 2115128

> PeptideScanner retained PubMed bibliographic metadata for PMID 2115128 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-05-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-2115128-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2115128-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2115128-leuprolide-v1
- Content SHA-256: `f1d7713379457ee302d50ad73d8cb2e4542d324c793612c3a949b80a05c831ce`

### Claims and source pins

#### Headline

PubMed record PMID 2115128 ([`pubmed-observation-pmid-2115128-2013-11-21-67e686dcd0d1`](#source-pubmed-observation-pmid-2115128-2013-11-21-67e686dcd0d1))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 2115128 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-05-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2115128-2013-11-21-67e686dcd0d1`](#source-pubmed-observation-pmid-2115128-2013-11-21-67e686dcd0d1))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 2115128 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-05-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2115128-2013-11-21-67e686dcd0d1`](#source-pubmed-observation-pmid-2115128-2013-11-21-67e686dcd0d1))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2115128-2013-11-21-67e686dcd0d1`](#source-pubmed-observation-pmid-2115128-2013-11-21-67e686dcd0d1))

### Sources

<a id="source-pubmed-observation-pmid-2115128-2013-11-21-67e686dcd0d1"></a>
- **PubMed record PMID 2115128 · retained source version 1:2013-11-21:current:67e686dcd0d155eb6d200dddc2ffbdc83a7a2cb38a07c475bc5f5076df73496a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2115128/) (`pubmed-observation-pmid-2115128-2013-11-21-67e686dcd0d1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 2115128." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2115128-leuprolide-v1 SHA-256: f1d7713379457ee302d50ad73d8cb2e4542d324c793612c3a949b80a05c831ce.

---

<a id="pubmed-pmid-2119048-leuprolide-v1"></a>

## PubMed record PMID 2119048

> PeptideScanner retained PubMed bibliographic metadata for PMID 2119048 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-08-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-2119048-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2119048-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2119048-leuprolide-v1
- Content SHA-256: `65fef98f0e382d2057676fae2312056b095cbde001139f2714545e062e233904`

### Claims and source pins

#### Headline

PubMed record PMID 2119048 ([`pubmed-observation-pmid-2119048-2013-11-21-9eced1134b78`](#source-pubmed-observation-pmid-2119048-2013-11-21-9eced1134b78))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 2119048 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-08-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2119048-2013-11-21-9eced1134b78`](#source-pubmed-observation-pmid-2119048-2013-11-21-9eced1134b78))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 2119048 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-08-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2119048-2013-11-21-9eced1134b78`](#source-pubmed-observation-pmid-2119048-2013-11-21-9eced1134b78))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2119048-2013-11-21-9eced1134b78`](#source-pubmed-observation-pmid-2119048-2013-11-21-9eced1134b78))

### Sources

<a id="source-pubmed-observation-pmid-2119048-2013-11-21-9eced1134b78"></a>
- **PubMed record PMID 2119048 · retained source version 1:2013-11-21:current:9eced1134b788ca4ac5323af27164728555fa4c75c98c51b798225b979a55d07** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2119048/) (`pubmed-observation-pmid-2119048-2013-11-21-9eced1134b78`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 2119048." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2119048-leuprolide-v1 SHA-256: 65fef98f0e382d2057676fae2312056b095cbde001139f2714545e062e233904.

---

<a id="pubmed-pmid-2120646-leuprolide-v1"></a>

## PubMed record PMID 2120646

> PeptideScanner retained PubMed bibliographic metadata for PMID 2120646 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-2120646-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2120646-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2120646-leuprolide-v1
- Content SHA-256: `c598b819004e06fd3b92881dc658632c530f4fff21b7171c7fac9c12e9f36148`

### Claims and source pins

#### Headline

PubMed record PMID 2120646 ([`pubmed-observation-pmid-2120646-2013-11-21-00d72121458c`](#source-pubmed-observation-pmid-2120646-2013-11-21-00d72121458c))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 2120646 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2120646-2013-11-21-00d72121458c`](#source-pubmed-observation-pmid-2120646-2013-11-21-00d72121458c))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 2120646 at 2026-07-30T21:56:47.795Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1990-11-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2120646-2013-11-21-00d72121458c`](#source-pubmed-observation-pmid-2120646-2013-11-21-00d72121458c))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2120646-2013-11-21-00d72121458c`](#source-pubmed-observation-pmid-2120646-2013-11-21-00d72121458c))

### Sources

<a id="source-pubmed-observation-pmid-2120646-2013-11-21-00d72121458c"></a>
- **PubMed record PMID 2120646 · retained source version 1:2013-11-21:current:00d72121458cc94b5220f4aafbd8cd04cf8ff3c40496b47b344e44cf1277a63c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2120646/) (`pubmed-observation-pmid-2120646-2013-11-21-00d72121458c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 2120646." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2120646-leuprolide-v1 SHA-256: c598b819004e06fd3b92881dc658632c530f4fff21b7171c7fac9c12e9f36148.

---

<a id="pubmed-pmid-23078121-leuprolide-v1"></a>

## PubMed record PMID 23078121

> PeptideScanner retained PubMed bibliographic metadata for PMID 23078121 at 2026-07-30T21:57:01.393Z. PubMed recorded a metadata revision date of 2013-01-16 and an Entrez history date of 2012-10-20. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23078121-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-01-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23078121-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-23078121-leuprolide-v1
- Content SHA-256: `7e255170d4929abdf7d3a335d09d9a3e205048efc401504b4dc7394bf90cd792`

### Claims and source pins

#### Headline

PubMed record PMID 23078121 ([`pubmed-observation-pmid-23078121-2013-01-16-03ac6c7ba7ae`](#source-pubmed-observation-pmid-23078121-2013-01-16-03ac6c7ba7ae))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23078121 at 2026-07-30T21:57:01.393Z. PubMed recorded a metadata revision date of 2013-01-16 and an Entrez history date of 2012-10-20. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23078121-2013-01-16-03ac6c7ba7ae`](#source-pubmed-observation-pmid-23078121-2013-01-16-03ac6c7ba7ae))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23078121 at 2026-07-30T21:57:01.393Z. PubMed recorded a metadata revision date of 2013-01-16 and an Entrez history date of 2012-10-20. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23078121-2013-01-16-03ac6c7ba7ae`](#source-pubmed-observation-pmid-23078121-2013-01-16-03ac6c7ba7ae))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23078121-2013-01-16-03ac6c7ba7ae`](#source-pubmed-observation-pmid-23078121-2013-01-16-03ac6c7ba7ae))

### Sources

<a id="source-pubmed-observation-pmid-23078121-2013-01-16-03ac6c7ba7ae"></a>
- **PubMed record PMID 23078121 · retained source version 1:2013-01-16:current:03ac6c7ba7aee158275bab25ee62ebb6aa8397166112fe593ba5bd3bba20bf09** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23078121/) (`pubmed-observation-pmid-23078121-2013-01-16-03ac6c7ba7ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23078121." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-23078121-leuprolide-v1 SHA-256: 7e255170d4929abdf7d3a335d09d9a3e205048efc401504b4dc7394bf90cd792.

---

<a id="pubmed-pmid-23594627-leuprolide-v1"></a>

## PubMed record PMID 23594627

> PeptideScanner retained PubMed bibliographic metadata for PMID 23594627 at 2026-07-30T21:57:01.413Z. PubMed recorded a metadata revision date of 2013-04-18 and an Entrez history date of 2013-04-19. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23594627-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-04-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23594627-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-23594627-leuprolide-v1
- Content SHA-256: `21764361d1e73e1249560b8aa816d2615cd225fa07dd83dd78fbaec7d1b56fbe`

### Claims and source pins

#### Headline

PubMed record PMID 23594627 ([`pubmed-observation-pmid-23594627-2013-04-18-bdf2de6c6ce5`](#source-pubmed-observation-pmid-23594627-2013-04-18-bdf2de6c6ce5))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23594627 at 2026-07-30T21:57:01.413Z. PubMed recorded a metadata revision date of 2013-04-18 and an Entrez history date of 2013-04-19. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23594627-2013-04-18-bdf2de6c6ce5`](#source-pubmed-observation-pmid-23594627-2013-04-18-bdf2de6c6ce5))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23594627 at 2026-07-30T21:57:01.413Z. PubMed recorded a metadata revision date of 2013-04-18 and an Entrez history date of 2013-04-19. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23594627-2013-04-18-bdf2de6c6ce5`](#source-pubmed-observation-pmid-23594627-2013-04-18-bdf2de6c6ce5))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23594627-2013-04-18-bdf2de6c6ce5`](#source-pubmed-observation-pmid-23594627-2013-04-18-bdf2de6c6ce5))

### Sources

<a id="source-pubmed-observation-pmid-23594627-2013-04-18-bdf2de6c6ce5"></a>
- **PubMed record PMID 23594627 · retained source version 1:2013-04-18:current:bdf2de6c6ce52724b328e91018ed9d2a4de97a2e99b1127b800678d922954d62** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23594627/) (`pubmed-observation-pmid-23594627-2013-04-18-bdf2de6c6ce5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23594627." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-23594627-leuprolide-v1 SHA-256: 21764361d1e73e1249560b8aa816d2615cd225fa07dd83dd78fbaec7d1b56fbe.

---

<a id="pubmed-pmid-2410765-leuprolide-v1"></a>

## PubMed record PMID 2410765

> PeptideScanner retained PubMed bibliographic metadata for PMID 2410765 at 2026-07-30T21:56:47.801Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1985-08-16. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-2410765-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2410765-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2410765-leuprolide-v1
- Content SHA-256: `54ddca28a672568da76abdd671f96ce46b0801301d0d6379c406ddfb02c00284`

### Claims and source pins

#### Headline

PubMed record PMID 2410765 ([`pubmed-observation-pmid-2410765-2013-11-21-56413f88d72e`](#source-pubmed-observation-pmid-2410765-2013-11-21-56413f88d72e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 2410765 at 2026-07-30T21:56:47.801Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1985-08-16. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2410765-2013-11-21-56413f88d72e`](#source-pubmed-observation-pmid-2410765-2013-11-21-56413f88d72e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 2410765 at 2026-07-30T21:56:47.801Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1985-08-16. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2410765-2013-11-21-56413f88d72e`](#source-pubmed-observation-pmid-2410765-2013-11-21-56413f88d72e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2410765-2013-11-21-56413f88d72e`](#source-pubmed-observation-pmid-2410765-2013-11-21-56413f88d72e))

### Sources

<a id="source-pubmed-observation-pmid-2410765-2013-11-21-56413f88d72e"></a>
- **PubMed record PMID 2410765 · retained source version 1:2013-11-21:current:56413f88d72e9d7545b5562dd5ff95240a64619e7fec8608e8493745f80109f8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2410765/) (`pubmed-observation-pmid-2410765-2013-11-21-56413f88d72e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 2410765." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2410765-leuprolide-v1 SHA-256: 54ddca28a672568da76abdd671f96ce46b0801301d0d6379c406ddfb02c00284.

---

<a id="pubmed-pmid-2474565-leuprolide-v1"></a>

## PubMed record PMID 2474565

> PeptideScanner retained PubMed bibliographic metadata for PMID 2474565 at 2026-07-30T21:56:47.803Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1989-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-2474565-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2474565-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2474565-leuprolide-v1
- Content SHA-256: `13418b3a2033aaecac8efdfc76b7e66f84871d0e939f91d3b93e745d470d8380`

### Claims and source pins

#### Headline

PubMed record PMID 2474565 ([`pubmed-observation-pmid-2474565-2013-11-21-4bfaaaff3894`](#source-pubmed-observation-pmid-2474565-2013-11-21-4bfaaaff3894))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 2474565 at 2026-07-30T21:56:47.803Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1989-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2474565-2013-11-21-4bfaaaff3894`](#source-pubmed-observation-pmid-2474565-2013-11-21-4bfaaaff3894))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 2474565 at 2026-07-30T21:56:47.803Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 1989-09-01. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-2474565-2013-11-21-4bfaaaff3894`](#source-pubmed-observation-pmid-2474565-2013-11-21-4bfaaaff3894))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2474565-2013-11-21-4bfaaaff3894`](#source-pubmed-observation-pmid-2474565-2013-11-21-4bfaaaff3894))

### Sources

<a id="source-pubmed-observation-pmid-2474565-2013-11-21-4bfaaaff3894"></a>
- **PubMed record PMID 2474565 · retained source version 1:2013-11-21:current:4bfaaaff3894238decc894a4d23726db947a0f1490f738ea325c2a4b5a83de98** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2474565/) (`pubmed-observation-pmid-2474565-2013-11-21-4bfaaaff3894`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 2474565." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-2474565-leuprolide-v1 SHA-256: 13418b3a2033aaecac8efdfc76b7e66f84871d0e939f91d3b93e745d470d8380.

---

<a id="pubmed-pmid-39177865-leuprolide-v1"></a>

## PubMed record PMID 39177865

> PeptideScanner retained PubMed bibliographic metadata for PMID 39177865 at 2026-08-10T10:49:06.892Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2024-08-23. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39177865-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-04
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39177865-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-39177865-leuprolide-v1
- Content SHA-256: `4d6b06ccf8907a0ad4412872477a46353ef0b945db5b9e34de69c3067b41ff6c`

### Claims and source pins

#### Headline

PubMed record PMID 39177865 ([`pubmed-observation-pmid-39177865-2026-08-04-16576cf2d1bf`](#source-pubmed-observation-pmid-39177865-2026-08-04-16576cf2d1bf))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39177865 at 2026-08-10T10:49:06.892Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2024-08-23. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39177865-2026-08-04-16576cf2d1bf`](#source-pubmed-observation-pmid-39177865-2026-08-04-16576cf2d1bf))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39177865 at 2026-08-10T10:49:06.892Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2024-08-23. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39177865-2026-08-04-16576cf2d1bf`](#source-pubmed-observation-pmid-39177865-2026-08-04-16576cf2d1bf))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39177865-2026-08-04-16576cf2d1bf`](#source-pubmed-observation-pmid-39177865-2026-08-04-16576cf2d1bf))

### Sources

<a id="source-pubmed-observation-pmid-39177865-2026-08-04-16576cf2d1bf"></a>
- **PubMed record PMID 39177865 · retained source version 1:2026-08-04:current:16576cf2d1bfa9981edf56f1c62b803909b4a21f0d91d6d0835a9f6f34ef15be** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39177865/) (`pubmed-observation-pmid-39177865-2026-08-04-16576cf2d1bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39177865." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-39177865-leuprolide-v1 SHA-256: 4d6b06ccf8907a0ad4412872477a46353ef0b945db5b9e34de69c3067b41ff6c.

---

<a id="pubmed-pmid-41712259-leuprolide-v1"></a>

## PubMed record PMID 41712259

> PeptideScanner retained PubMed bibliographic metadata for PMID 41712259 at 2026-08-10T18:13:42.694Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-02-19. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41712259-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41712259-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-41712259-leuprolide-v1
- Content SHA-256: `8cd56733d4c6d661fb0296745fb96f3e0b12ee012afa4a4bca11bb6b7cd26bba`

### Claims and source pins

#### Headline

PubMed record PMID 41712259 ([`pubmed-observation-pmid-41712259-2026-07-28-c8c69dc41647`](#source-pubmed-observation-pmid-41712259-2026-07-28-c8c69dc41647))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41712259 at 2026-08-10T18:13:42.694Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-02-19. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41712259-2026-07-28-c8c69dc41647`](#source-pubmed-observation-pmid-41712259-2026-07-28-c8c69dc41647))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41712259 at 2026-08-10T18:13:42.694Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-02-19. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41712259-2026-07-28-c8c69dc41647`](#source-pubmed-observation-pmid-41712259-2026-07-28-c8c69dc41647))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41712259-2026-07-28-c8c69dc41647`](#source-pubmed-observation-pmid-41712259-2026-07-28-c8c69dc41647))

### Sources

<a id="source-pubmed-observation-pmid-41712259-2026-07-28-c8c69dc41647"></a>
- **PubMed record PMID 41712259 · retained source version 1:2026-07-28:current:c8c69dc41647608720fd921d5f7e2627c4bad9485bda42b66e813881a35d50a1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41712259/) (`pubmed-observation-pmid-41712259-2026-07-28-c8c69dc41647`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41712259." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-41712259-leuprolide-v1 SHA-256: 8cd56733d4c6d661fb0296745fb96f3e0b12ee012afa4a4bca11bb6b7cd26bba.

---

<a id="pubmed-pmid-41824265-leuprolide-v1"></a>

## PubMed record PMID 41824265

> PeptideScanner retained PubMed bibliographic metadata for PMID 41824265 at 2026-08-10T10:49:08.794Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-03-13. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41824265-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41824265-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-41824265-leuprolide-v1
- Content SHA-256: `0abe4d5625e3754424d74bb389a0157424e1f20b1c54dc8be81dd9300840df75`

### Claims and source pins

#### Headline

PubMed record PMID 41824265 ([`pubmed-observation-pmid-41824265-2026-08-03-aa97d9285233`](#source-pubmed-observation-pmid-41824265-2026-08-03-aa97d9285233))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41824265 at 2026-08-10T10:49:08.794Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-03-13. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41824265-2026-08-03-aa97d9285233`](#source-pubmed-observation-pmid-41824265-2026-08-03-aa97d9285233))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41824265 at 2026-08-10T10:49:08.794Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-03-13. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41824265-2026-08-03-aa97d9285233`](#source-pubmed-observation-pmid-41824265-2026-08-03-aa97d9285233))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41824265-2026-08-03-aa97d9285233`](#source-pubmed-observation-pmid-41824265-2026-08-03-aa97d9285233))

### Sources

<a id="source-pubmed-observation-pmid-41824265-2026-08-03-aa97d9285233"></a>
- **PubMed record PMID 41824265 · retained source version 1:2026-08-03:current:aa97d92852330c283c433fc9bfcee91ba6b2cf4aa6f1127836c2896a2ebad415** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41824265/) (`pubmed-observation-pmid-41824265-2026-08-03-aa97d9285233`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41824265." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-41824265-leuprolide-v1 SHA-256: 0abe4d5625e3754424d74bb389a0157424e1f20b1c54dc8be81dd9300840df75.

---

<a id="pubmed-pmid-41931341-leuprolide-v1"></a>

## PubMed record PMID 41931341

> PeptideScanner retained PubMed bibliographic metadata for PMID 41931341 at 2026-08-10T18:13:46.810Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-04-03. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41931341-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-14
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41931341-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-41931341-leuprolide-v1
- Content SHA-256: `2bf25a82584f86a9c5850a92f0508e518926b407af4088ee62c1301daf7b69a9`

### Claims and source pins

#### Headline

PubMed record PMID 41931341 ([`pubmed-observation-pmid-41931341-2026-07-14-e64a6e3d9fde`](#source-pubmed-observation-pmid-41931341-2026-07-14-e64a6e3d9fde))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41931341 at 2026-08-10T18:13:46.810Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-04-03. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41931341-2026-07-14-e64a6e3d9fde`](#source-pubmed-observation-pmid-41931341-2026-07-14-e64a6e3d9fde))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41931341 at 2026-08-10T18:13:46.810Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-04-03. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41931341-2026-07-14-e64a6e3d9fde`](#source-pubmed-observation-pmid-41931341-2026-07-14-e64a6e3d9fde))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41931341-2026-07-14-e64a6e3d9fde`](#source-pubmed-observation-pmid-41931341-2026-07-14-e64a6e3d9fde))

### Sources

<a id="source-pubmed-observation-pmid-41931341-2026-07-14-e64a6e3d9fde"></a>
- **PubMed record PMID 41931341 · retained source version 1:2026-07-14:current:e64a6e3d9fde1d9ee5056c61862ed803c360d50b0a9b011731475f6143fdfa3c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41931341/) (`pubmed-observation-pmid-41931341-2026-07-14-e64a6e3d9fde`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41931341." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-41931341-leuprolide-v1 SHA-256: 2bf25a82584f86a9c5850a92f0508e518926b407af4088ee62c1301daf7b69a9.

---

<a id="pubmed-pmid-42003759-leuprolide-v1"></a>

## PubMed record PMID 42003759

> PeptideScanner retained PubMed bibliographic metadata for PMID 42003759 at 2026-08-10T18:13:48.759Z. PubMed recorded a metadata revision date of 2026-07-20 and an Entrez history date of 2026-04-20. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42003759-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-20
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42003759-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-42003759-leuprolide-v1
- Content SHA-256: `83e81fd60370dc673540fd0bb5f9db307caef899b2ea24883c0d41f6aaec09b0`

### Claims and source pins

#### Headline

PubMed record PMID 42003759 ([`pubmed-observation-pmid-42003759-2026-07-20-42274954b1e7`](#source-pubmed-observation-pmid-42003759-2026-07-20-42274954b1e7))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42003759 at 2026-08-10T18:13:48.759Z. PubMed recorded a metadata revision date of 2026-07-20 and an Entrez history date of 2026-04-20. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42003759-2026-07-20-42274954b1e7`](#source-pubmed-observation-pmid-42003759-2026-07-20-42274954b1e7))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42003759 at 2026-08-10T18:13:48.759Z. PubMed recorded a metadata revision date of 2026-07-20 and an Entrez history date of 2026-04-20. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42003759-2026-07-20-42274954b1e7`](#source-pubmed-observation-pmid-42003759-2026-07-20-42274954b1e7))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42003759-2026-07-20-42274954b1e7`](#source-pubmed-observation-pmid-42003759-2026-07-20-42274954b1e7))

### Sources

<a id="source-pubmed-observation-pmid-42003759-2026-07-20-42274954b1e7"></a>
- **PubMed record PMID 42003759 · retained source version 1:2026-07-20:current:42274954b1e703ae7397cf477d5e50907578902437fadf0eebcc9bd13266cac3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42003759/) (`pubmed-observation-pmid-42003759-2026-07-20-42274954b1e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42003759." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-42003759-leuprolide-v1 SHA-256: 83e81fd60370dc673540fd0bb5f9db307caef899b2ea24883c0d41f6aaec09b0.

---

<a id="pubmed-pmid-42299119-leuprolide-v1"></a>

## Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS.

> PubMed lists PMID 42299119 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2026-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42299119-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42299119-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-42299119-leuprolide-v1
- Content SHA-256: `054921045ad755091eff9e7d3668aaadd4639752d3fba95c96b229496f04bb19`

### Claims and source pins

#### Headline

Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS. ([`pubmed-observation-pmid-42299119-2026-06-16-a72a3b0b2306`](#source-pubmed-observation-pmid-42299119-2026-06-16-a72a3b0b2306))

#### Summary

PubMed lists PMID 42299119 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2026-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42299119-2026-06-16-a72a3b0b2306`](#source-pubmed-observation-pmid-42299119-2026-06-16-a72a3b0b2306))

#### Paragraph 1

PubMed lists PMID 42299119 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2026-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42299119-2026-06-16-a72a3b0b2306`](#source-pubmed-observation-pmid-42299119-2026-06-16-a72a3b0b2306))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42299119-2026-06-16-a72a3b0b2306`](#source-pubmed-observation-pmid-42299119-2026-06-16-a72a3b0b2306))

### Sources

<a id="source-pubmed-observation-pmid-42299119-2026-06-16-a72a3b0b2306"></a>
- **Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS. · retained source version 1:2026-06-16:current:a72a3b0b23069215b1d687e2b1a48169ccd0b5b3821f5a89b1f18a666be6c3b3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42299119/) (`pubmed-observation-pmid-42299119-2026-06-16-a72a3b0b2306`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-42299119-leuprolide-v1 SHA-256: 054921045ad755091eff9e7d3668aaadd4639752d3fba95c96b229496f04bb19.

---

<a id="pubmed-pmid-42962871-leuprolide-v1"></a>

## Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy.

> PubMed lists PMID 42962871 in Physiology & behavior as Journal Article, with publication-date metadata of 2026-10-30 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42962871-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-06
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42962871-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-42962871-leuprolide-v1
- Content SHA-256: `b5ae89248dffb3c9a459d0a56ad1a2a16971a66f5a1f6b32a6fd9241e807c92a`

### Claims and source pins

#### Headline

Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy. ([`pubmed-observation-pmid-42962871-2026-11-06-a9c10c81369a`](#source-pubmed-observation-pmid-42962871-2026-11-06-a9c10c81369a))

#### Summary

PubMed lists PMID 42962871 in Physiology & behavior as Journal Article, with publication-date metadata of 2026-10-30 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42962871-2026-11-06-a9c10c81369a`](#source-pubmed-observation-pmid-42962871-2026-11-06-a9c10c81369a))

#### Paragraph 1

PubMed lists PMID 42962871 in Physiology & behavior as Journal Article, with publication-date metadata of 2026-10-30 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42962871-2026-11-06-a9c10c81369a`](#source-pubmed-observation-pmid-42962871-2026-11-06-a9c10c81369a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42962871-2026-11-06-a9c10c81369a`](#source-pubmed-observation-pmid-42962871-2026-11-06-a9c10c81369a))

### Sources

<a id="source-pubmed-observation-pmid-42962871-2026-11-06-a9c10c81369a"></a>
- **Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy. · retained source version 1:2026-11-06:current:a9c10c81369ac410792fe219332cb79d14d9242b1d63a5dc2ae63f157cfb2a38** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42962871/) (`pubmed-observation-pmid-42962871-2026-11-06-a9c10c81369a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-42962871-leuprolide-v1 SHA-256: b5ae89248dffb3c9a459d0a56ad1a2a16971a66f5a1f6b32a6fd9241e807c92a.

---

<a id="pubmed-pmid-7651647-leuprolide-v1"></a>

## Leuprolide acetate treatment and myoma arterial size.

> PubMed lists PMID 7651647 in Obstetrics and gynecology as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7651647-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7651647-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-7651647-leuprolide-v1
- Content SHA-256: `265075526d2b974f2599a0d6bf53f2c0459708baf93dc1bd6ab2f9b5f06d03b8`

### Claims and source pins

#### Headline

Leuprolide acetate treatment and myoma arterial size. ([`pubmed-observation-pmid-7651647-2013-11-21-5bca8092c85f`](#source-pubmed-observation-pmid-7651647-2013-11-21-5bca8092c85f))

#### Summary

PubMed lists PMID 7651647 in Obstetrics and gynecology as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7651647-2013-11-21-5bca8092c85f`](#source-pubmed-observation-pmid-7651647-2013-11-21-5bca8092c85f))

#### Paragraph 1

PubMed lists PMID 7651647 in Obstetrics and gynecology as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1995-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7651647-2013-11-21-5bca8092c85f`](#source-pubmed-observation-pmid-7651647-2013-11-21-5bca8092c85f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7651647-2013-11-21-5bca8092c85f`](#source-pubmed-observation-pmid-7651647-2013-11-21-5bca8092c85f))

### Sources

<a id="source-pubmed-observation-pmid-7651647-2013-11-21-5bca8092c85f"></a>
- **Leuprolide acetate treatment and myoma arterial size. · retained source version 1:2013-11-21:current:5bca8092c85f4bc5e85f14314de747b6c38779b7d8fd5b85f63c8c46b1a61842** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7651647/) (`pubmed-observation-pmid-7651647-2013-11-21-5bca8092c85f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide acetate treatment and myoma arterial size." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-7651647-leuprolide-v1 SHA-256: 265075526d2b974f2599a0d6bf53f2c0459708baf93dc1bd6ab2f9b5f06d03b8.

---

<a id="pubmed-pmid-7936386-leuprolide-v1"></a>

## \[Short-term treatment with leuprolide acetate depot before surgical intervention for uterine leiomyomatosis\].

> PubMed lists PMID 7936386 in Minerva ginecologica as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1994-06 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7936386-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7936386-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-7936386-leuprolide-v1
- Content SHA-256: `e884b4cc3ce5bec8be2caccee8714e8fb7bfc1a1fec6db95b16b960d7abea393`

### Claims and source pins

#### Headline

\[Short-term treatment with leuprolide acetate depot before surgical intervention for uterine leiomyomatosis\]. ([`pubmed-observation-pmid-7936386-2013-11-21-b3357144e898`](#source-pubmed-observation-pmid-7936386-2013-11-21-b3357144e898))

#### Summary

PubMed lists PMID 7936386 in Minerva ginecologica as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1994-06 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7936386-2013-11-21-b3357144e898`](#source-pubmed-observation-pmid-7936386-2013-11-21-b3357144e898))

#### Paragraph 1

PubMed lists PMID 7936386 in Minerva ginecologica as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1994-06 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7936386-2013-11-21-b3357144e898`](#source-pubmed-observation-pmid-7936386-2013-11-21-b3357144e898))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7936386-2013-11-21-b3357144e898`](#source-pubmed-observation-pmid-7936386-2013-11-21-b3357144e898))

### Sources

<a id="source-pubmed-observation-pmid-7936386-2013-11-21-b3357144e898"></a>
- **\[Short-term treatment with leuprolide acetate depot before surgical intervention for uterine leiomyomatosis\]. · retained source version 1:2013-11-21:current:b3357144e898710557df9a0e549882ccdd0fa72a330a4608bffede9dba9467a9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7936386/) (`pubmed-observation-pmid-7936386-2013-11-21-b3357144e898`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Short-term treatment with leuprolide acetate depot before surgical intervention for uterine leiomyomatosis\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-7936386-leuprolide-v1 SHA-256: e884b4cc3ce5bec8be2caccee8714e8fb7bfc1a1fec6db95b16b960d7abea393.

---

<a id="pubmed-pmid-7991863-leuprolide-v1"></a>

## \[Advanced endometriosis treatment with leuprolide acetate\].

> PubMed lists PMID 7991863 in Revista chilena de obstetricia y ginecologia as Case Reports, English Abstract, Journal Article, with publication-date metadata of 1993 (year precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7991863-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7991863-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-7991863-leuprolide-v1
- Content SHA-256: `7336aa11d03ce361d75c37676bef4795e1a59f8fb5f40ed6dfd16aedef8e3715`

### Claims and source pins

#### Headline

\[Advanced endometriosis treatment with leuprolide acetate\]. ([`pubmed-observation-pmid-7991863-2013-11-21-48b145b58064`](#source-pubmed-observation-pmid-7991863-2013-11-21-48b145b58064))

#### Summary

PubMed lists PMID 7991863 in Revista chilena de obstetricia y ginecologia as Case Reports, English Abstract, Journal Article, with publication-date metadata of 1993 (year precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7991863-2013-11-21-48b145b58064`](#source-pubmed-observation-pmid-7991863-2013-11-21-48b145b58064))

#### Paragraph 1

PubMed lists PMID 7991863 in Revista chilena de obstetricia y ginecologia as Case Reports, English Abstract, Journal Article, with publication-date metadata of 1993 (year precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7991863-2013-11-21-48b145b58064`](#source-pubmed-observation-pmid-7991863-2013-11-21-48b145b58064))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7991863-2013-11-21-48b145b58064`](#source-pubmed-observation-pmid-7991863-2013-11-21-48b145b58064))

### Sources

<a id="source-pubmed-observation-pmid-7991863-2013-11-21-48b145b58064"></a>
- **\[Advanced endometriosis treatment with leuprolide acetate\]. · retained source version 1:2013-11-21:current:48b145b58064fa5e1964c405530fd790d5abf01bd4feb64092325a0db55b8410** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7991863/) (`pubmed-observation-pmid-7991863-2013-11-21-48b145b58064`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Advanced endometriosis treatment with leuprolide acetate\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-7991863-leuprolide-v1 SHA-256: 7336aa11d03ce361d75c37676bef4795e1a59f8fb5f40ed6dfd16aedef8e3715.

---

<a id="pubmed-pmid-8041380-leuprolide-v1"></a>

## Leuprolide acetate for exhibitionism in Huntington's disease.

> PubMed lists PMID 8041380 in Movement disorders : official journal of the Movement Disorder Society as Case Reports, Journal Article, with publication-date metadata of 1994-05 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8041380-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8041380-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8041380-leuprolide-v1
- Content SHA-256: `79765d12a1c61a581e4253353d5e94ca1619dc4aeb9c412b75d6bc1c41690743`

### Claims and source pins

#### Headline

Leuprolide acetate for exhibitionism in Huntington's disease. ([`pubmed-observation-pmid-8041380-2013-11-21-ba028385972d`](#source-pubmed-observation-pmid-8041380-2013-11-21-ba028385972d))

#### Summary

PubMed lists PMID 8041380 in Movement disorders : official journal of the Movement Disorder Society as Case Reports, Journal Article, with publication-date metadata of 1994-05 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8041380-2013-11-21-ba028385972d`](#source-pubmed-observation-pmid-8041380-2013-11-21-ba028385972d))

#### Paragraph 1

PubMed lists PMID 8041380 in Movement disorders : official journal of the Movement Disorder Society as Case Reports, Journal Article, with publication-date metadata of 1994-05 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8041380-2013-11-21-ba028385972d`](#source-pubmed-observation-pmid-8041380-2013-11-21-ba028385972d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8041380-2013-11-21-ba028385972d`](#source-pubmed-observation-pmid-8041380-2013-11-21-ba028385972d))

### Sources

<a id="source-pubmed-observation-pmid-8041380-2013-11-21-ba028385972d"></a>
- **Leuprolide acetate for exhibitionism in Huntington's disease. · retained source version 1:2013-11-21:current:ba028385972de1eb6e7baebd606025ac1f421cbec7c1022c2e0af52ae7710c27** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8041380/) (`pubmed-observation-pmid-8041380-2013-11-21-ba028385972d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide acetate for exhibitionism in Huntington's disease." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8041380-leuprolide-v1 SHA-256: 79765d12a1c61a581e4253353d5e94ca1619dc4aeb9c412b75d6bc1c41690743.

---

<a id="pubmed-pmid-8063245-leuprolide-v1"></a>

## Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma.

> PubMed lists PMID 8063245 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8063245-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8063245-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8063245-leuprolide-v1
- Content SHA-256: `f9148b6e6c56d47ba272c806c6171e178185e54c4fd17827b8be2e984f7ab53d`

### Claims and source pins

#### Headline

Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma. ([`pubmed-observation-pmid-8063245-2013-11-21-106e08f55429`](#source-pubmed-observation-pmid-8063245-2013-11-21-106e08f55429))

#### Summary

PubMed lists PMID 8063245 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8063245-2013-11-21-106e08f55429`](#source-pubmed-observation-pmid-8063245-2013-11-21-106e08f55429))

#### Paragraph 1

PubMed lists PMID 8063245 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8063245-2013-11-21-106e08f55429`](#source-pubmed-observation-pmid-8063245-2013-11-21-106e08f55429))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8063245-2013-11-21-106e08f55429`](#source-pubmed-observation-pmid-8063245-2013-11-21-106e08f55429))

### Sources

<a id="source-pubmed-observation-pmid-8063245-2013-11-21-106e08f55429"></a>
- **Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma. · retained source version 1:2013-11-21:current:106e08f55429b6e17db7a37aa400329bf9ea2a63b7acbe9451338a7ee6a76021** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8063245/) (`pubmed-observation-pmid-8063245-2013-11-21-106e08f55429`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8063245-leuprolide-v1 SHA-256: f9148b6e6c56d47ba272c806c6171e178185e54c4fd17827b8be2e984f7ab53d.

---

<a id="pubmed-pmid-8065589-leuprolide-v1"></a>

## \[Clinical use of a GnRH analogue in a depot preparation (leuprolide acetate) in patients with surgical indication for uterine fibromyoma\].

> PubMed lists PMID 8065589 in Minerva ginecologica as English Abstract, Journal Article, with publication-date metadata of 1994-04 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8065589-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8065589-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8065589-leuprolide-v1
- Content SHA-256: `44e5ef89b06bdf97791186497f619a9265762586c1ae2558af32a33f99a0e477`

### Claims and source pins

#### Headline

\[Clinical use of a GnRH analogue in a depot preparation (leuprolide acetate) in patients with surgical indication for uterine fibromyoma\]. ([`pubmed-observation-pmid-8065589-2013-11-21-a72c5d8cbc0d`](#source-pubmed-observation-pmid-8065589-2013-11-21-a72c5d8cbc0d))

#### Summary

PubMed lists PMID 8065589 in Minerva ginecologica as English Abstract, Journal Article, with publication-date metadata of 1994-04 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8065589-2013-11-21-a72c5d8cbc0d`](#source-pubmed-observation-pmid-8065589-2013-11-21-a72c5d8cbc0d))

#### Paragraph 1

PubMed lists PMID 8065589 in Minerva ginecologica as English Abstract, Journal Article, with publication-date metadata of 1994-04 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8065589-2013-11-21-a72c5d8cbc0d`](#source-pubmed-observation-pmid-8065589-2013-11-21-a72c5d8cbc0d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8065589-2013-11-21-a72c5d8cbc0d`](#source-pubmed-observation-pmid-8065589-2013-11-21-a72c5d8cbc0d))

### Sources

<a id="source-pubmed-observation-pmid-8065589-2013-11-21-a72c5d8cbc0d"></a>
- **\[Clinical use of a GnRH analogue in a depot preparation (leuprolide acetate) in patients with surgical indication for uterine fibromyoma\]. · retained source version 1:2013-11-21:current:a72c5d8cbc0ded78dda860997d63b78a44db8d53e181c460cbc71e1e95ea952a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8065589/) (`pubmed-observation-pmid-8065589-2013-11-21-a72c5d8cbc0d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Clinical use of a GnRH analogue in a depot preparation (leuprolide acetate) in patients with surgical indication for uterine fibromyoma\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8065589-leuprolide-v1 SHA-256: 44e5ef89b06bdf97791186497f619a9265762586c1ae2558af32a33f99a0e477.

---

<a id="pubmed-pmid-8065590-leuprolide-v1"></a>

## \[Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol\].

> PubMed lists PMID 8065590 in Minerva ginecologica as Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1994-04 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8065590-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8065590-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8065590-leuprolide-v1
- Content SHA-256: `6aa0833ed66a98d3e390d50296dc22a5ed99e26f513eb38b450f268bb0f37261`

### Claims and source pins

#### Headline

\[Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol\]. ([`pubmed-observation-pmid-8065590-2013-11-21-922ce937a831`](#source-pubmed-observation-pmid-8065590-2013-11-21-922ce937a831))

#### Summary

PubMed lists PMID 8065590 in Minerva ginecologica as Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1994-04 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8065590-2013-11-21-922ce937a831`](#source-pubmed-observation-pmid-8065590-2013-11-21-922ce937a831))

#### Paragraph 1

PubMed lists PMID 8065590 in Minerva ginecologica as Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1994-04 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8065590-2013-11-21-922ce937a831`](#source-pubmed-observation-pmid-8065590-2013-11-21-922ce937a831))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8065590-2013-11-21-922ce937a831`](#source-pubmed-observation-pmid-8065590-2013-11-21-922ce937a831))

### Sources

<a id="source-pubmed-observation-pmid-8065590-2013-11-21-922ce937a831"></a>
- **\[Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol\]. · retained source version 1:2013-11-21:current:922ce937a83130fbba1502af2254d4fdbdf15c47a2247fed5ec80ab794e8521d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8065590/) (`pubmed-observation-pmid-8065590-2013-11-21-922ce937a831`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8065590-leuprolide-v1 SHA-256: 6aa0833ed66a98d3e390d50296dc22a5ed99e26f513eb38b450f268bb0f37261.

---

<a id="pubmed-pmid-8348161-leuprolide-v1"></a>

## Obesity affects circulating estradiol levels of premenopausal hirsute women receiving leuprolide acetate depot.

> PubMed lists PMID 8348161 in International journal of fertility and menopausal studies as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1993 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8348161-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8348161-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8348161-leuprolide-v1
- Content SHA-256: `6f9ca6d779650971d11e5a37a891552cd004062a950bbd04750d2cebbbcf8f04`

### Claims and source pins

#### Headline

Obesity affects circulating estradiol levels of premenopausal hirsute women receiving leuprolide acetate depot. ([`pubmed-observation-pmid-8348161-2013-11-21-9fd559e7bf1e`](#source-pubmed-observation-pmid-8348161-2013-11-21-9fd559e7bf1e))

#### Summary

PubMed lists PMID 8348161 in International journal of fertility and menopausal studies as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1993 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8348161-2013-11-21-9fd559e7bf1e`](#source-pubmed-observation-pmid-8348161-2013-11-21-9fd559e7bf1e))

#### Paragraph 1

PubMed lists PMID 8348161 in International journal of fertility and menopausal studies as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1993 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8348161-2013-11-21-9fd559e7bf1e`](#source-pubmed-observation-pmid-8348161-2013-11-21-9fd559e7bf1e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8348161-2013-11-21-9fd559e7bf1e`](#source-pubmed-observation-pmid-8348161-2013-11-21-9fd559e7bf1e))

### Sources

<a id="source-pubmed-observation-pmid-8348161-2013-11-21-9fd559e7bf1e"></a>
- **Obesity affects circulating estradiol levels of premenopausal hirsute women receiving leuprolide acetate depot. · retained source version 1:2013-11-21:current:9fd559e7bf1eab2d16214d3c86f0fae69a53c7395ed9a4760e80c1e0228b7aae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8348161/) (`pubmed-observation-pmid-8348161-2013-11-21-9fd559e7bf1e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Obesity affects circulating estradiol levels of premenopausal hirsute women receiving leuprolide acetate depot." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8348161-leuprolide-v1 SHA-256: 6f9ca6d779650971d11e5a37a891552cd004062a950bbd04750d2cebbbcf8f04.

---

<a id="pubmed-pmid-8530573-leuprolide-v1"></a>

## Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.

> PubMed lists PMID 8530573 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1995-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8530573-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8530573-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8530573-leuprolide-v1
- Content SHA-256: `13c7190ea51e66eb5ad09f8e0cce882e6827af481409ae6ee9685dd369d96281`

### Claims and source pins

#### Headline

Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. ([`pubmed-observation-pmid-8530573-2013-11-21-9eb1b67ba63b`](#source-pubmed-observation-pmid-8530573-2013-11-21-9eb1b67ba63b))

#### Summary

PubMed lists PMID 8530573 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1995-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8530573-2013-11-21-9eb1b67ba63b`](#source-pubmed-observation-pmid-8530573-2013-11-21-9eb1b67ba63b))

#### Paragraph 1

PubMed lists PMID 8530573 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1995-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8530573-2013-11-21-9eb1b67ba63b`](#source-pubmed-observation-pmid-8530573-2013-11-21-9eb1b67ba63b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8530573-2013-11-21-9eb1b67ba63b`](#source-pubmed-observation-pmid-8530573-2013-11-21-9eb1b67ba63b))

### Sources

<a id="source-pubmed-observation-pmid-8530573-2013-11-21-9eb1b67ba63b"></a>
- **Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. · retained source version 1:2013-11-21:current:9eb1b67ba63b550f7e014a6cd841af34edea8a04354ff7152853c478ae265f20** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8530573/) (`pubmed-observation-pmid-8530573-2013-11-21-9eb1b67ba63b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8530573-leuprolide-v1 SHA-256: 13c7190ea51e66eb5ad09f8e0cce882e6827af481409ae6ee9685dd369d96281.

---

<a id="pubmed-pmid-8995560-leuprolide-v1"></a>

## A phase II study of leuprolide in advanced/recurrent endometrial cancer.

> PubMed lists PMID 8995560 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-01 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8995560-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8995560-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8995560-leuprolide-v1
- Content SHA-256: `233631f02c5fd79a10890511ccb1793b2a2de2d934615d5237f364829adbbff6`

### Claims and source pins

#### Headline

A phase II study of leuprolide in advanced/recurrent endometrial cancer. ([`pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828`](#source-pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828))

#### Summary

PubMed lists PMID 8995560 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-01 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828`](#source-pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828))

#### Paragraph 1

PubMed lists PMID 8995560 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-01 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828`](#source-pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828`](#source-pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828))

### Sources

<a id="source-pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828"></a>
- **A phase II study of leuprolide in advanced/recurrent endometrial cancer. · retained source version 1:2013-11-21:current:d245a72c68285a8a7baed582e1ba5641855eff1aaf78f888759d24d411412bad** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8995560/) (`pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A phase II study of leuprolide in advanced/recurrent endometrial cancer." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-8995560-leuprolide-v1 SHA-256: 233631f02c5fd79a10890511ccb1793b2a2de2d934615d5237f364829adbbff6.

---

<a id="pubmed-pmid-9146615-leuprolide-v1"></a>

## Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not?

> PubMed lists PMID 9146615 in The Journal of urology as Journal Article, with publication-date metadata of 1997-06 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9146615-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9146615-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-9146615-leuprolide-v1
- Content SHA-256: `874f7bb16e91f554051919a3dd01bdd5b73c78128dff37f47fcf7537406a1e68`

### Claims and source pins

#### Headline

Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not? ([`pubmed-observation-pmid-9146615-2013-11-21-b89bda76954b`](#source-pubmed-observation-pmid-9146615-2013-11-21-b89bda76954b))

#### Summary

PubMed lists PMID 9146615 in The Journal of urology as Journal Article, with publication-date metadata of 1997-06 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9146615-2013-11-21-b89bda76954b`](#source-pubmed-observation-pmid-9146615-2013-11-21-b89bda76954b))

#### Paragraph 1

PubMed lists PMID 9146615 in The Journal of urology as Journal Article, with publication-date metadata of 1997-06 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9146615-2013-11-21-b89bda76954b`](#source-pubmed-observation-pmid-9146615-2013-11-21-b89bda76954b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9146615-2013-11-21-b89bda76954b`](#source-pubmed-observation-pmid-9146615-2013-11-21-b89bda76954b))

### Sources

<a id="source-pubmed-observation-pmid-9146615-2013-11-21-b89bda76954b"></a>
- **Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not? · retained source version 1:2013-11-21:current:b89bda76954b9bd540fdf9388f65030f2adc27d836765e6b0b81c8844bf92671** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9146615/) (`pubmed-observation-pmid-9146615-2013-11-21-b89bda76954b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not?" Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-9146615-leuprolide-v1 SHA-256: 874f7bb16e91f554051919a3dd01bdd5b73c78128dff37f47fcf7537406a1e68.

---

<a id="pubmed-pmid-9156052-leuprolide-v1"></a>

## Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new?

> PubMed lists PMID 9156052 in Clinical endocrinology as Comment, Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9156052-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9156052-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-9156052-leuprolide-v1
- Content SHA-256: `256e1f4b9b8c70136166d23fdb256b054ec60f9778bc1bdf5984cfa2df072967`

### Claims and source pins

#### Headline

Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new? ([`pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813`](#source-pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813))

#### Summary

PubMed lists PMID 9156052 in Clinical endocrinology as Comment, Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813`](#source-pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813))

#### Paragraph 1

PubMed lists PMID 9156052 in Clinical endocrinology as Comment, Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813`](#source-pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813`](#source-pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813))

### Sources

<a id="source-pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813"></a>
- **Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new? · retained source version 1:2013-11-21:current:b51eb4621813afe7992641f0c673678bed5182ff92e0ff74767c41f0abb1cec9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9156052/) (`pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new?" Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-9156052-leuprolide-v1 SHA-256: 256e1f4b9b8c70136166d23fdb256b054ec60f9778bc1bdf5984cfa2df072967.

---

<a id="pubmed-pmid-9299275-leuprolide-v1"></a>

## Leuprolide in the treatment of endometrial cancer.

> PubMed lists PMID 9299275 in Gynecologic oncology as Letter, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9299275-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9299275-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-9299275-leuprolide-v1
- Content SHA-256: `8685bf1fb58220a785969adbe1893bc0cfd7da2c95cbb81c041cc901a9000d28`

### Claims and source pins

#### Headline

Leuprolide in the treatment of endometrial cancer. ([`pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d`](#source-pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d))

#### Summary

PubMed lists PMID 9299275 in Gynecologic oncology as Letter, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d`](#source-pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d))

#### Paragraph 1

PubMed lists PMID 9299275 in Gynecologic oncology as Letter, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d`](#source-pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d`](#source-pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d))

### Sources

<a id="source-pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d"></a>
- **Leuprolide in the treatment of endometrial cancer. · retained source version 1:2013-11-21:current:8d5da1f0ef9da0108a0e3d229168a67c1a5779048a2a99c2260b4121dafe229a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9299275/) (`pubmed-observation-pmid-9299275-2013-11-21-8d5da1f0ef9d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Leuprolide in the treatment of endometrial cancer." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/leuprolide.json#pubmed-pmid-9299275-leuprolide-v1 SHA-256: 8685bf1fb58220a785969adbe1893bc0cfd7da2c95cbb81c041cc901a9000d28.

